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ABSTRACT 
 
Multiple sclerosis (MS) is an inflammatory-demyelinating disease of the central nervous 
system (CNS). Pathological studies have revealed that MS lesions can have hypoxia-
like properties, raising the possibility that the inflamed CNS may suffer an energy 
deficit. We recently demonstrated that the spinal cord of rats with active experimental 
autoimmune encephalomyelitis (EAE, a model of MS) is hypoxic, and that hypoxia can 
be reversed by inspiring oxygen-enriched air. This thesis examines the contribution of 
hypoxia to the neurological deficits, and the use of oxygen as a therapy. Demyelinating 
and non-demyelinating models of EAE in rats were evaluated, namely active and 
passive EAE respectively. Room air controls were used for comparison. Assessment of 
neurological deficits in active EAE revealed that oxygen (95%) promptly improved 
neurological function in paralysed rats, within only 1 hour of exposure. Furthermore, 
prolonged administration of oxygen (75%) applied either prophylactically (from the day 
of immunisation for 23 days) or therapeutically from the onset of disease (for 24, 48 or 
72 hours) produced a greater and long-lasting amelioration of disease severity.  
Interestingly, oxygen treatment from disease onset reduced oligodendrocyte cell-stress 
and death, demyelination, microglial activation and macrophage infiltration in the spinal 
cord, without exacerbating oxidative damage. The protective effect was proportional to 
the duration of the treatment and significant in rats treated for 72 hours. Other 
experiments have revealed that the spinal cord of rats with passive EAE is also hypoxic 
and oxygen treatment significantly ameliorated disease progression when administered 
prophylactically. We also tested polynitroxylated pegylated hemoglobin (PNPH) as an 
alternative oxygen-based treatment in active EAE, revealing an acute improvement of 
the neurological function 1 hour after the injection of PNPH. We conclude that hypoxia 
contributes to neurological deficits and demyelination in inflammatory autoimmune 
demyelinating disease, and that oxygen therapy can reduce both the deficits and the 
demyelination. 
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CHAPTER 1 
1. INTRODUCTION 
 
1.1.0.0 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system 
(CNS) which causes debilitating neurological dysfunction in young adults and affects 
almost 2.5 million individuals worldwide (Noseworthy et al., 2000). MS was first 
described as a distinct disease in 1868 by the French neurologist Jean-Martin Charcot, 
and it represents the prototypical demyelinating disease of the CNS. MS usually starts 
early in adulthood with a relapsing-remitting disease course (relapse-remitting MS; 
RRMS), in which periodic attacks of neurological deficits are alternated with complete or 
partial recovery of neurological function (Compston and Coles, 2008). After a variable 
period of time, the majority of patients with RRMS (~65%) suffer a progressive and 
persistent accumulation of the deficits without remission, termed secondary progressive 
MS (SPMS) (Compston and Coles, 2008). In some cases, patients with MS (~20%) 
experience a progressive disease course directly from the beginning of the first 
neurological signs and in the absence of any recovery of neurological function (primary 
progressive MS; PPMS) (Compston and Coles, 2008).  
MS is characterised by multifocal demyelinating lesions within the CNS, which consist 
of well-demarcated areas of myelin loss and parallel formation of an astrocytic scar 
(Lassmann, 2013). Neurological deficits are widely believed to be due to demyelination 
(Noseworthy et al., 2000), given that the absence of myelin impairs normal axonal 
conduction (McDonald and Sears, 1970; Waxman et al., 1977; Smith et al., 1979; 
Smith, 1994). As the disease progresses, demyelination and inflammation can lead to 
irreversible axonal destruction and neurodegeneration (Noseworthy et al., 2000). In 
particular, demyelinated axons may suffer a series of pathological changes resulting in 
axonal swelling and transection (Trapp et al., 1998; Nikic et al., 2011). These 
processes may finally result in neuronal death and tissue atrophy, causing irreversible 
disabilities (Friese et al., 2014).  
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MS lesions can develop throughout the CNS, although they arise more often in 
particular locations such as the optic nerves, periventricular white matter, brain stem, 
cerebellum and spinal cord white matter (Noseworthy et al., 2000). Depending on their 
anatomical location, MS lesions can cause a variety of neurological signs and 
symptoms including:  visual problems, limb weakness, sensory disturbance, gait 
instability and ataxia (Hauser and Oksenberg, 2006; Compston and Coles, 2008). Many 
patients also describe augmented fatigue during normal daily activities, accompanied 
by physiological increase in body temperature (Noseworthy et al., 2000).  
MS is commonly diagnosed based on an evaluation of the neurological signs and 
symptoms in combination with neuroimaging and laboratory tests. Especially at the 
early stage of disease, the clinical signs alone are difficult to attribute specifically to MS 
due to their similarities with other neurological disorders (Compston and Coles, 2008). 
The most commonly used diagnostic procedure includes the application of the revised 
McDonald criteria (Polman et al., 2011). The McDonald criteria emphasize the need for 
combining an evaluation of neurological deficits with magnetic resonance imaging 
(MRI) used to localize demyelinating lesions disseminated in space (different locations) 
and time (Polman et al., 2011). Laboratory tests such as the analysis of cerebrospinal 
fluid (CSF) and evoked potential (EP) can additionally be used to achieve an earlier and 
more uniform diagnosis of MS (Polman et al., 2011). In particular, the electrophoretic 
analysis of CSF is used to disclose the presence of oligoclonal bands of IgG, a 
neuroinflammatory marker found in about 75-80% of patients with MS (Link and Huang, 
2006). The EP evaluates the functional response of the brain to a specific stimulus. The 
electrical potentials are measured by placing electrodes on the scalp in the area of the 
brain that responds to the stimulation. Decreased speed in electrical transmission 
implies the presence of a demyelinated lesion.    
In the past, three different EP tests were used to detect MS lesions in the brain, 
namely: visual evoked potentials (VEP), brainstem auditory evoked potentials and 
sensory evoked potentials. More recently, only the VEP is used for the diagnosis of MS 
(and optic neuritis). VEP discloses delays in the electrical transmission along the optic 
nerve, which is an early feature in many patients with MS and it is commonly present 
even in the absence of evident visual impairment (McDonald, 1980). 
The expanded disability status scale (EDSS) is used to assess the magnitude of 
disability in patients with MS, and to monitor how the severity of the neurological deficit 
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changes over time. The EDSS is commonly used to assess the efficacy of therapies in 
clinical trials. 
Current treatments for MS include a number of anti-inflammatory and 
immunomodulatory drugs that have beneficial effects mainly in patients with RRMS but 
that are only poorly, or not, effective in patients with SPMS or PPMS (Winkelmann et 
al., 2016). Glucocorticoids are often used at high doses for the treatment of acute 
exacerbations of the neurological deficits in MS (Winkelmann et al., 2016). The anti-
inflammatory effects of glucocorticoids consist of a reduced production of numerous 
inflammatory mediators and reduced extravasation of inflammatory cells across the 
BBB (Winkelmann et al., 2016). Disease modifying treatments (described below) are 
instead used to attenuate disease progression in the long term. Interferon-β (IFN-β) is a 
cytokine whose mechanism of action is complex and involves downregulation of 
immune recognition molecules such as MHC class II antigens, co-stimulatory molecules 
and adhesion molecules, modulation of the balance between pro-inflammatory and anti- 
inflammatory cytokines, and reduction of lymphocyte migration into the CNS 
(Winkelmann et al., 2016). Glatiramer acetate is a synthetic polymer that decreases the 
expression of MHC class II molecules, deactivates macrophages and monocytes, and 
shifts the lymphocyte activation from a pro-inflammatory (T-helper 1; Th1) to an anti-
inflammatory (T-helper 2; Th2) phenotype (Winkelmann et al., 2016). Fingolimod is a 
first-in-class sphingosine- 1-phosphate (S1P) receptor activator. The activation of the 
S1P receptor on T-cells blocks their emigration from lymph nodes into the CNS and 
recent evidence suggest that the activation of S1P receptors by fingolimod on glial cells 
could also promote reparative processes (Aktas et al., 2010; Winkelmann et al., 2016). 
Dimethyl fumarate (DMF, also known as BG12) is another treatment option for MS. This 
drug acts on MS by attenuating the activity of pro-inflammatory Th1 and Th-17 cells, 
and by scavenging toxic oxygen metabolites (Winkelmann et al., 2016). Teriflunomide 
is an inhibitor of the enzyme dihydroorotate dehydrogenase, which is essential for de-
novo pyrimidine synthesis by proliferating T-cells, and it preferentially diminishes the 
activity of antigen-activated T lymphocytes (Winkelmann et al., 2016). Azathioprine is 
an immunosuppressive drug whose effect derives from its analogy with purines: it 
inhibits DNA synthesis, mostly affecting highly proliferative cells such as T-cells 
(Winkelmann et al., 2016). Natalizumab is a humanized monoclonal antibody that binds 
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α4 integrins and disrupts their interaction with the adhesion molecule VCAM-1, resulting 
in reduced migration of leukocytes from the blood to the CNS (Winkelmann et al., 
2016). These drugs have proven, to some extent, to be effective in attenuating the 
severity of neurological deficits, and to delay the progression of the disease, in patients 
with RRMS, but they also have side effects as they can cause leukopaenia and 
increased risk of viral, bacterial and fungal infections (Winkelmann et al., 2016). 
Although several studies have shown that the risk of developing MS is increased by 
genetic and environmental factors (Ramagopalan et al., 2010), the initial cause of MS 
remains unknown. A common proposed idea is that MS is an autoimmune disease. The 
proposed autoimmune aetiology of MS, which has come to be known as the “outside-in” 
hypothesis, consists of the idea that an aberrant immune response against the CNS is 
the primary event that triggers the disease (McFarland and Martin, 2007). In brief, auto-
reactive lymphocytes against CNS antigen(s) migrate from the blood stream (the 
“outside”) into the CNS parenchyma (“-in”), eliciting an inflammatory, autoimmune 
reaction that causes tissue damage and demyelination (McFarland and Martin, 2007). 
This hypothesis is supported by some features of MS (see following). One feature is 
that MS, similarly with other well-recognized human autoimmune diseases, often 
present a relapsing-remitting course (Wildner and Kaufmann, 2013) and it has an 
increased incidence in female population compared with male individuals (2:1) 
(Noseworthy et al., 2000; Ngo et al., 2014). However the latter aspect seems not to be 
applicable in the case of PPMS in which the incidence of the disease is similar between 
men and women (1:1) (Noseworthy et al., 2000). Another indication in support of the 
outside-in hypothesis was provided by the genetic association between specific types 
of the human leukocyte antigen class-II (HLA-II) with higher risk of developing MS 
(McFarland and Martin, 2007; Ramagopalan et al., 2010). It has been suggested that 
these HLA-II molecules associated with MS, might bind preferentially specific CNS 
epitopes and subsequently prime an antigenic T-cell response against the CNS, 
although this mechanism has not been directly proven (McFarland and Martin, 2007). In 
the last four decades a considerable effort has been expended in identifying the CNS 
antigen that triggers the autoimmune response in MS (McFarland and Martin, 2007). 
The demyelinating nature of MS and its similarity with animal models in which a similar 
pathology is triggered by an autoimmune reaction against myelin, led to focus the 
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attention on myelin proteins (McFarland and Martin, 2007). A greater number of CD4+ 
T-cells reactive against encephalitogenic epitopes of myelin was found in MS patients  
(Bielekova et al., 2004), but the specificity of these T-cells for the antigens was very 
similar to that of T-cells found also in healthy individuals (Bielekova et al., 2004; 
McFarland and Martin, 2007). Interestingly, the immunodominant epitopes found in 
patients with MS showed a predicted low affinity to HLA-II molecules, suggesting a role 
for thymic selection in the generation of the autoimmune T-cell repertoire (Bielekova et 
al., 2004). It has been suggested that MS-associated HLA molecules could poorly bind 
CNS epitopes causing a dysfunctional negative selection of self-reactive T-cells in the 
thymus during early life, possibly leaving in circulation a larger pool of auto-reactive 
lymphocytes that could eventually trigger the autoimmune response against the CNS 
(Bielekova et al., 2004; McFarland and Martin, 2007). However, the HLA-related 
genetic susceptibility to MS may account only for a subgroup of patients with MS, and it 
cannot explain the development of the disease in patients in which these MS-
associated alleles are not present. Nevertheless, the investigation of the mechanisms 
underlying the autoimmune aetiology of MS has yielded much information about the 
immune responses in this disease, leading to the development of useful medications. 
Indeed, a panel of twelve immunomodulatory therapies exists and these drugs have 
been shown to ameliorate both the severity of the neurological deficits and delay the 
onset of new relapses (Winkelmann et al., 2016). However, these therapies are 
effective only in patients with RRMS and not in the progressive phase of the disease 
(PPMS and SPMS) (Winkelmann et al., 2016), suggesting that other pathological 
mechanisms, in addition to inflammation and autoimmunity, can contribute to the 
disease progression. 
An alternative hypothesis suggests that MS is a cytodegenerative disease, where 
autoimmunity is an important, but only a subsequent reaction that occurs in 
predisposed hosts (Stys, 2010). This hypothesis is known as an “inside-out” 
hypothesis. The “inside-out” hypothesis suggests that MS develops from an intrinsic 
degeneration of CNS cells (the “inside”), possibly oligodendrocytes, which only later 
result in the recruitment of inflammatory cells into the CNS parenchyma (“-in”), which 
can subsequently elicit an autoimmune response (Stys, 2010). The “inside-out” 
hypothesis is based on recent evidence that has begun to challenge the “outside-in” 
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hypothesis. In particular, pathological studies on newly forming lesions in MS have 
revealed early loss of oligodendrocytes in the absence of conspicuous T- and B-
lymphocyte infiltrates and with only macrophages scavenging myelin debris (Henderson 
et al., 2009). In addition, ultrastructural analysis of biopsy samples in areas proximal to 
foci of maximal inflammation, revealed that a large number of the myelinated axons still 
present exhibted widening of the inner myelin lamellae, but intact outer myelin layers 
(Rodriguez and Scheithauer, 1994). It has been pointed out that if an autoimmune 
reaction is the initial cause of the myelin damage, it would be expected that an early 
event would be the disruption of the external layers of the myelin sheaths, given that 
these layers are more exposed to the attack of inflammatory cells and mediators, rather 
than an initial alteration of the innermost, and thereby protected myelin lamellae (Stys, 
2010). In addition, the fact that PPMS and SPMS patients have a worsening of the 
neurological deficits while the inflammatory/autoimmune response decreases (Stys, 
2010; Lassmann, 2013), has been used to support the hypothesis that an intrinsic 
cytodegeneration of the CNS drives the disease (Stys, 2010). However, this view does 
not exclude the possibility that an autoimmune response causes the initial CNS 
damage, which might be asymptomatic in some individuals (for example in patients with 
PPMS), while the progression of the neurological deficits is driven by autoimmune-
independent pathological mechanisms such as the nitrative/oxidative stress and 
mitochondrial dysfunction, which have also been revealed to be prominent in MS 
lesions (Smith and Lassmann, 2002; Dutta et al., 2006; Haider et al., 2011; Lassmann 
and Van Horssen, 2011; Fischer et al., 2012; Mahad et al., 2015). 
While the causative mechanisms of MS seem to be still far from being understood, it is 
becoming clearer that several pathological events can contribute to the damage of the 
CNS including autoimmunity, inflammation, oxidative and nitrative stress, hypoxia, 
mitochondrial dysfunction and an energy deficit (Bo et al., 1994; Smith and Lassmann, 
2002; Aboul-Enein et al., 2003; Dutta et al., 2006; McFarland and Martin, 2007; Trapp 
and Stys, 2009; Haider et al., 2011; Lassmann and Van Horssen, 2011; Fischer et al., 
2012; Mahad et al., 2015). Interestingly, evidence revealed that demyelinating lesions 
in MS can have different appearances suggestive of one or more of these pathological 
mechanisms (Lucchinetti et al., 2000; Aboul-Enein and Lassmann, 2005). Indeed, some 
lesions indicate an autoimmune aetiology while others indicate a primary 
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oligodendrocyte dystrophy and a hypoxic cause (Lucchinetti et al., 2000). Therefore, it 
has been suggested that MS may be a series of syndromes with different causes and 
pathogenic mechanisms (Noseworthy et al., 2000). Therefore, a combinatorial 
treatment that targets different pathogenic mechanisms at the same time may be 
especially effective in delaying or even stopping the progression of the disease. 
Concurrently, neuro-regenerative approaches (e.g. neural stem cells) could be 
important in repairing the damaged CNS and restoring normal neurological function 
(Franklin et al., 2012). 
 
1.2.0.0 Animal models of MS: experimental autoimmune 
encephalomyelitis (EAE) 
Important knowledge about the pathogenic mechanisms in MS has been sought by the 
study of inflammatory-demyelinating models of encephalopathy in rodents. These 
models also represent a useful tool to develop and test therapeutic approaches before 
these are applied in MS patients. The most commonly used animal model of MS is 
experimental autoimmune encephalomyelitis (EAE) (Constantinescu et al., 2011). EAE 
is an autoimmune-mediated inflammatory disease of the CNS, triggered by CD4+ T-
cells reactive against a specific antigen, typically of the myelin sheath. Two major types 
of EAE are commonly used in preclinical studies, namely active and passive EAE. 
Active EAE is induced by the injection of a myelin encephalitogenic antigen emulsified 
in a mineral oil-based adjuvant (Freund’s adjuvant) (Freund et al., 1947; Stromnes and 
Goverman, 2006a). The immunization of susceptible rodents with the antigen primes an 
autoimmune response in which reactive T-cells enter the CNS, causing myelin damage 
(Stromnes and Goverman, 2006a). Passive EAE is instead induced via the 
administration of encephalitogenic T-cells reactivated in vitro against the antigen before 
being injected in the recipient animal (Stromnes and Goverman, 2006b).  
Various factors, including genetic susceptibility, species, age and sex of the immunized 
animal, in addition to type, preparation, dose and administration route of the 
immunogen, can influence the pathogenesis, sensitivity and clinical course of EAE 
(Mannie et al., 2009). Accordingly, each animal species and type of EAE, potentially 
allows the study of one or more aspects of MS. In the majority of susceptible rodent 
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strains, the disease presents as an ascending flaccid paralysis, beginning with tail 
weakness and progressing to hind limb paralysis. In severe cases it can even lead to 
forelimb paralysis and death. However, rodents with EAE less commonly develop 
lesions in the brain or optic nerves. This pattern is unlike MS (Simmons et al., 1982), a 
point which was often ignored and that has not been entirely understood.  
Although no known animal model reflects the entire pathological spectrum of the human 
disease, EAE shows neurological signs, and immunological and histopathological 
similarities with MS (Hohlfeld and Wekerle, 2001). Both active and passive EAE are 
autoimmune-mediated models of CNS inflammation, but whether they are accurate 
models of MS remains uncertain.  
 
1.2.1.0 Active EAE 
Active EAE refers to the disease resulting from the co-injection, with adjuvant, of spinal 
cord homogenate or myelin antigens such as myelin basic protein (MBP), myelin 
proteolipid protein (PLP) or myelin oligodendrocyte glycoprotein (MOG). Active EAE 
has the advantage that, as in MS, many aspects of the acquired immune system play 
important roles, and the prominent inflammation commonly occurs in conjunction with 
the structural damage of the CNS, including demyelination and degeneration. In active 
EAE, CD4+ T-cells are primed by the interaction between the T-cell receptor and the 
injected antigen presented by MHC class II complexes in the peripheral immune 
system, leading to the differentiation of T-naïve in T helpers 1 and and 17 (Stromnes 
and Goverman, 2006a). In contrast to resting T-cells, T-cells primed for CNS-antigens 
gain the ability to enter the CNS parenchyma (Ludowyk et al., 1992; Hickey, 2001; 
Larochelle et al., 2011) via a multi-step process known as leukocyte extravasation (or 
diapedesis, described below). However, some molecular factors involved in the specific 
interaction and extravasation of these cells through cerebral capillaries and post-
capillary venules in EAE remain unknown (Wilson et al., 2010).  Briefly, leukocyte 
diapedesis involves adhesion of leukocytes to the endothelial surface (Liu et al., 2003; 
Engelhardt and Wolburg, 2004), and their migration either through the inter-endothelial 
cell junctions (paracellular migration), or through the endothelial cells themselves 
(transcellular migration) (Engelhardt and Wolburg, 2004). The first step of this process 
represents the rolling of leukocytes over the luminal surface of endothelial cells, 
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mediated by weak interactions between adhesion molecules on leukocytes (such as L-
selectin, PSGl-1 and Syalil Lewis X) and their ligands on endothelial cells (such as P-, 
E-selectin, Glycam-1, CD34 and MadCAM-1) (van Buul and Hordijk, 2004). 
Subsequently, loosely attached leukocytes can be activated by chemotactic cytokines 
presented on the apical surface of the endothelium, and firmly adhere to the 
endothelium through immobilized chemoattractants and adhesion molecules such as 
integrins on the leukocytes and CAMs on the endothelium (van Buul and Hordijk, 2004). 
Finally, leukocyte migration through the endothelial cell-cell junctions (paracellular 
extravasation) involves homophilic-binding molecules such as the JAMs, PECAM-1, 
CD99 and VE-cadherin (van Buul and Hordijk, 2004). Although there is a lack of 
evidence regarding the specific molecular components involved in the transcellular 
migration, it has been speculated that at least some molecules involved in the junctional 
migration may also play a critical role for transcellular migration (Engelhardt and 
Wolburg, 2004).  
In the CNS, infiltrated myelin-specific T-cells are reactivated via an interaction with 
resident antigen presenting cells (Wekerle et al., 1986; Stromnes and Goverman, 
2006a). Once reactivated, these cells start to produce inflammatory cytokines and 
chemokines (IL-1, IL-17, TGFβ, etc.) initiating an inflammatory cascade that recruits 
predominantly macrophages to the sites of T-cell activation (Stromnes 2006). Pro-
inflammatory mediators secreted by macrophages, such as TNFα, ROS and matrix 
metalloproteinase can also directly and indirectly (via neuroglial cells) increase the 
permeability of the BBB via disruption of the endothelial tight junctions, alteration of the 
vascular basement membrane, and increased expression of chemokines and CAMs by 
endothelial cells, resulting in a further extravasation of leukocytes into the CNS 
(Stromnes and Goverman, 2006a; Larochelle et al., 2011). Furthermore, macrophages, 
along with other inflammatory cells (such as T- and B-cells) and mediators (e.g. 
antibodies) contribute to CNS tissue damage and demyelination in EAE (von Budingen 
et al., 2001; Kuchroo et al., 2002; Stromnes and Goverman, 2006a; Fletcher et al., 
2010; O’Brien et al., 2010).  
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Active EAE is commonly used in mice and rats, producing a chronic-progressive or 
relapsing-remitting disease with demyelination, depending on the species and strain 
immunised. A common encephalitogen is MOG (or MOG peptides), a minor myelin 
component. MOG elicits an encephalitic T-cell response, but also widespread antibody-
mediated CNS demyelination (Johns et al., 1995; Gold et al., 2006), resulting in a 
chronic relapsing or progressive disease in mice (Stromnes and Goverman, 2006a).  
MOG is commonly used to induce active EAE in C57BL/6 and SJL mouse strains, 
which are maybe the most commonly used rodents for the study of MS (Stromnes and 
Goverman, 2006a). C57BL/6 is a popular strain used in EAE studies because most 
transgenic and gene knockouts are generated in this background (Al-Izki et al., 2012). 
C57BL/6 mice with active EAE develop a chronic disease in which animals rapidly 
accumulate permanent disabilities (Stromnes and Goverman, 2006a; Al-Izki et al., 
2012). The fast progression of the disease may represent a clear disadvantage, as it 
can be an endpoint for experimental design (Al-Izki et al., 2012). SJL is likewise a 
commonly used mouse strain for the induction of active EAE. Sensitization of SJL mice 
with MOG leads to a relapsing-remitting disease course in which the frequency of 
relapses can be quite variable (Brown et al., 1982; Al-Izki et al., 2012). Furthermore, 
SJL mice with active EAE undergo an aggressive disease course often characterized 
by hindlimb and forelimb paralysis that can lead to the death of the animal within a 
relatively short period after the onset of deficits (Brown et al., 1982; Al-Izki et al., 2012). 
The Biozzi AB/H mouse is another commonly used strain for the induction of active 
EAE. Although Biozzi AB/H mice respond to a variety of myelin epitopes including 
MOG, immunization with spinal cord homogenate has most consistently produced a 
high incidence of relapsing disease and does not require co-injection of pertussis toxin 
and co-adjuvant (Al-Izki et al., 2012), as instead required for the induction of active EAE 
in other mice strains such as SJL and C57BL/6 (see also below). Active EAE in Biozzi 
AB/H mice results in a predictable relapsing-remitting disease that reproduces several 
characteristics of MS (Baker et al., 1990; Al-Izki et al., 2012). The disease course in 
Biozzi AB/H mice is less aggressive compared with C57BL/6 and SJL mice with active 
EAE, and in this model relapses are more easily distinguished (Baker et al., 1990; Al-
Izki et al., 2012). Moreover, Biozzi AB/H mice with active EAE, after a first relapsing-
remitting phase, slowly develop a secondary progressive disease course in which 
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neurological disabilities accumulate concomitantly with persistent demyelination, gliosis, 
glial cell activation and neuronal loss (Baker et al., 1990; Al-Izki et al., 2012). 
Importantly, it has been shown that Biozzi AB/H mice during the progressive phase of 
EAE are resistant to immunosuppressive treatments, similarly to patients with 
progressive MS (Al-Izki et al., 2011). Thus, it represents a useful model in which to 
study the mechanisms underlying the progression of the neurological deficits in 
advanced stages of the disease, allowing the development of new therapeutic 
approaches for the treatment of patients with progressive MS (Al-Izki et al., 2012).      
MOG also induces EAE in the female dark agouti (DA) rat, and yields a relatively 
predictable and reliable disease course that, similarly with Biozzi AB/H mice, more fully 
represents the pathology and clinical course of MS than other EAE models available 
(Storch et al., 1998). DA rats are particularly susceptible to the development of EAE, 
and a single injection of MOG (50-100μg) emulsified in incomplete Freund’s adjuvant 
(IFA) is sufficient to elicit the autoimmune response in the great majority of immunised 
animals (incidence: ~95%) (Storch et al., 1998), causing an initial relapsing-remitting 
disease course followed by a chronic progression of the neurological deficits (Mannie et 
al., 2009). In contrast, C57BL/6 and SJL mice develop only a progressive or a 
relapsing-remitting disease course respectively, and they are less prone to develop 
EAE compared with DA rats. Indeed, in order to induce EAE in these mice, the 
immunogen has to be emulsified in adjuvant supplemented with inactivated 
Mycobacteria tuberculosis (complete Freund’s adjuvant; CFA), in order to enhance an 
adequate inflammatory reaction. Furthermore, higher doses of antigen are required to 
induce EAE in C57BL/6 and SJL mice, as the emulsion containing MOG has to be 
injected twice through two immunisations interspersed by 1-week (50-100μg for each 
administration) (Stromnes and Goverman, 2006a; Sadeghian et al., 2016). Moreover, 
and in contrast with DA rats (Mannie et al., 2009), in these mice the immunisations are 
usually followed by the injection of pertussis toxin to increase blood-brain barrier (BBB) 
permeability and this facilitates the immune cells and mediators to enter the CNS 
parenchyma (Stromnes and Goverman, 2006a; Sadeghian et al., 2016).   
In DA rats, it has been shown that a greater percentage of MOG-immunised animals 
can develop inflammatory-demyelinating lesions in the optic nerves (~36%) and in the 
cerebellum (~12%), in conjunction with the typical lesions in the spinal cord (Storch et 
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al., 1998). By contrast, lesions in the optic nerves and cerebellum are rarely observed 
in classically MOG-immunised mice (Stromnes and Goverman, 2006a), and only occur 
in certain strain/antigen combinations (Muller et al., 2000; Bettelli et al., 2003; Stromnes 
and Goverman, 2006a) and on a background of IFNγ deficiency (Wensky et al., 2005; 
Stromnes and Goverman, 2006a).   
Thus, MOG-immunised DA rats can represent one of the better active EAE models in 
which to study the different factors related to MS.  
  
1.2.2.0 Passive EAE 
Passive EAE is induced via an adoptive transfer of encephalitogenic CD4+ T-cells 
isolated from an actively immunised syngenic animal and injected in the proposed 
recipient (Stromnes and Goverman, 2006b). Passive immunization of rats with 
encephalitogenic T-cells reactive against MOG, yields an ascending paresis/paralysis 
of tail and hind limbs similar to active EAE, but in the absence of major structural 
damage of the CNS such as demyelination and degeneration, and in a relatively mild 
inflammatory environment (Linington et al., 1993). Indeed, one advantage of passive 
EAE relative to active EAE is the comparative immunological and pathological 
simplicity, which allows studying the effects of inflammation in relative isolation. The 
injection of encephalitogenic T-cells in naïve syngeneic rats induces an extensive T-cell 
mediated inflammatory reaction in the spinal cord (Linington et al., 1993), but a milder 
severity of the neurological deficits compared with actively induced EAE. The failure to 
induce gross neurological deficits has been attributed to the fact that passive EAE leads 
to a limited infiltration of activated macrophages in the spinal cord, which in this model 
are largely confined in the perivascular areas (Linington et al., 1993) and not widely 
diffused in the CNS parenchyma as observed in active EAE (Davies et al., 2013). 
Another aspect, can be that the passive transfer of encephalitogenic T-cells does not 
result in spinal cord demyelination (Linington et al., 1993), but demyelination only 
occurs when the T-cells are co-transferred with MOG-specific monoclonal antibodies 
(mAb) (Linington et al., 1993). Indeed, the co-transfer of MOG-specific mAb synergizes 
with the encephalitogenic T-cells, causing increased macrophage recruitment in the 
spinal cord, and white matter demyelination (Linington et al., 1993). Therefore, it has 
been suggested that the T-cells reactive against MOG are sufficient in yielding an 
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encephalitogenic (inflammatory) response in the CNS, but an autoantibody response 
against myelin is necessary to initiate demyelination (Linington et al., 1993). 
Intriguingly, the mechanisms underlying the neurological deficits, caused by the 
encephalitogenic T-cells alone, in the absence of demyelination and pronounced 
macrophage infiltration, remain unclear. 
Another important advantage of passive EAE is the possibility to label the T-cells before 
the transfer, so that their location and activity can be monitored in the recipient 
(Stromnes and Goverman, 2006b).  
 
1.3.0.0 Pathology of MS lesions 
The pathology of MS is characterized by multifocal, perivascular inflammation and 
demyelination. Demyelination was traditionally considered a white matter phenomenon, 
but now it is known that it also affects the grey matter (Lassmann, 2013). Different 
molecular mechanisms can take place in different regions of the same MS lesion 
(Lassmann, 2013), making it difficult to understand the sequence of events that initiate 
the tissue damage. Characteristics of white matter MS lesions include demyelination, 
oligodendrocytes loss, inflammation, the formation of an astrocytic scar (Lassmann, 
2013) and the preferential degeneration of small caliber axons (Evangelou et al., 2001). 
Inflammation is present at all stages of the disease, although the abundance of the 
inflammatory infiltrate and its composition can vary with the stage of disease 
(Lassmann, 2013) and it can differ between different types of MS lesions (Lucchinetti et 
al., 2000). It has been observed that the inflammatory component is more pronounced 
in patients with RRMS compared with patients in the progressive stage (Frischer et al., 
2009; Lassmann, 2013). In early stages of MS new lesions in the white matter are 
characterized by gadolinium-enhancement at MRI examination, indicating damage of 
the BBB and inflammation as driving forces (Grossman et al., 1988; Miller et al., 1988). 
In contrast, new lesions, and particularly gadolinium-enhancing lesions, become rare 
when patients have entered the progressive phase (Grossman et al., 1988; Miller et al., 
1988; Lassmann, 2013). The autoimmune and inflammatory response in MS appears 
intricate, with many cell types of the innate and adaptive immune system taking part in 
the formation and progression of the lesions. T-helper lymphocytes (Th1 and Th17) 
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have been shown to be implicated in the pathogenesis of MS and EAE, while cytotoxic 
T-cells (CD8+), B-cells/plasma cells and macrophages have been recognized to play a 
major role in the development of demyelinating lesions and the progression of 
neurological deficits (Magliozzi et al., 2007; McFarland and Martin, 2007; Ajami et al., 
2011; Hemmer et al., 2015). Relatively little is known about the role of granulocytes in 
MS, such as neutrophils, which comprise the greatest percentage of leukocytes 
circulating in the blood stream. Recent studies in MS (Naegele et al., 2012; Rumble et 
al., 2015) and EAE (Rumble et al., 2015) raised the possibility that neutrophils may play 
an important role in causing damage of the CNS. Naegele and colleagues (2012) 
reported that neutrophils in patients with MS are more numerous and they often exist in 
an activate state consisting of enhanced degranulation and activation of the oxidative 
burst. Rumble and colleagues (2015) also reported an increased number of neutrophils 
in the blood of patients with MS, and such neutrophils were characterized by elevated 
expression of CXC chemokines (such as CXCL1 and CXCL5) that correlated with the 
extension of MS lesions and the severity of clinical disabilities (Rumble et al., 2015). 
Mice with EAE deficient for the granulocyte colony stimulating factor (G-CSF) receptor 
and treated with a CXCL1 antagonist showed a reduced number of activated 
neutrophils in the blood and less severe neurological deficits compared with controls, 
suggesting that also neutrophils can play an important role in the pathogenesis of EAE 
(Rumble et al., 2015).   
Patients with RRMS are characterized by a large number of active demyelinating 
lesions in the CNS, which present elevated lymphocyte and macrophage infiltration and 
profound microglial activation (Brück et al., 1995; Frischer et al., 2009). Furthermore, 
active lesions localize in perivenular regions characterized by gadolinium enhancement 
upon MRI examination (Grossman et al., 1988; Miller et al., 1988; Noseworthy et al., 
2000). Active lesions can in turn be divided in early and late active lesions (Lassmann, 
2013). The distinction between early and late active lesions is based on the amount of 
phagocytic macrophages present in the lesion (greater in early active lesions), and the 
type of myelin-degradation products contained in their lysosomes (Brück et al., 1995; 
Lassmann, 2013). Phagocytic degradation of minor, small myelin proteins (e.g. MOG, 
and MAG) occurs rapidly, within 1 to 3 days, and the presence in macrophages of 
degradation products derived from these proteins indicates early active demyelination 
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(Brück et al., 1995; Popescu et al., 2013). By contrast, larger and more abundant 
myelin proteins such as MBP and PLP are digested more slowly and may persist in 
macrophages for up to 10 days (Brück et al., 1995; Popescu et al., 2013). Thus, the 
presence within macrophages of degradation products derived from the phagocytosis of 
major myelin proteins (PLP and MBP) in the absence of minor degradation products 
(MOG and MAG), demarcates late active lesions (Brück et al., 1995; Popescu et al., 
2013). In the area surrounding active lesions there is an initial or pre-phagocytic zone 
(Barnett and Prineas, 2004; Marik et al., 2007). Here, myelin is largely intact but there 
are apoptotic oligodendrocytes, microglial activation (Barnett and Prineas, 2004; 
Henderson et al., 2009) and cells positive for oxidized DNA and lipids (Haider et al., 
2011).  
Although sometimes the white matter of patients with MS can appear normal at a 
superficial morphological analysis or at the MRI examination, it can instead be affected 
by biochemical and histological alterations. Indeed, while no evidence of demyelination 
or leukocyte infiltration is observed in the normal appearing white matter (NAWM) of 
patients with MS (De Groot et al., 2001), other peculiar alterations can occur. The 
NAWM often shows activated clusters of microglial cells expressing MHC class-II 
molecules (De Groot et al., 2001). Furthermore, the microglial clusters are usually 
associated with stressed olidodendrocytes (van Noort et al., 2010) and elevated levels 
of inflammatory cytokines (van Horssen et al., 2012). These lesions are named pre-
active lesions and can occur throughout the CNS of patients with MS, but often develop 
in the proximity of active lesions (van Horssen et al., 2012). As not all the pre-active 
lesions progress in demyelinating active lesions, it is possible that the pre-active lesion 
may be the earliest, and potentially reversible, stage of the development of an MS 
plaque. 
Patients in the chronic or progressive stage of MS are characterized by a higher 
number of inactive lesions in the CNS (Lassmann, 2013). In these lesions the inactive 
core show extensive demyelination and axonal degeneration, and it is surrounded by a 
narrow rim of activated microglia and macrophages, few of which contain products of 
myelin degradation, suggesting a slow expansion of the lesion (Prineas et al., 2001; 
Lassmann, 2013). Furthermore, inactive lesions show both moderate perivascular cuffs 
and signs of acute inflammation (Prineas et al., 2001). Interestingly, inactive lesions are 
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particularly frequent in the cortex of patients with progressive MS (Kutzelnigg et al., 
2005). Here, lymphocytic inflammation is present in the meningeal areas proximal to 
the demyelinated plaques, while perivascular, parenchymal infiltration of lymphocytes is 
rare or absent (Magliozzi et al., 2010; Lassmann, 2013). A minor demyelinating activity 
is associated with the activated microglia at the border between the cortical plaques 
and the NAWM (Magliozzi et al., 2010; Lassmann, 2013). This observation raises the 
possibility that the cortical demyelination at late stages of the disease is induced by 
soluble factors produced by the meningeal infiltrates that activate microglial cells, which 
in turn can directly or indirectly cause demyelination (Magliozzi et al., 2007; Choi et al., 
2012; Lassmann, 2013).  
Interestingly, in the progressive phase of MS, inflammatory cells are frequently seen 
around vessels with intact BBB (Hochmeister et al., 2006; Lassmann, 2013), 
suggesting that at this stage of disease the inflammatory response could be "trapped" 
within the CNS (Lassmann, 2013). Therefore, it is possible that the “trapped” 
inflammation and other cytodegenerative processes, rather than further inflammatory 
cells entering from the periphery, can drive the expansion of lesions in the progressive 
stage of MS.     
Remyelination can occur throughout the disease (Lassmann, 2013). However, 
neuropathological studies have revealed that remyelination is more often observed at 
late stages of MS, although it is usually incomplete (Lassmann, 2013). Remyelinated 
lesions usually show weak staining for myelin upon histological examination, and they 
are often referred to as “shadow plaques” (Lassmann, 2013).     
    
1.3.1.0 Heterogeneity of MS lesions 
In addition to the previously described classification in early and late active lesions, 
early active MS lesions show additional features which can permit them to be further 
sub-classified. Lucchinetti and colleagues (2000) recognised four different subtypes 
(pattern I-IV) of active demyelinating lesions based on their histological characteristics, 
which are also suggestive of different pathogenic mechanisms (Lucchinetti et al., 2000). 
Indeed, while pattern I and II suggest an inflammatory-autoimmune aetiology, pattern III 
and IV are indicative of oligodendrocyte dystrophic causes.  
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Pattern I and II share some similarities with inflammatory-demyelinating lesions 
observed in animals with active EAE (Lucchinetti et al., 2000). In particular, in these 
subtypes of lesion, demyelination is centered on blood vessels and it is associated with 
prominent perivascular lymphocyte infiltration and partial remyelination (Lucchinetti et 
al., 2000). In addition, Pattern-II lesions present specific deposition of immunoglobulin 
and complement (Lucchinetti et al., 2000). Pattern-III lesions are also characterized by 
perivascular inflammation, but in this pattern demyelination is not centered on blood 
vessels, and a rim of myelinated axons is often preserved in the area surrounding the 
vessels (Lucchinetti et al., 2000). Furthermore, pattern-III lesions are associated with 
apoptosis of oligodendrocytes, selective loss of myelin-associated glycoprotein (MAG, a 
protein located in the innermost lamellae of the myelin sheaths) and increased 
expression of hypoxia inducible factor 1α (HIF1α) (Lucchinetti et al., 2000; Aboul-Enein 
et al., 2003). Pattern-III lesions share these characteristics with demyelinating lesions 
due to ischaemic stroke; raising the possibility that hypoxia-like events could contribute 
to its pathogenesis (Aboul-Enein et al., 2003). Pattern-IV lesions also show abundant 
inflammation, dominated by T-cells and macrophages, but this lesion subtype is 
characterized by apoptosis of oligodendrocytes specifically in a small rim of the 
periplaque, adjacent to the active lesion (Lucchinetti et al., 2000). Intriguingly, in 
pattern-IV lesions oligodendrocyte death was revealed by the presence of nuclear DNA 
fragmentation, but these cells did not show the classical morphological features of 
apoptotic oligodendrocytes (Lucchinetti et al., 2000).  
One school of thought considers that MS lesions belong to the same subtype in a given 
patient (Lucchinetti et al., 2000; Noseworthy et al., 2000). However, other investigators 
report that different subtypes of lesion can co-exist in the same patient. In particular, the 
presence of two different types of lesion has been reported in patients with MS within 
the same individual, with some lesions indicating oligodendrocyte dystrophy and others 
suggesting an inflammatory/autoimmune aetiology (Barnett and Prineas, 2004). This 
finding suggests that a stage-dependent evolution of the lesion may occur. Possibly a 
first stage is represented by a primary apoptosis of oligodendrocyte that can 
subsequently elicit a T-cell mediated inflammatory response (second stage) (Barnett 
and Prineas, 2004). 
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Interestingly, recent findings revealed that there are some mechanisms of tissue 
damage which are common in all MS lesions at all stages of the disease, such as the 
oxidative/nitrative damage and mitochondrial dysfunction (Stadelmann et al., 2005; 
Dutta et al., 2006; Marik et al., 2007; Trapp and Stys, 2009; Haider et al., 2011; 
Lassmann and Van Horssen, 2011; Fischer et al., 2012). Evidence in active EAE has 
shown that both oxidative and nitrative stress can directly harm axonal mitochondrial 
function (Nikic et al., 2011), raising the possibility that the mitochondrial impairment 
occurring in MS lesions (Mahad et al., 2008; Witte et al., 2014) can be due to similar 
mechanisms. Impaired mitochondrial function can lead to an energy crisis which can 
explain many pathological features of MS, such as demyelination, oligodendrocyte 
apoptosis, axonal degeneration and functional alterations of astrocytes and 
oligodendrocytes progenitor cells (Lassmann and Van Horssen, 2011). 
 
1.3.2.0 Energy insufficiency and mitochondrial dysfunction 
Increasing evidence suggests that an energy insufficiency may represent a key event in 
MS (Aboul-Enein and Lassmann, 2005; Mahad et al., 2008). Indeed, an insufficient 
energy supply of the CNS is hypothesized to be one of the main mechanisms involved 
in axonal degeneration (Trapp and Stys, 2009). Large amounts of ATP are produced 
via oxidative mitochondrial respiration; it represents the energy currency of the cells 
and it is required for a number of physiological processes, including signal transduction, 
ionic balance and protein synthesis and transport. It is not surprising that ATP depletion 
can have devastating consequences on cellular function and survival. Essentially, any 
mechanism that impairs ATP production during inflammatory demyelination is likely to 
result in energy insufficiency. In the CNS, ATP is of pivotal importance for the 
maintenance of the ionic membrane gradient through the activity of the Na+/K+ ATPase, 
which uses more than 50% of total CNS energy (Ames  3rd, 2000). ATP deficiency can 
severely affect the function of the Na+/K+ ATPase, potentially leading to remarkable 
alterations of vulnerable, polarised cell types such as oligodendrocytes (Kettenmann et 
al., 1983), astrocytes (Bolton et al., 2006) and neurons (Trapp and Stys, 2009). 
Impaired activity of the Na+/K+ ATPase can limit the extrusion of sodium cations from 
the cell. It has been shown that sodium cations can quickly accumulate in demyelinated 
axons due to the redistribution of sodium channels, which are normally confined in the 
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nodes of Ranvier (Ritchie and Rogart, 1977; Waxman et al., 1977), along the 
axolemma (Bostock and Sears, 1978; Foster et al., 1980; Waxman, 2006). 
Furthermore, demyelinated axons can be intrinsically more excitable than myelinated 
axons due to increased spontaneous depolarization of the membrane (Smith and 
McDonald, 1980; Felts et al., 1995; Hamada and Kole, 2015), which leads to a greater 
influx of sodium cations. In demyelinated axons, the conduction of the electric impulse 
has been suggested to be also energetically more expensive due to the need of 
restoring the trans-axolemmal Na+/K+ gradient on a larger non-myelinated surface 
(Trapp and Stys, 2009). Therefore, in demyelinated axons, both the increased axonal 
excitability and elevated energy cost to sustain the electrical conduction may cause 
mitochondrial stress.  
Elevated concentration of sodium cations into demyelinated axons, caused by the 
increased excitability and the reduced extrusion of these ions through the Na+/K+ 
ATPase, can reverse the operation of the sodium-calcium exchanger, increasing the 
influx of calcium cations (Ca2+) (Stys et al., 1992; Stys, 1998; Bechtold and Smith, 
2005; Waxman, 2006; Smith, 2007). Increased cellular concentration of Ca2+ can trigger 
cell death via either necrotic or apoptotic pathways (Orrenius et al., 2003), and it has 
been suggested as a mechanism of axonal degeneration in MS (Smith, 2007; Trapp 
and Stys, 2009). Indeed, evidence shows signs of Ca2+-mediated protease activity in 
demyelinated axons of patients with MS, such as fragmented neurofilaments, 
depolymerised microtubules and organelle disruption (Dutta et al., 2006). Interestingly, 
studies demonstrated that sodium and calcium channel blockers can protect from 
axonal degeneration (Kapoor et al., 2003).  
Mitochondrial dysfunction is increasingly recognised as a source of energy insufficiency 
and axonal damage in both acute and chronic MS lesions (Mahad et al., 2008; Witte et 
al., 2014).  Indeed, defects in the mitochondrial respiratory chain have been described 
in MS (see following). In particular, impaired activity of complex-IV has been found in 
pattern-III active MS lesions, and dysfunctional complex-I has been observed in chronic 
MS lesions (Mahad et al., 2008). In the motor cortex of patients with MS an impaired 
activity of both mitochondrial complexes-I and III has been detected, in combination 
with reduced expression of nuclear mitochondrial genes (Dutta et al., 2006). Here, the 
reduced activity of these complexes has been associated with decreased inhibitory 
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input from γ-aminobutyric acid (GABA) (Dutta et al., 2006). It is possible that GABA 
signal is implicated in the transcriptional regulation of mitochondrial genes in neuronal 
nuclei (Dutta et al., 2006). Furthermore, decreased inhibitory innervation of cortical 
neurons may exacerbate the energy deficit by increasing the firing of downstream 
demyelinated axons, which have higher than normal energy demands and an impaired 
ability to produce ATP (Dutta et al., 2006).  
Increasing evidence in MS and animal models has partially revealed the sequence of 
events that can impair the activity of axonal mitochondria during neuroinflammation. A 
recent study in active EAE, showed that depolarised mitochondria, a sign of 
mitochondrial dysfunction, can appear in non-demyelinated axons even before the 
onset of neurological deficits (Sadeghian et al., 2016). In demyelinated axons, 
mitochondria increase in number, size and speed of movement and tend to accumulate 
in demyelinated regions (Nikic et al., 2011; Ohno et al., 2014). This has been 
suggested as an axonal mitochondrial response to demyelination (Ohno et al., 2014; 
Mahad et al., 2015). It is believed that the increased number of mitochondria in 
demyelinated areas of the axon, provides energetic support to the energetically costly 
conduction in this region (Ohno et al., 2014; Mahad et al., 2015). However, as the 
disease progresses, inflammatory mediators, such as free radicals, damage the 
mitochondria causing mitochondrial DNA deletion, depolarisation of the mitochondrial 
membrane, and dysfunction of the mitochondrial respiratory chain (Dahlgren and 
Karlsson, 1999; Nikic et al., 2011; Guo et al., 2013; Mahad et al., 2015). Over time the 
mitochondrial dysfunction may be amplified via both the clonal expansion of 
mitochondria with DNA deletions and decreased levels of nuclear-derived mitochondrial 
transcripts (Dutta et al., 2006; Mahad et al., 2015); exacerbating the energy deficit in a 
vicious cycle that can lead to axonal transection and degeneration (Trapp and Stys, 
2009; Witte et al., 2014).  
A number of factors can compromise the normal activity of mitochondria (Mahad et al., 
2008; Trapp and Stys, 2009) and some of these are present during the early phases of 
an inflammatory response, including nitric oxide (NO) and reactive oxygen and nitrogen 
species (ROS/RNS) (Brown and Cooper, 1994; Cleeter et al., 1994; Bolaños et al., 
1997; Clementi et al., 1998; Haider et al., 2011; Nikic et al., 2011; Fischer et al., 2012). 
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Recently, specific types of ceramides have also been found enriched in the CSF of 
patients with MS, and these are able to impair the mitochondrial respiration of cultured 
neurons via unknown mechanisms (Vidaurre et al., 2014).  
Interestingly, Nikic and colleagues (2011) have shown that, especially at early stage of 
injury, axonal degeneration can be rescued by neutralizing the free radical-mediated 
mitochondrial damage (Nikic et al., 2011). This suggests the possibility that the 
mitochondrial dysfunction and energy deficit may be reversible, and therapies targeting 
these mechanisms could potentially protect the CNS from axonal degeneration and loss 
of neurological function. 
 
 1.3.3.0 Free radical mediators of tissue damage 
1.3.3.1 Nitric oxide and nitrative damage 
The inflammatory response is characterized by release of a number of inflammatory 
mediators that can cause tissue damage. Some of these mediators include free 
radicals, which have been found to play a direct effect in damaging the CNS during MS 
(Stadelmann et al., 2005; Marik et al., 2007; Haider et al., 2011; Lassmann and Van 
Horssen, 2011; Nikic et al., 2011; Fischer et al., 2012). An important role is played by 
nitric oxide (NO) and other NO-derived free radicals (reactive nitrogen species; RNS) 
(Smith and Lassmann, 2002; Moncada and Bolanos, 2006). NO is synthesized by an 
enzymatic reaction mediated by nitric oxide synthases (NOS) (Bredt, 1999). NOS 
catalyzes the reaction of arginine with molecular oxygen to produce citrullin and NO 
(Bredt, 1999). Three forms of NOS have been identified, named: endothelial-NOS 
(eNOS), neuronal-NOS (nNOS) and inducible-NOS (iNOS) (Alderton et al., 2001). 
eNOS and nNOS are constitutionally expressed in the CNS, as the names suggest, by 
endothelial and neuronal cells respectively, and contribute to the basal, low 
concentration of NO in the tissue (Alderton et al., 2001). In contrast, the expression of 
iNOS is transcriptionally regulated and it is responsible for the synthesis of high levels 
of NO within sites of inflammation (Koprowski et al., 1993). Interestingly, elevated 
concentrations of iNOS have been found within active MS lesions, expressed mainly by 
infiltrated macrophages and activated microglia (Stadelmann et al., 2005; Marik et al., 
2007). Furthermore, increased levels of nitrate (derived from NO) have been detected 
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in the CSF of patients with MS (Giovannoni, 1998), and they seem to correlate with the 
severity of disease (Rejdak et al., 2004). However, in chronic lesions, as the 
inflammation becomes less prominent, the expression of iNOS also diminishes 
(Oleszak et al., 1998; Smith and Lassmann, 2002).  
NO is a reactive molecule that gives rise to several other RNS, including: nitroxyl ion 
(NO-), nitrous acid (HNO2), nitrogen dioxide (NO2), peroxynitrite (ONOO-) and 
peroxynitrous acid (ONOOH) (Smith and Lassmann, 2002). The forms that NO takes at 
the site of inflammation are not known (Smith and Lassmann, 2002), so in this thesis 
we will refer to them by simply using the term “NO”. NO is a potent signalling molecule 
which plays several physiological roles, but at higher concentrations it can mediate 
tissue damage (see following). One important physiological function of NO is its potent, 
endogenous vasodilator effect (Kobari et al., 1993). During MS the vasodilator effect of 
NO may exacerbate the inflammatory response in the CNS. Indeed, vessel vasodilation 
decreases the velocity of blood flow, and this may give more time for inflammatory cells 
to adhere at the endothelial surface and migrate into the CNS parenchyma (Smith and 
Lassmann, 2002). Furthermore, it has been shown that NO can increase the BBB 
permeability (Mayhan, 2000; Martinelli et al., 2009) contributing to the extravasation of 
inflammatory cells such as lymphocytes (Martinelli et al., 2009) and mediators into the 
CNS. However, anti-inflammatory effects of NO such as the inhibition of antigen 
presentation and T-cell proliferation have also been reported (Albina and Henry, 1991; 
Sicher et al., 1994).  
NO can have direct toxic effects via a variety of molecular mechanisms that potentially 
affect all cell types. NO can damage cells by reacting with proteins, nucleic acids and 
lipids. Nitration is a common NO-mediated protein modification, and nitrotyrosine levels 
have been found increased in inflammatory lesions of patients with MS, as well as in 
animals with EAE (Liu et al., 2001; Smith and Lassmann, 2002; Schuh et al., 2014). An 
interesting protein modification mediated by NO is the S-nitrosation of cysteins, which 
can give rise to new self-antigens and antibodies against these NO-modified epitopes 
have been found increased in patients with MS (Boullerne et al., 1995). In addition, NO 
can damage nuclear and mitochondrial DNA both directly, via altering the chemical 
structure of DNA through a peroxynitrite-mediated reaction, and indirectly by inhibiting 
various DNA-repair processes (Zhang et al., 1994; Graziewicz et al., 1996). Studies in-
vitro revealed that oligodendrocytes are more susceptible than astrocytes and microglia 
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to peroxynitrite-toxicity, although they experience a similar degree of DNA damage 
(Mitrovic et al., 1994, 1995). A possible explanation can be that peroxynitrite induces 
not only strand breakdown of DNA (Zhang et al., 1994; Witte et al., 2014), but also 
triggers lipid peroxidation, which can alter the fluidity and permeability of cell 
membranes (van der Veen and Roberts, 1999). This detrimental effect may be more 
severe in oligodendrocytes given the larger surface of their plasma membrane.  
Interestingly, a study revealed that NO at elevated concentration can reversibly block 
axonal conduction of both normal and demyelinated axons (Redford et al., 1997). The 
mechanisms through which NO impairs axonal conduction are not clear, but it has been 
suggested that the conduction block may be caused by a NO-mediated structural 
modification of sodium channels (Renganathan et al., 2002; Smith and Lassmann, 
2002). In addition, an NO-mediated damage of mitochondrial function may also play a 
relevant role. NO affects mitochondria in three principal ways: reversible inhibition of 
respiration; irreversible inactivation of mitochondrial enzymes; and induction of the 
mitochondrial permeability transition (Murphy, 1999) (see also paragraph 1.3.3.2). NO 
can compete with oxygen for binding to complex-IV blocking oxidative phosphorylation 
(Cooper et al., 2003). The NO-mediated impairment of mitochondrial complex-IV in MS 
lesions has been previously defined as “virtual hypoxia” (Trapp and Stys, 2009), 
because the resulting reduction in cellular ATP synthesis can be similar to what would 
be observed in conditions of decreased oxygen supply (true hypoxia). Furthermore, NO 
may initiate a destructive cascade of peroxynitrite-mediated mitochondrial damages 
(Murphy, 1999). Peroxynitrite is generated by the reaction of NO with superoxide (O2-, a 
reactive oxygen species) (Pacher et al., 2007), and its detrimental effects on 
mitochondria are described in the next paragraph. 
1.3.3.2 Oxidative damage   
Inflammation can also generate reactive oxygen species (ROS) (Dahlgren and 
Karlsson, 1999). Superoxide (O2-) is a free radical produced by transfer of one electron 
to molecular oxygen, and it is the precursor of many other forms of ROS (Beckman and 
Koppenol, 1996). Dismutation of superoxide generates hydrogen peroxide (H2O2), 
which can be fully reduced in water, or partially reduced in the hydroxyl radical (OH-). 
The reaction between superoxide and NO can give rise to peroxynitrite (ONOO-), which 
is highly reactive and toxic for cells (Beckman and Koppenol, 1996; Murphy, 1999; 
 40 
 
Pacher et al., 2007). Inflammatory cells of the innate response can generate superoxide 
through an enzymatic reaction which occurs on the outer plasma-membrane and that 
involves NADPH oxidase and molecular oxygen, in a process known as the respiratory 
(or oxidative) burst (Dahlgren and Karlsson, 1999).  
In MS, a large amount of ROS is produced by reactive microglia and macrophages. 
Indeed, increased expression of the active form of NADPH oxidase has been detected 
in these cells within active MS lesions (Fischer et al., 2012). ROS can be generated 
also in mitochondria, particularly when these are dysfunctional (Murphy, 2009), a 
condition that has been well characterized in MS (Mahad et al., 2008). Some 
components of the mitochondrial electron transport chain can leak electrons and such 
electrons can be directly transferred to molecular oxygen forming superoxide (Murphy, 
2009). The rate of superoxide production is dependent from the amount of molecular 
oxygen available (Murphy, 2009). Interestingly, it has been shown that hypoxia, as well 
as hyperoxia, can exacerbate oxidative stress through mechanisms that are not entirely 
clear (Xu et al., 2004; Strapazzon et al., 2016) (see also Chapter 5; paragraph 5.3.0.0). 
ROS can mediate a variety of mechanisms toxic for the cells, including DNA (Cooke et 
al., 2003) and lipid (Ayala et al., 2014) oxidation. Notably, these markers of oxidative 
damage have been found to be increased within active MS lesions (Haider et al., 2011; 
Fischer et al., 2012). As mentioned before, ROS can also severely damage 
mitochondria (Nikic et al., 2011; Witte et al., 2014). Here, ROS can either damage 
mitochondrial constituents directly, oxidizing mitochondrial DNA and lipids, or form 
peroxynitrite by reacting with NO (Smith, 2011). Peroxynitrite can permanently nitrate 
tyrosine residues of mitochondrial proteins, affecting their functionality (Smith, 2011). In 
addition, peroxynitrite can irreversibly damage mitochondria by reacting with iron-
sulphur domains contained in respiratory chain complexes I, II and III, and in Kreb’s 
cycle enzymes (Hausladen and Fridovich, 1994; Radi et al., 1994; Rubbo et al., 1994; 
Lizasoain et al., 1996; Murphy, 1999). Peroxynitrite can also induce mitochondrial 
calcium efflux by oxidizing the thiols of mitochondrial membrane proteins that can finally 
lead to the mitochondrial permeability transition (Packer and Murphy, 1994, 1995; 
Scarlett et al., 1996; Murphy, 1999). The mitochondrial permeability transition is 
induced by oxidative stress in conjunction with elevated calcium, and consists in the 
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formation of a 2–3nm diameter protein pore in the mitochondrial inner membrane with 
subsequent depolarization, swelling of the mitochondrion, and release of solutes from 
the matrix (Murphy, 1999; Biasutto et al., 2016). Depolarization of mitochondria and 
induction of the permeability transition cause the release in the cytosol of elevated 
amount of Ca2+ (Gunter et al., 1994; Richter et al., 1994). Indeed, mitochondria are 
particularly enriched in Ca2+ because they directly modulate cellular Ca2+ 
concentrations acting as a sink for excessive cytosolic-Ca2+ (Gunter et al., 1994; 
Murphy, 1999). Increased cytosolic Ca2+ concentrations, caused by mitochondrial 
damage, can cause cell death via both apoptotic and necrotic pathways (Orrenius et al., 
2003). Moreover, damaged mitochondria can in turn produce more ROS, which can 
further damage the mitochondria and the surrounding tissue, setting up a vicious cycle 
(Smith, 2011).  
In addition, as the generation of ROS and RNS involves the use of molecular oxygen as 
substrate, their production in sites of inflammation can deprive the surrounding tissue of 
oxygen, causing hypoxia. Therefore, in MS, the increased expression of enzymes 
involved in the synthesis of both ROS and NO/RNS, in combination with evidence of 
dysfunctional mitochondria, suggest a high risk of an energy deficit within MS lesions 
(Trapp and Stys, 2009). 
 
1.3.4.0 Inflammatory mediators of tissue damage: TNFα-mediated 
necroptosis 
The level of pro-inflammatory cytokines such as TNFα has been shown to be increased 
in active MS lesions as well as in the serum and CSF of patients with MS (Sharief and 
Hentges, 1991). TNFα and TNFα-related apoptosis-inducing ligands (TRAILs) activate 
caspase-8 and -10, pro-apoptotic enzymes that lead to the assembly of a multi-protein 
death-induced signal complex (DISC), culminating in the endoproteolysis of several 
cellular proteins and the formation of apoptotic bodies which are then cleared from the 
tissue by scavenger cells (Dhib-Jalbut and Kalvakolanu, 2015). However, under 
conditions of failed caspase activation, possibly due to the inhibition caused by FLICE-
inhibitor protein (cFLIP) and/or oxidized caspase active sites (Dhib-Jalbut and 
Kalvakolanu, 2015) it has been shown that TNFα can lead to cell death also via a finely 
 42 
 
regulated necrotic pathway, which has been defined as necroptosis (Pasparakis and 
Vandenabeele, 2015; Newton and Manning, 2016). Although it has been shown that 
necroptosis can be activated by a number of pro-inflammatory stimuli including IFNs, 
Toll-like receptors, TRAILs and Fas-ligands the molecular pathway triggered by TNFα 
is the better characterized one and it will be discussed here (Pasparakis and 
Vandenabeele, 2015; Newton and Manning, 2016; Su et al., 2016). In MS, it has been 
shown that necroptosis occurs in oligodendrocytes (Selmaj and Raine, 1988; Jurewicz 
et al., 2005; Dhib-Jalbut, 2007) and neurons (Dhib-Jalbut and Kalvakolanu, 2015) within 
active lesions and it is largely triggered by the activation of the TNFα receptor-1 
(TNFR1) (Sharief and Hentges, 1991; Dhib-Jalbut and Kalvakolanu, 2015; Ofengeim et 
al., 2015). Upon activation of TNFR1 and under apoptosis deficient conditions (inactive 
caspase-8), the kinase RIPK1 interacts with RIPK3 to induce its phosphorylation and to 
form a RIPK1/RIPK3-containing complex, known as complex IIb or necrosome, a 
critical regulator of necroptosis (Dhib-Jalbut and Kalvakolanu, 2015; Ofengeim et al., 
2015). The necrosome phosphorylates mixed-lineage kinase like (MLKL), which can 
then form trimers that are able to penetrate cell membranes creating pores in the 
membrane of the cells and organelles (Dhib-Jalbut and Kalvakolanu, 2015). These 
pores permeabilize cellular contents causing the release of solutes (such as Ca2+) from 
organelles and the consequent osmotic swelling and necrosis of the cell (Dhib-Jalbut 
and Kalvakolanu, 2015). In addition, RIPK3 can activate, by phosphorylation, a number 
of enzymes such as glycogen phosphorylase, glutamate-ammonia ligase, and 
glutamate dehydrogenase, resulting in high levels of ROS production that in turn can 
further cause mitochondrial damage and a necrotic demise of cells (Dhib-Jalbut and 
Kalvakolanu, 2015). Recently, Ofengeim and colleagues (2015) showed that the 
inhibition of RIPK1 protects from oligodendrocyte death both in-vivo (in mice with active 
EAE) and in-vitro, suggesting that targeting RIPK1 and the necroptosis pathway may 
represent a new therapeutic strategy for MS (Ofengeim et al., 2015).  
  
1.4.0.0 The integrated stress response 
Inflammation, ROS/RNS, endoplasmic reticulum (ER) stress, energy deficiency and 
hypoxia are all factors that can cause severe cellular stress (Donnelly et al., 2013). In 
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the CNS of patients with MS, all these factors can potentially occur and stress 
susceptible cells. Cells try to counteract the stress insult by activating a number of 
molecular mechanisms that form the so-called integrated stress response (Way et al., 
2016). The hallmark of integrated stress response is the phosphorylation of the 
eukaryotic initiation factor 2α (eIF2α) (Lin and Popko, 2009), a key player in protein 
synthesis. The phosphorylation of eIF2α (p-eIF2α) leads to a reduction in the rate of 
general protein synthesis, but selectively promotes the transcriptional expression and 
translation of cytoprotective and cell-repairing genes (Lin and Popko, 2009; Donnelly et 
al., 2013). Therefore, the integrated stress response protects cells by reducing normal 
physiological activities (such as protein synthesis), focusing the cellular efforts on 
mechanisms that increase cellular endurance. However, if the stress persists, a 
prolonged inhibition of the protein synthesis is not sustainable, pro-apoptotic genes are 
expressed and the cell dies (Tabas and Ron, 2011).  
The activation of the integrated stress response has been reported in several 
neurodegenerative disorders, including Alzheimer disease, Parkinson disease, cerebral 
ischemia and MS (Roussel et al., 2013). Histological analyses of CNS samples of 
patients with MS, revealed increased levels of p-eIF2α predominantly in activated 
microglia, macrophages and astrocytes within the lesions (Allen et al., 2001; Kutzelnigg 
et al., 2005; Cunnea et al., 2011; McMahon et al., 2012; Ní Fhlathartaigh et al., 2013), 
and such increased p-eIF2α expression has been also associated with the expression 
of hypoxia-related markers (McMahon et al., 2012). Elevated levels of p-eIF2α have 
been detected also in mice with active EAE, and especially in neurons and 
oligodendrocytes (Chakrabarty et al., 2004). Notably, oligodendrocytes appeared to be 
particularly susceptible to the activation of the integrated stress response during active 
EAE (Chakrabarty et al., 2004; Lin and Popko, 2009). Indeed, while oligodendrocytes 
are mainly negative for p-eIF2α upon histological examinations in healthy mice, p-eIF2α 
expression increases significantly during active EAE (Chakrabarty et al., 2004; Lin and 
Popko, 2009). It is possible that the MS studies did not detect oligodendrocytes positive 
for p-eIF2α (Allen et al., 2001; Kutzelnigg et al., 2005; Cunnea et al., 2011; McMahon et 
al., 2012; Ní Fhlathartaigh et al., 2013) due to the advanced stage of disease at which 
the samples were examined. Probably in these studies, olidogendrocytes within the 
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inspected MS lesions had already undergone cell death, but eIF2α phosphorylation in 
oligodendrocytes could have occurred at earlier stages.  
Studies in active EAE have revealed that the integrated stress response in 
oligodendrocytes can be triggered by the inflammatory cytokine interferon-γ (IFNγ), via 
activation of the protein RNA-like endoplasmic reticulum kinase (PERK) (Lin and 
Popko, 2009). In mice with active EAE, Lin and colleagues demonstrated that 
augmented release of IFNγ in the CNS increases PERK activation and eIF2α 
phosphorylation particularly in oligodendrocytes, and this phenotype is rescued in 
mouse knockouts for the expression of PERK (Lin et al., 2006, Lin et al., 2012; Lin and 
Popko, 2009). Interestingly, the investigators observed that the IFNγ-mediated 
enhancement of the integrated stress response can both ameliorate and exacerbate the 
progression of EAE, dependent upon whether the stress response is induced before or 
after the onset of the disease (Lin et al., 2006, 2007). In particular, IFNγ 
preconditioning, before the onset of neurological deficits in actively immunized EAE 
mice, delays the onset and attenuates the severity of disease by both reducing 
demyelination and promoting oligodendrocyte survival (Lin et al., 2007). By contrast, 
treatment with IFNγ during the symptomatic-phase in mice with active EAE exacerbates 
disease progression, worsens demyelination and impairs remyelination and 
oligodendrocyte survival (Lin et al., 2006; Roussel et al., 2013). Possibly, the stress 
preconditioning of the CNS prepares oligodendrocytes to face the upcoming injury, 
whereas, once the disease is established, a persistent inhibition of protein synthesis 
may impair the self-repair capacity of oligodendrocytes, suppress remyelination, and 
lead to apoptosis.   
      
1.5.0.0 Cerebral blood flow and oxygenation 
The brain has a high demand for energy, such that although it comprises only 2% of 
body weight it takes 20% and 25% of the total oxygen and glucose consumption 
respectively, and 15% of cardiac output (Clarke and Sokoloff, 1999). The adequate 
supply of nutrients and oxygen to the CNS is guaranteed by a finely regulated cerebral 
blood flow (CBF). CBF promptly increases in activated areas of the CNS in order to 
provide a sufficient supply of nutrients to ratify increased demand; for example, CBF 
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increases in the visual cortex after a visual input (Ances et al., 1999; Lu et al., 2004) or 
in the motor cortex during finger movement (Allison et al., 2000). Evidence has shown 
that under physiological conditions, cerebral activity is followed by a 50% local increase 
in both CBF and glucose uptake, but only a 5% increase in oxygen consumption (Fox 
and Raichle, 1986; Fox et al., 1988). More recently, elevated lactate concentration has 
been detected in activated areas of the brain (Figley and Stroman, 2011), suggesting 
that at least part of the energy demand is fulfilled by glycolysis (Figley and Stroman, 
2011). Lactate is emerging as an important energy source for the CNS (Schurr et al., 
1999; Smith et al., 2003; Gallagher et al., 2009; Bélanger et al., 2011). Complexes 
designated for the entrance and oxidation of lactate, such as the monocarboxylate 
transporter isoforms 1 and 2 (MCT-1 and 2) and lactate dehydrogenase (LDH), have 
been found expressed in the inner membrane of neuronal mitochondria, and associated 
with components of oxidative respiration (Hashimoto et al., 2008). Recent observations 
suggest that neurons can even “prefer” lactate over glucose when both are available 
(Itoh et al., 2003; Bouzier-Sore et al., 2006; Bélanger et al., 2011) and utilize lactate as 
a metabolic substrate for oxidative phosphorylation (Walz and Mukerji, 1988; Magistretti 
and Pellerin, 1999; Schurr, 2006). Recently, oligodendrocytes have been suggested to 
supply lactate to axons (Fünfschilling et al., 2012; Jones, 2012; Lee et al., 2012). Axons 
have very high-energy demands but are isolated from extracellular metabolites by their 
myelin sheaths (Jones, 2012). Therefore, it is possible that axons depend on energy 
substrates provided by oligodendrocytes (Jones, 2012). Oligodendrocytes produce 
lactate via anaerobic glycolysis (Fünfschilling et al., 2012; Lee et al., 2012), and the 
lactate may then be transferred to axons via the MCT-1 expressed in the myelin 
sheaths (Lee et al., 2012). Then, axons could use lactate (as well as glucose) in 
mitochondrial oxidative phosphorylation in order to accomplish their energy need.   
More than 90% of the oxygen imported into the brain is used by mitochondria for 
oxidative phosphorylation to produce energy in the form of ATP (Sciamanna and Lee, 
1993). The process of oxidative phosphorylation yields up to 34 moles of ATP from just 
one mole of glucose compared to a meager two moles of ATP for every mole of glucose 
produced via anaerobic glycolysis. It has been estimated that almost 80% of the ATP is 
utilized to support electrical (e.g. synaptic) activity (Sibson et al., 1998; Rothman et al., 
2003), most of which is consumed by the Na+/K+ ATPase, while the other 20% is used 
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to maintain basic cellular and neuronal functions such as protein synthesis (Attwell and 
Laughlin, 2001). Therefore, an adequate and continuous supply of nutrients and oxygen 
is essential to maintain neuronal survival and normal brain function. Accordingly, 
cessation of oxygen and glucose supply leads to unconsciousness within less than 10 
seconds (Clarke and Sokoloff, 1999). It is understandable why oxygen is essential to 
ensure an efficient rate of energy production.  
 
1.6.0.0 Hypoxia and the CNS 
Hypoxia refers to a decrease in the availability of inspired oxygen, or decreased oxygen 
tension (oxygen partial pressure, PaO2) within the tissue (LaManna, 2007). At 
physiological pressure of inspired oxygen (around 16 kPa), arterial haemoglobin is 
almost saturated with oxygen (97-99%), and even a slight decrease in the ambient 
oxygen does not influence the haemoglobin saturation, so that tissue oxygenation 
remains the same (LaManna, 2007). In mild hypoxic conditions (below 12 kPa but 
above 6 kPa), successful long-term adaptation occurs, and it is these adaptations that 
allow mammals to live at high altitudes (e.g. up to 3500 meters of altitude) (LaManna et 
al., 2004). However, at oxygen pressures between 4 and 6 kPa (e.g. up to 5000 m of 
altitude) permanent brain damage may occur. Indeed, longer exposure at severe 
hypoxic conditions (below 4 kPa; e.g. at more than 5000 m of altitude) cause loss of 
consciousness and neurodegeneration (Fayed et al., 2006; LaManna, 2007; Di Paola et 
al., 2008). Systemic compensatory changes begin in response to mild hypoxia including 
increased ventilation, increased erythropoiesis, decreased core temperature and weight 
loss (LaManna et al., 2004); furthermore organ-specific compensations also occur. To 
maintain normal tissue oxygenation, the CNS regulates regional and total blood flow at 
a constant rate over a wide range of blood pressures, through a process known as 
“cerebral auto-regulation” (Johnston and Czosnyka, 2003). These adaptations include 
increased CBF (Kety and Schmidt, 1948) and cerebral blood volume (CBV) (Shockley 
and LaManna, 1988; Julien-Dolbec et al., 2002). Furthermore, neovascularisation 
occurs approximately after 1 week of prolonged hypoxia (LaManna et al., 2004). The 
increased vascular bed is not the only factor that enhances the intake of metabolites 
into the tissue. Indeed, angiogenesis is accompanied by an increased expression of 
 47 
 
glucose transporter-1 (GLUT-1) on endothelial cells (Xu and Lamanna, 2006) that 
results in a greater migration of glucose from the bloodstream into the CNS.  
 
1.7.0.0 Hypoxia and MS 
Increasing evidence suggests that hypoxia and an energy deficit may occur in patients 
with MS and contribute to the pathogenesis and progression of CNS lesions. As 
mentioned before (paragraph 1.3.1.0), Lucchinetti et al. (2000) have demonstrated that 
demyelinated Pattern-III MS lesions present “hypoxia-like” characteristics showing 
pathological similarities with white matter lesions forming due to ischaemic stroke 
(Aboul-Enein et al., 2003). In pattern-III lesions, increased expression of HIF1α, 
predominantly in oligodendrocytes, astrocytes and some endothelial cells (Aboul-Enein 
et al., 2003), can be indicative of an actual low concentration of oxygen (see 
introduction 1.10.1.0). Interestingly, a microarray study disclosed the over-expression of 
other hypoxia-related genes in the NAWM of patients with MS (Graumann et al., 2003), 
raising the possibility that tissue hypoxia may be an early feature of newly forming 
lesions. However, these findings have been typically attributed to an energy deficit 
resulting from NO-mediated mitochondrial dysfunction (virtual hypoxia), rather than an 
actual insufficiency of oxygen (true hypoxia) within the lesion. 
Interestingly, the brain of patients with MS can suffer from reduced blood perfusion 
(reviewed in D’haeseleer et al., 2015). It is easy to image that diminished blood supply 
to the CNS can cause hypoxia. Initially, it was suggested that the decreased CBF in 
patients with MS was a consequence of the decreased metabolic demand due to 
axonal degeneration and CNS atrophy. However, recent evidence has shown that in 
MS, the NAWM can also suffer from a number of alterations in cerebral 
haemodynamics including prolonged arterial bolus arrival time (Paling et al., 2014) and 
decreased CBF (Varga et al., 2009; D’haeseleer et al., 2015). Varga and colleagues 
(2009) observed reduced CBF in the NAWM of patients with MS already in the first five 
years of disease, and before the formation of sub-cortical grey matter lesions. These 
findings suggest that the widespread reduction in cerebral blood perfusion is not 
secondary to axonal degeneration and brain atrophy. However, the mechanisms 
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underlining the cerebral hypoperfusion in MS remain enigmatic, and they will be 
discussed later in this thesis (Chapter 5; paragraph 5.1.0.0).  
Although further studies are needed to disclose the sequence of events leading to 
cerebral hypoperfusion in MS, it is becoming clearer that perfusion abnormalities are 
present even at the very early stages of disease, when loss of neuronal activity is still 
not prominent and CNS atrophy is absent (reviewed in D’haeseleer et al., 2015). If so, 
the decreased CBF may not be a consequence of tissue loss and reduced cell activity 
that would require less blood supply, but rather, it may be a factor involved in causing 
tissue damage and disease progression.  
 
1.8.0.0 Hyperbaric oxygen treatment in MS 
The suggestion that hyperbaric oxygen therapy (HBOT) could slow or reverse the 
progression of MS, has led to a number of clinical trials in which HBOT was tested in 
patients with MS. The early use of HBOT in MS was clearly not based on the recent 
observations that MS lesions can have hypoxia-like characteristics (Lucchinetti et al., 
2000; Aboul-Enein et al., 2003; Aboul-Enein and Lassmann, 2005) or suffer of reduced 
blood perfusion (D’haeseleer et al., 2015) and energy deficit (Trapp and Stys, 2009). 
Instead, HBOT in MS was taken in consideration in part because some MS lesions 
share similarities, including perivenular location of the lesions and vessel reactivity, with 
lesions caused by gas embolism and decompression illness in which HBOT has 
therapeutic beneficial effects (Bennett and Heard, 2010), and in part because HBOT 
has been shown to have an immunosuppressive effect in rats with active EAE (Warren 
et al., 1978).  
HBOT efficacy in MS was evaluated in several clinical trials during the 1980’s (Fischer 
et al., 1983; Murthy et al., 1985; Massey et al., 1985; Neiman et al., 1985; Wood et al., 
1985; Confavreux et al., 1986; Harpur et al., 1986; Wiles C. M., Clarke C. R. A., Irwin H. 
P., 1986; Barnes et al., 1987; Oriani et al., 1990). All these trials examined the role of 
HBOT in patients with chronic MS, the treatment consisted in exposure to hyperbaric 
oxygen-enriched (~70%) air at pressures between 1.75 and 2.5 ATA for only 60-90 
minutes per day, for a maximum of 20 exposures in total. Interestingly, some trials 
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reported beneficial effects after treatment (Fischer et al., 1983; Murthy et al., 1985; 
Barnes et al., 1987; Oriani et al., 1990). These beneficial effects were usually transient 
and mainly included improvements in bladder functionality, fatigue, and in few cases 
also in motor functions. Only in one trial (Fischer et al., 1983) was a long-lasting 
beneficial effect achieved, and the disease severity was attenuated up to six months 
after treatment cessation. However, a number of other independent trials reported no 
changes in disease severity after the administration of HBOT (Massey et al., 1985; 
Neiman et al., 1985; Wood et al., 1985; Confavreux et al., 1986; Harpur et al., 1986). 
Recently, Bennett and Heard (2010) performed a critical meta-analysis of all the data 
arising from these trials in order to establish whether HBOT is a valid treatment for MS, 
or not. They did not identify plausible benefits of HBOT on the clinical course of MS, 
concluding that the routine treatment of MS with HBOT is not recommended (Bennett 
and Heard, 2010), despite that some neurologists and MS patients claimed a beneficial 
effect of HBOT in ameliorating the neurological deficits.  
Some weak aspects in the design of HBOT clinical trials can be identified, and they can 
possibly explain the overall failure of those trials. First, the number of MS patients 
examined in each trial was small. Indeed, the majority of the trials included only 30-60 
patients with MS (Fischer et al., 1983; Murthy et al., 1985; Wood et al., 1985; 
Confavreux et al., 1986; Oriani et al., 1990), in some cases even less than 30 patients 
were examined (Massey et al., 1985; Neiman et al., 1985), while only Wiles (1986) and 
Harpur (1986) included a slightly bigger number of patients in their trials, respectively 
88 and 82 patients with MS. Interestingly, Barnes and colleagues (1987) examined the 
efficacy of HBOT in a relatively larger number of patients with MS (n = 120), and their 
study was one of the trials that disclosed the greatest, though transient, beneficial effect 
(Barnes et al., 1987). This raises the possibility that only a subgroup of patients with 
MS can benefit from HBOT and therefore a clinical trial that employs a larger cohort of 
patient is more likely to be informative. Second, as mentioned before, HBOT was tested 
only in patients with chronic MS. The advanced stage of disease may have reduced the 
efficacy of the therapy given that in patients with chronic MS, it is unlikely to achieve an 
amelioration of the neurological deficits. In support to these hypotheses, a recent trial 
with HBOT, that included a large cohort of patients with MS, was performed in the 
2000s and the results were recently published (2009) exclusively online (no authors 
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formally recognized; reviewed in Bennett and Heard, 2010). In this trial, 703 patients 
with MS were examined, of which: 417 with chronic-progressive, 43 with chronic-static 
and 167 with relapsing-remitting MS (Bennett and Heard, 2010). Thus, also different 
stages of MS were considered. Interestingly, transient improvements at the disability 
score were detected in many patients exposed to HBOT and in particular in the ones 
with RRMS (Bennett and Heard, 2010). Therefore, it is possible that HBOT may be 
effective in a subgroup of MS patients and mainly when administered during the acute 
phase of disease. This aspect may not have been clearly identified at the time of the 
clinical trials conducted in the 1980’s, due to the advanced stage of  disease and the 
small number of patients examined.  
In addition, the hyperbaric pressures of oxygen could have affected the efficacy of the 
therapy in MS. It is now known that high concentrations of inspired oxygen result in 
increased arterial PaO2 proportional to the pressure at which oxygen is administered 
(Nemoto and Betterman, 2007). Indeed, higher pressures of inspired oxygen 
correspond to greater concentrations of oxygen freely dissolved in the plasma (Nemoto 
and Betterman, 2007). Although HBOT can result in a greater oxygenation of the tissue 
compared with normobaric oxygen, recent evidence has shown that HBOT can 
exacerbate the oxidative/nitrative damage in disease characterized by prominent 
inflammation such as ischemic stroke (Singhal, 2007; Ding et al., 2014). Therefore it is 
possible that HBOT could also worsen oxidative damage occurring in active MS 
lesions. Interestingly, studies in animal models (S. Liu et al., 2006; Shin et al., 2007) 
and patients (Singhal et al., 2005) with ischaemic stroke revealed that, in contrast with 
HBOT, oxygen therapy at normobaric pressure ameliorates the neurological deficits 
without exacerbating the oxidative damage (reviewed in Weaver and Liu, 2015), and it 
is especially effective when applied in the acute phase of disease (Singhal, 2007). 
These findings raise the possibility that normobaric oxygen may be beneficial for the 
treatment of MS, and possibly have fewer side effects than HBOT.   
 
1.9.0.0 Hypoxia in EAE 
In a recent study, Davies et al. (2013) have demonstrated that the spinal cord of rats 
with active EAE is hypoxic. The findings have shown that tissue hypoxia is 
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quantitatively, temporally, and spatially associated with the expression of neurological 
deficits (Davies et al., 2013). The methods have detected tissue hypoxia both ex-vivo, 
labeling spinal cord sections for markers of hypoxia (pimonidazole and HIF-1α), and in-
vivo, recording the oxygen tension via a microelectrode oxygen-sensitive probe inserted 
in the spinal cord (Davies et al., 2013). Furthermore, an enlargement of the spinal blood 
vessels during the first days of EAE was noticed, followed by an increase in vessel 
number during relapse, consistent with the observations regarding hypoxia (Davies et 
al., 2013). Indeed, in hypoxic conditions a prompt vasodilation occurs to increase the 
local blood supply and then new vessels form to provide a richer vascular bed in the 
hypoxic region (Xu and Lamanna, 2006). Similar changes in the vasculature were 
observed also in MS (Holley et al., 2010).  
Interestingly, the hypoxia appeared to contribute to neurological dysfunction, because 
upon administration of normobaric oxygen-enriched air, hypoxia has been promptly 
reversed and notably the severity of the deficits was also reduced (Davies et al., 2013). 
These findings suggest that improving the oxygenation of inflammatory lesions may be 
beneficial as a therapy in MS. The further evaluation of the effects resulting from the 
administration of normobaric oxygen-enriched air in neuroinflammatory disease, and 
the optimization of the treatment, are fundamental topics of this thesis.  
  
1.10.0.0 Markers of tissue hypoxia 
Although hypoxia plays a key role in the pathophysiology of a number of diseases, it is 
not routinely measured, in part due to limitations associated with conventional invasive 
methods such as oxygen microelectrodes. However, the expression of a number of 
genes is altered in response to hypoxia (Leonard et al., 2003; Manalo et al., 2005; Xia 
et al., 2009) and they can be used as indirect markers to disclose hypoxic tissue. In 
particular, the transcription factor HIF1α plays a key role in the adaptive response to 
low oxygen concentration, and, therefore, its presence within the tissue is often used as 
an indicator of hypoxia. Pimonidazole, a chemically stable drug that can cross the BBB, 
is sometimes used in tumour studies and represents another means to detect tissue 
hypoxia. This drug is thought to facilitate the measurement of oxygen gradients at the 
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cell level. The mechanisms of action of HIF1α and pimonidazole will be discussed in 
further detail below.  
 
1.10.1.0 Hypoxia inducible factor 1-alpha (HIF1α) 
HIF1 is a heterodimeric transcription factor formed by two constitutively expressed 
subunits, namely HIF1α and HIF1β (Wang et al., 1995; Semenza, 2002). HIF1α and 
HIF1β are continuously expressed within the cell, but only HIF1α is subjected to an 
oxygen-dependent regulation (see following). In normoxic conditions, two conserved 
prolines (P402 and P564) in HIF1α are hydroxylated by prolyl hydroxylate enzymes 
(PHDs) in a reaction that consumes oxygen as substrate (Schofield and Zhang, 1999). 
Hydroxylated HIF1α is ubiquitinated by an E3 ligase (von Hippel-Lindau protein, VHL) 
and consequently degraded into the proteasome (Figure 1.1) (Maxwell et al., 1999; Ivan 
et al., 2001; Jaakkola et al., 2001; Klimova and Chandel, 2008). This mechanism 
contributes to maintaining a very low level of HIF1α in cells. Another oxygen-dependent 
control of HIF1α is mediated by the hydroxylation of a conserved asparagine (N803) on 
the c-terminal transactivation domain (CAD) (Figure 1.1) (Coleman and Ratcliffe, 2007). 
CAD is essential for recruiting the co-transcription factors p300 and CREB-binding 
protein (CBP) with which HIF1 binds the DNA and activates the transcription of 
hypoxia-responsive genes, but, when CAD is hydroxylated this function is inhibited 
(Figure 1.1) (Coleman and Ratcliffe, 2007; Klimova and Chandel, 2008). The factor 
inhibiting HIF (FIH) is responsible for the hydroxylation of CAD, and similarly to PHD, 
FIH requires oxygen to catalyze the reaction (Figure 1.1) (Schofield and Ratcliffe, 2004) 
During hypoxia, PHD and FIH have not enough oxygen to exert their activity. Therefore 
stabilized HIF1α accumulates within the cell and translocates into the nucleus where it 
binds the HIF1β subunit, forming the transcriptionally active factor HIF1 (Masson and 
Ratcliffe, 2003). HIF1 recruits the co-transcriptional factors p300 and CBP (Figure 1.1), 
and activates the expression of specific genes via the interaction with hypoxia 
responsive elements (HRE) in their promoter regions (Masson and Ratcliffe, 2003; 
Klimova and Chandel, 2008). HIF1 mediates the expression of a variety of genes 
involved in the adaptation of cells to hypoxia, including genes implicated in energy 
metabolism, cell growth, survival and migration (Coleman and Ratcliffe, 2007). Studies 
in-vitro have estimated that HIF1 directly and indirectly regulates the expression of 
 53 
 
more than 50% of the genes responding to hypoxia (Coleman and Ratcliffe, 2007). For 
example, HIF1 enhances the synthesis of vascular endothelial growth factor (VEGF), a 
pro-angiogenesis factor, and the endothelial expression of glucose transporter-1 
(GLUT-1) (Elvidge et al., 2006). The several adaptation mechanisms to hypoxia that 
derive from the stabilization of HIF1α make this factor the master regulator of the tissue 
response to hypoxia.  
 
Figure 1.1 - Regulation of HIF1α activity in response to cellular oxygen levels. 
In normoxic conditions, oxygen availability allows PHD-dependent hydroxylation of two 
conserved prolines (P) of HIF1α. This post-translational modification makes HIF1α ubiquitinated 
by VHL and consequently degraded into the proteasome. Oxygen allows also FIH to inactivate 
via hydroxylation of a conserved asparagine (N) the CAD domain of HIF1α. Inactivated CAD 
impairs the transcriptional function of HIF1α. In hypoxia, deficiency of oxygen impairs the activity 
of both PHD and FIH. Therefore, HIF1α is not degraded and its CAD domain remains active. 
Stable HIF1α translocates into the nucleus where it dimerizes with HIF1β and binds, at the CAD 
level, co-transcriptional factors such as p300 and CBP, activating the expression of genes 
involved in the response to hypoxia. The image was adapted from Masson and Ratcliffe, 2003.  
 
Although HIF1α stabilization within cells is oxygen dependent, recent findings have 
shown that during hypoxia its expression can also be increased by pro-inflammatory 
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stimuli and that HIF1α can be involved in the control of the inflammatory response (see 
following). In naïve T-cells, HIF1α has been discovered to be a key factor regulating the 
diffentiation of T-naïve cells in Th17, and to inhibit directly T-naïve to T-regulatory 
(Treg) cell polarisation via degradation of the Forkhead Box-P3 transcription factor 
(Dang et al., 2011; Shi et al., 2011; Clambey et al., 2012). It has been demonstrated 
that in naïve T-cells, the inhibition of HIF1α leads to Treg polarization, which 
consequently enhances an anti-inflammatory response (Dang et al., 2011). 
Interestingly, Dang et al. (2011) showed that HIF1α knockout mice have a reduced 
incidence of developing EAE upon rMOG immunization, and when sick, these mice 
experience milder deficits compared with wild-type controls. At the peak of neurological 
deficits, in these mice the draining lymph nodes, spleen and CNS were found 
significantly enriched in Treg and impoverished in Th17, in contrast with EAE wild-type 
mice (Dang et al., 2011).  
HIF1α has been reported also to be involved in monocyte-to-macrophage differentiation 
(Riboldi et al., 2013). Recent studies have demonstrated that pro-inflammatory 
cytokines (e.g. TGFβ and IL-6), microbial products (e.g. lipopolysaccharide, LPS), and 
hypoxia can induce monocytes to undertake a M1 pro-inflammatory differentiation via a 
HIF1α/NFkb dependent pathway (Sica and Mantovani, 2012; Poitz et al., 2013; Riboldi 
et al., 2013; Tugal et al., 2013). By contrast, the inhibition of HIF1α and the presence of 
anti-inflammatory signals (e.g. IL-4 and IL-10) can lead monocytes to M2 alternative 
activation (Lawrence and Natoli, 2011; Sica and Mantovani, 2012; Poitz et al., 2013; 
Riboldi et al., 2013; Tugal et al., 2013). M2 macrophages express general markers of 
macrophage activation (e.g. ED-1) and are involved in tissue repair by producing 
extracellular matrix molecules, anti-inflammatory cytokines and more recently it has 
been discovered that they are also implicated in the stimulation of oligodendrocyte 
progenitor cells to differentiate and repair demyelinating lesions (Verreck et al., 2006; 
Parsa et al., 2012; Miron et al., 2013). Briefly, the overexpression and stabilization of 
HIF1α in inflammatory precursor cells has been associated with the acquisition of a pro-
inflammatory phenotype. Accordingly with these recent discoveries, HIF1α can be 
considered a double-edged sword in inflammatory diseases. From a therapeutic 
perspective, the time-point of HIF1α modulation appears crucial. In MS, it has been 
suggested that before the inflammatory reaction occurs, a preventive activation of 
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HIF1α via hypoxic preconditioning may protect from the formation of new lesions 
(Stadelmann et al., 2005; Dore-Duffy et al., 2011) and HIF1α has been demonstrated to 
protect the brain from ischaemic damage in animal models of stroke (Wacker et al., 
2012; Monson et al., 2014), possibly by making tissue more resistant to the upcoming 
energy deficit. Vice versa, when the triggering factor of the inflammatory response is 
already present (for e.g. after EAE immunisation), a later inhibition of HIF1α may be 
beneficial, as has been shown in models of autoimmune-inflammatory diseases such 
as rheumatoid arthritis (Yang et al., 2014) and EAE (Dang et al., 2011), possibly limiting 
the ability of naïve inflammatory cells (monocytes and T-cells) to acquire a pro-
inflammatory phenotype.  
 
1.10.2.0 Pimonidazole 
Pimonidazole is a probe that allows the immunohistochemical detection of tissue 
hypoxia. Pimonidazole consists in a chemical compound that, when administered 
intravenously can readily reach all tissues in the body, including the CNS (Arteel et al., 
1998). In the presence of adequate oxygen concentration, pimonidazole is oxidised to 
an amine oxide, or conjugated to sulphate groups or glucuronic acid by 
sulfotransferases and glucuronyl transferases respectively (Figure 1.2) (Arteel et al., 
1998). Oxidised or conjugated pimonidazole is then excreted from the body (Arteel et 
al., 1998). Alternatively, pimonidazole can be also reduced by nitroreductases such as 
NADPH and NADH to form the nitro-intermediate pimonidazole compound (Figure 1.2) 
(Arteel et al., 1998). At this stage, oxygen is the limiting factor. At adequate oxygen 
concentrations, the nitro-intermediate is oxidised back to pimonidazole by oxygen, 
preventing further reduction of the pimonidazole nitro-intermediate (Arteel et al., 1998). 
By contrast, if the concentration of oxygen into the cell is low, the pimonidazole nitro-
intermediate is further reduced by nitroreductases, gaining the ability to bind thiol-
containing molecules, such as glutathione and proteins, forming stable adducts (Figure 
1.2) (Arteel et al., 1998). These pimonidazole adducts can be detected in 
immunohistochemistry by using specific antibodies (Arteel et al., 1998). The localization 
of these pimonidazole adducts can disclose both the cell types and tissue area 
suffering of hypoxia, while the intensity of the labelling may be suggestive of the degree 
of hypoxia.     
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Figure 1.2 - Pimonidazole metabolism in-vivo. 
In vivo, under normoxic conditions, pimonidazole is rapidly metabolised and eliminated from the 
body, by oxidation or conjugation. b) In the absence of oxygen, pimonidazole is reduced by 
nitroreductases to a nitro-intermediate. However, oxygen concentration is the limiting factor at 
this point, and can oxidise the nitro-intermediate back to pimonidazole (c). In hypoxic cells, the 
nitro intermediate is subject to a series of reductions (d), until reduced pimonidazole can bind to 
thiol (SH-) containing molecules resulting in the formation of pimonidazole adducts (e). Adapted 
from Arteel et al., 1998. 
 
Pimonidazole is used to disclose tissue hypoxia in tumour studies (Raleigh et al., 1998; 
Wykoff et al., 2000; Janssen et al., 2002; Airley et al., 2003; van Laarhoven et al., 
2006). A number of studies have demonstrated a correlation between the localization of 
pimonidazole adducts and the expression of endogenous markers of tissue hypoxia 
(Raleigh et al., 1998; Wykoff et al., 2000; Janssen et al., 2002; Airley et al., 2003; van 
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Laarhoven et al., 2006). For example, in cervical carcinoma, pimonidazole labelling 
significantly correlated with the expression of HIF1α and GLUT-1 (Airley et al., 2003) 
whereas it did not correlate with the expression of VEGF (Raleigh et al., 1998). It 
seems that the correlation between pimonidazole labelling and the expression of other 
endogenous markers for tissue hypoxia is variable, and it may depend on the model 
and organ examined. Furthermore, while the expression of endogenous markers 
related to hypoxia can be affected by other stimuli, the formation of pimonidazole 
adducts is strictly dependent to the oxygen availability within the cell, making this 
marker one of the best ways to detect tissue hypoxia.  
 
1.11.0.0 Hypothesis and aims 
Our hypothesis is that cerebral hypoxia in MS and EAE can contribute to neurological 
deficits and CNS damage. We have investigated whether reversing cerebral hypoxia, 
by increasing the concentration of oxygen in the inspired air or by the systemic 
administration of a haemoglobin-based oxygen carrier, it is possible to ameliorate the 
neurological disabilities and reduce CNS damage. To examine this hypothesis we used 
two animal models of MS, namely active and passive EAE.  
The aims of this study are 1) to evaluate whether oxygen treatment can ameliorate 
neurological deficits due to EAE, and to identify the optimal timing and duration for the 
treatment, and 2) to examine the effects of oxygen on the pathology of the disease with 
particular regard to inflammation, demyelination, oxidative stress, hypoxia and 
metabolic changes.   
  
 58 
 
CHAPTER 2 
2. NORMOBARIC OXYGEN-ENRICHED AIR FOR THE 
TREATMENT OF NEUROLOGICAL DEFICITS IN AN 
INFLAMMATORY DEMYELINATING MODEL OF MULTIPLE 
SCLEROSIS 
 
2.0.0.0 Background 
Studies have revealed that demyelinating lesions in MS can have different appearances 
(Lucchinetti et al., 2000; Lassmann, 2013). Four distinct patterns of demyelination have 
been identified, with some indicating an autoimmune aetiology (Pattern I and II), while 
others are characterized by diffuse oligodendrocyte dystrophy (Pattern III and IV) in 
some cases suggestive of a hypoxic cause (Pattern III). Notably, Pattern III lesions 
show similarities with ischaemic stroke injury including 1) the preferential loss of the 
myelin protein MAG, 2) lesion non-centered around venules with 3) a rim of preserved 
myelin in the surrounding (and therefore better oxygenated) regions of blood vessels 
and 4) the over-expression of hypoxia related antigens (Lucchinetti et al., 2000; Aboul-
Enein et al., 2003). Interestingly, a gene expression comparison between patients with 
MS and healthy controls has revealed a consistent upregulation of genes associated 
with hypoxic adaptation of the NAWM in MS, thus indicating the presence of tissue 
hypoxia also in non-demyelinating areas of the CNS parenchyma (Graumann et al., 
2003). More recently, MRI studies have revealed that the brain of patients with MS can 
be characterized by altered cerebral hemodynamics (D’haeseleer et al., 2015) 
consistent with reduced blood perfusion. These and other evidence suggest that the 
CNS can suffer an energy failure during MS (Paling et al., 2011; Witte et al., 2014), 
raising the possibility that at least some neurological deficits may be due to tissue 
hypoxia and an energy crisis.  
A recent study from our group has shown that the spinal cord of rats with active EAE is 
strongly immunolabelled for markers of tissue hypoxia (HIF1α and pimonidazole) and 
interestingly, it suffers from an actual reduction of oxygen concentration (Davies et al., 
2013). Importantly, Davies and colleagues have shown that by simply giving rats 
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normobaric oxygen-enriched air to breathe, it is possible to restore normal oxygenation 
of the spinal cord and reverse tissue hypoxia.  
Here, we hypothesized that the administration of normobaric oxygen-enriched air (in 
this thesis referred simply as “oxygen”) may represent a therapeutic approach for the 
treatment of the neurological deficits due to inflammatory demyelinating disease. To 
investigate this possibility we used an inflammatory-demyelinating model of MS, namely 
active EAE. 
  
2.0.1.0 Aims 
• To determine the efficacy of oxygen treatment in improving neurological function 
in rats with active EAE.  
• To explore the optimal timing and duration of oxygen exposure for the treatment 
of neurological dysfunction in active EAE. 
• To evaluate the effects of oxygen administration on the pathology 
(demyelination, inflammation and metabolic changes) of active EAE. 
• To determine the consequences of oxygen administration with regard to 
oxidative and nitrative damage due to active EAE. 
 
2.1.0.0 Material and methods 
2.1.1.0 Animal model: induction of active EAE 
Female Dark Agouti (DA; n = 173; 8-9 weeks-old, ~150g, Harlan, UK) rats were kept in 
standard cages with food and water ad libitum on a twelve hour light - dark cycle. One 
week was left between the arrival of the rats and the induction of active EAE, to 
acclimatize the rats to their new environment. Active EAE was induced by a 
subcutaneous injection at the base of the tail of 100μg of rMOG (MOG1-124; synthetised 
in the laboratory of Prof Christopher Linington, University of Glasgow) in incomplete 
Freund‘s adjuvant (IFA) (Davies et al., 2013). Control animals received an injection of 
IFA and saline emulsion alone. Rats that developed cerebellum-like neurological 
dysfunction, which is difficult to score using our behavioural tests (see below), were 
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excluded. All experiments were performed in accordance with the UK Animals 
(Scientific Procedures) Act of 1986, and the ARRIVE guidelines. 
 
2.1.2.0 Behavioural assessment of the neurological deficits 
All behaviour assessments and analysis were performed blinded. Disease progression 
was monitored on a daily basis, including assessment of general health (weight) and 
neurological function. Neurological function was assessed using a 10-point behavioural 
test. One point was given for each of the following neurological signs: tail tip weakness, 
tail weakness, tail paralysis, absence of toe spreading reflex, abnormal gait, left and 
right hind limb paresis, left and right hind limb paralysis and moribund (Davies et al., 
2013). To assess neurological function before and after treatment in more detail, a 30-
point scale was also used, and a score from 0 to 2 points per hind limb was given for 
each of the following functions: stretch withdrawal, toe spreading reflex, spasticity and 
plantar placement, whereas 0 to 3 points were given for pinch withdrawal and 
nociception. Tail paresis and paralysis (0 - 3 points), nociceptive response to tail pinch 
(0 - 3 points), flexion of the hip (0 - 2 points), paralysis per forelimb (0 – 2 points) were 
also tested. Zero indicates normal function, while ascending scores indicate increasing 
disabilities. 
 
2.1.3.0 Therapeutic oxygen administration 
Oxygen treatment was administered by placing the animals in a chamber (Biospherix, 
USA) with defined raised oxygen concentration. Control rats were kept in a similar 
chamber containing room air (21% oxygen). Therapeutic treatment with oxygen was 
administered after the onset of neurological deficit. To assess the optimal timing and 
duration of the therapy, independent trials were performed as described below. 
2.1.3.1 1-hour oxygen treatment 
To study the acute effect of oxygen therapy, 95% oxygen was administered for 1 hour 
to rats with active EAE (n = 10) at the peak of disease, alternating with 1 hour of room 
air before and after oxygen exposure. For a more detailed analysis of the efficacy of 
oxygen the enhanced 30-point neurological scale was employed to assess the 
neurological deficits before and after the treatment. 
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2.1.3.2 24 hours oxygen treatment 
To study the effects of timing on the efficacy of oxygen treatment, rats with active EAE 
(n = 72) were randomly assigned to receive either room air or 75% oxygen for 24 hours, 
starting at different stages of disease progression (first, second or third day from onset 
of deficits, n = 12 per group). All animals were perfused at the end of the treatment 
period and the spinal cords were collected for histological analysis. IFA control animals 
receiving either oxygen for 24 hours (n = 4) or room air (n = 4) were added for 
comparison.  
2.1.3.3 24, 48 and 72 hours of oxygen treatment from the onset of 
deficits 
To study the effects of duration on the efficacy of oxygen treatment, two independent 
trials of active EAE were performed (n = 74). In the first trial (n = 28) rats with active 
EAE were randomly assigned to receive 75% oxygen for 24 (n = 6), 48 (n = 8) or 72 (n 
= 7) hours from the first day of deficits, and active EAE rats that did not receive oxygen 
(room air, n = 7) were used as controls. All animals were returned to room air after 
cessation of oxygen treatment and monitored up to the ninth day of disease (second 
peak of disease) to assess the long-term effects of oxygen treatment. In the second trial 
(n = 36), rats with active EAE were also treated with oxygen (75%) for 24 (n = 10), 48 (n 
= 9) or 72 (n = 9) hours from the onset of disease or exposed to room air (n = 8), but in 
this case animals were perfused three days after the onset of deficits (first peak of 
disease) for histological analysis aimed to investigate the acute effect of the therapy on 
the disease. IFA controls (n = 8) were added for comparison. 
 
2.1.4.0 Prophylactic oxygen administration 
To evaluate the role of oxygen treatment on the pathogenesis of the disease, rats with 
active EAE (n = 16) were randomly assigned to receive either oxygen (75%, n = 8) or 
room air (n = 8) from the day of the immunization (before the onset of deficits) up to 23 
days post-immunisation (second peak of disease). 
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2.1.5.0 Tissue processing and histology 
At the end of the experiment (at times indicated previously), animals were deeply 
anaesthetized with isoflurane (5%) and intracardially perfused with 0.1 M phosphate 
buffer saline (PBS) containing heparin, followed by fixation with 4% paraformaldehyde 
(PFA) in PBS. Following perfusion, the spinal cords were excised and post-fixed in 4% 
PFA overnight. Tissue was subsequently transferred into 30% sucrose in PBS solution 
for five days for cryoprotection. The spinal cords were embedded in blocks with 
TissueTek O.C.T and frozen in 2-methylbutan (Sigma, UK) in liquid nitrogen at -150° C. 
Tissue blocks were stored at -80°C prior to cryosectioning (12 μm transverse sections) 
and immunohistochemical examination. 
2.1.5.1 Neuropathology and immunohistochemistry 
Basic neuropathological evaluation was performed on luxol fast blue (LFB) staining. 
The frozen sections were air dried for more than one hour and dehydrated through a 
graded alcohol scale (50%, 70%, 90% and 100% ethanol). They were then incubated in 
neat LFB solution (BDH 34044, BDH International, UK) in acidified 95% ethanol at 50° 
C overnight. On day 2, tissues were washed in running tap water and differentiated in 
saturated lithium carbonate for 10 seconds to remove the staining from non-myelinated 
tissue. Where needed, sections were counterstained with Harris‘s haematoxylin (VWR 
International, UK). Each step was followed by washing in running tap water.  
Immunohistochemistry was performed on frozen sections air dried for more than one 
hour, and rehydrated in PBS for at least 5 minutes. Next, the sections were incubated in 
0.3% hydrogen peroxide (H2O2; Sigma-Aldrich, USA) in neat methanol (BDH 
International, UK) for 15 minutes, with gentle agitation, to block endogenous 
peroxidase. Only the sections labelled for 8-OHdG (see below) were not incubated in 
H2O2 as recommended in the manufacturer’s instructions (Trevigen; cod. 4354MC050). 
Where necessary, the sections were treated twice with 1mg/ml sodium borohydride 
(NaBH4; VWR International, UK) for 5 minutes to reduce aldehyde binding to antigens 
due to PFA fixation. Each step was followed by washing with PBS. All sections were 
incubated in the appropriate blocking buffer for at least 15 minutes, to decrease non-
specific antibody binding, before incubation with primary monoclonal or polyclonal 
antibodies, diluted in the same blocking buffer, overnight at 4°C. Negative controls were 
incubated with blocking buffer alone. The following day, all sections were washed in 
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PBS prior to incubation with a biotinylated anti-mouse, anti-rabbit or anti-goat 
secondary antibody, diluted to 1/200 in the appropriate blocking buffer, for at least an 
hour at room temperature (RT). Next, the sections were incubated with avidin-
peroxidase complex (Vectastain Elite: Vector Laboratories Ltd, USA), for at least one 
hour at RT. PBS washes were carried out between each step. Finally, the sections 
were exposed to the 3,3'-diaminobenzidine (DAB) reaction mixture (Vector DAB kit; 
Vector Laboratories Ltd, USA). When the developing brown colour appeared optimal, 
the sections were quickly immersed in tap water to stop the reaction, and then washed 
for an additional 10 minutes in PBS. Dehydration through graded alcohol to xylene was 
performed, before mounting in DPX medium (VWR International, UK). Positive controls 
were used where available to ensure the staining method was operating as expected. 
Immunolabelling of myelin was performed by using an antibody against myelin 
oligodendrocyte glycoprotein (MOG). Microglial activation and macrophage infiltration 
was detected using a primary antibody against ED-1. Free radical injury mediated by 
activated microglia and macrophages was detected using antibodies for: inducible nitric 
oxide synthase (iNOS), 8-hydroxy-2'-deoxyguanosine (8-OHdG) and oxidized 
phospholipids (E06). Changes in the vasculature were evaluated using the rat 
endothelial cell antigen-1 (Reca1); hypoxia was detected using antibodies against 
hypoxia inducible factor-1α (HIF1α), while the activation of the glycolytic pathway was 
studied using anti-phosphofructokinase-2 (PFK-2). Application and dilution of the above 
primary antibodies are reported in Table 2.1. 
2.1.5.2 Immunofluorescence 
Air-dried sections of the spinal cords were rehydrated with PBS for a minimum duration 
of 5 minutes. The sections were then washed twice with NaBH4 (in PBS, 1mg/ml) for 5 
minutes each. PBS washes were carried out between each step. Next, sections were 
incubated with the appropriate blocking buffer, for a minimum of 30 minutes at room 
temperature, before incubation with primary antibodies diluted in the appropriate 
blocking buffer, overnight at 4°C. Negative controls were incubated in blocking buffer 
alone overnight. The next day, following three washes of PBS, the sections were 
incubated in secondary Alexa fluor 568 donkey anti-mouse IgG (1/200; Invitrogen) and 
Alexa fluor 488 donkey anti-goat IgG (1/200; Invitrogen). Single labelling with a mouse 
anti-cluster of differentiation 3 (CD3) was used to mark T-lymphocytes (T-cells). Double 
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labelling included the following primary antibody combinations: mouse anti-neuronal 
nuclei (NeuN) with goat anti-phosphorylated eukaryotic initiation factor 2α (p-eIF2α); 
and mouse anti-adenomatous poli coli protein (clone CC1) with goat anti p-eIF2α. 
Application and dilution of the primary antibodies are reported in Table 2.2. 
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Antibody Origin Target Marker Dilution Source 
8-OHdG Mouse (mAb) 
8-hydroxy-2'-
deoxyguanosine 
Oxidized DNA/RNA, 
oxidative damage 1/200 
Trevigen; 
4354MC050 
CC1 Mouse (mAb) 
Adenomatous poli coli 
protein,clone CC1 
Oligodendrocyte cell 
body 
1/200 Abcam; ab16794 
CD3 Mouse (mAb) Cluster of differentiation 3 T-lymphocytes 
1/200 AbD Serotec; 
MCA772 
E06 Mouse (mAb) Oxidized phospholipids Oxidative damage 
1/200 Avanti; 330001 
ED-1 Mouse (mAb) Rat CD68 
Activated microglia and 
macrophages 
1/200 AbD Serotec; 
MCA341G 
HIF1α Rabbit (pAB) Hypoxia inducible factor-1α Tissue hypoxia 
1/200 Abcam; ab85886 
iNOS Rabbit (pAB) 
Inducible nitric oxide 
synthase 
inflammation, nitrative 
damage 
1/200 BD Laboratories; 
NB300-605 
MOG Mouse (mAb) 
Myelin oligodendrocyte 
glycoprotein Myelin 
1/500 Millipore; MAB5680 
NeuN Mouse (mAb) Neuronal nuclei Neuronal cell body 
1/200 Millipore; MAB377 
peIF2α Goat (pAb) 
Phosphorylated eukaryotic 
initiation factor-2α 
Integrated stress 
response  
1/200 Santa Cruz; 
sc12412 
PFK-2 Goat (pAb) Phosphofructokinase-2 Glycolisis  
1/200 Santa Cruz; 
sc10091 
Reca1 Mouse (mAb) 
Rat endothelial cell 
antigen-1 Blood vessels 
1/200 Abcam; ab22492 
Table 2.1 - Primary antibodies.  
Antibodies were used on rat tissue for immunohistochemistry and/or immunofluorescence as 
described in the material and methods above. mAb = monoclonal antibody, pAb = polyclonal 
antibody. 
 
2.1.6.0 Microscopy and histological analysis 
Tissue stained with DAB and LFB was viewed using an Axiophot light microscope 
(Zeiss, Germany) and pictures taken with a Nikon D300 camera (Nikon, USA). 
Quantification was carried out on 5 different levels of the spinal cord for a total of 10 
sections per rat (sacral, lower lumbar, upper lumbar, lower thoracic and upper thoracic; 
2 sections per level, 120μm apart). ImageJ software (NIH, USA) was used for image 
analysis. All quantification was carried out in a blinded manner. Analysis of the immuno-
reactivity for ED-1, iNOS, HIF1α, PFK-2, 8-OHdG and E06 was done by making the 
images binary, tracing the area around the whole spinal cord sections with the freehand 
selection tool, before counting the number of pixels above a set threshold and 
expressing the result in percentage coverage of the total cross-sectional spinal cord 
area. Quantification of RECA1 was performed on binary converted images, with the 
automated analyse particles tool, to quantify the number and size of vessels. LFB and 
MOG analysis for demyelination was done by tracing the area around the white matter 
of the spinal cords and measuring the surface covered by LFB or MOG labelling above 
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a set threshold. This area was then subtracted from the total area and expressed as the 
percentage of demyelination of the total white matter. Where no clear demyelinated 
lesions were detected, a value of zero was given. Fluorescently labelled tissue was 
viewed, and images acquired, using an AxioImager-Z.2 confocal microscope (Zeiss, 
Germany). Immunofluorescent labelling was quantified on 4 spinal cord sections per rat 
at the lumbar level (2 sections for the lower and upper lumbar level respectively; 
sections in the same spinal cord region were distant 120μm). CC1/peIF2α co-labelling 
was analysed by counting positive cells within the dorsal column and the anteromedian 
white matter of the spinal cord. The percentage of double-positive cells was calculated 
by normalizing the number of cells double positive for CC1/p-eIF2α against the total 
number of CC1 positive cells. CD3 labelling was quantified by counting the number of 
positive cells within the dorsal column and the anteromedian white matter of the spinal 
cord. Isolated groups of CD3 positive cells were considered “clusters” and quantified on 
the entire surface of the spinal cord cross-sections. Both the number and the size of 
such clusters were considered. The size of CD3 clusters was quantified by measuring 
the area covered by CD3 signal above a set threshold. All immunofluorescent analyses 
were carried out using DAPI to distinguish cells from unspecific labelling artefacts. The 
quantifications among the different sections of spinal cord were averaged within each 
rat and used for statistical analysis.  
 
2.1.7.0 RT-PCR 
Rats with active EAE (n = 10) were either treated with oxygen (75%, n = 5) for 72 hours 
from the onset of disease or kept in room air (n = 5, controls). IFA rats (n = 6) were 
added for comparison. At the peak of disease (three days after onset), all rats were 
perfused in PBS-heparin and the spinal cords were snap frozen on dry-ice. RNA was 
extracted from 2 cm frozen sections at the level of the lumbar spinal cord enlargement, 
using TRIzol Plus purification kit (12183555). RNA quality and integrity was measured 
using the Agilent Bioanalyzer 6000 Nano LabChip platform. cDNA was synthesized 
using the Qiagen QuantiTect® Reverse Transcription Kit following the manufacturer’s 
instructions. Cycling parameters were as follows: first cycle (DNA wipeout step) 42°C 
for 2 min, after adding reverse transcriptase, reaction buffer and primer mix second 
cycle: 42°C for 20min, then 3 min for 95°C. Primers were designed from sequences 
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from the NCBI nucleotide data base, using NCBI Primer Designing Tool software. 
Primer sequences were tested with BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and 
were purchased from Integrated DNA Technologies (UK). Real-time PCR was 
performed using 1X SYBR Green master mix (Applied Biosystems, USA), 10ng cDNA 
template, 50 pmol/µl of forward and reverse primers, and distilled water. The reaction 
was amplified in an Applied Biosystems Fast Real-Time PCR System (ABI 7500, USA) 
using the following cycle settings: 50°C for 5 min, 95°C for 10 min, followed by 40 
cycles of 95°C for 15 seconds, 60°C for 1 minute, and a final dissociation step at 95°C 
for 15 seconds. Melt curve analysis was then performed between 75–99°C in 1°C 
increments. The comparative CT method (or the 2-ΔCT method) was used to determine 
differences in gene expression between control and treated EAE rats. IFA controls were 
used for comparison. RT-PCR primers and conditions are summarized in Table 2.2. 
Gene Full name Primer sequences Size (bp) 
Annealin
g (°C) Gene bank 
Arg1 Arginase-1 FW: 5’-CATATCTGCCAAGGACATCG-3’ RV: 5’-GGTCTCTTCCATCACTTTGC-3’ 142 56 NM_017134.3 
Ccr5 C-C chemokine receptor 5 
FW: 5’-GAAGGTGAGACATCCGTTCCC-3’ 
RV: 5’-CAGACGTCCCCTCAGGATTTC-3’ 126 60 NC_005107.4 
Foxp3 Forkhead box P3 FW: 5’-TTCTCAAGCACTGCCAAGCA-3’ RV: 5’-GTCTCCGCACAGCAAACAAG-3’ 291 60 NM_001108250.1 
IFNγ Interferon-γ FW: 5’-GCCCTCTCTGGCTGTTACTG-3’ RV: 5’-CCAAGAGGAGGCTCTTTCCT-3’ 112 60 NM_138880.2 
IL-2 Interleukine-2 FW: 5’-CCAAGCAGGCCACAGAATTG-3’ RV: 5’- ACCACAGTTGCTGGCTCATC-3’ 208 60 NM_053836.1 
IL-12b Interleukine-12b FW: 5’-ACCTCTGCCGAAGTCCAATG-3’ RV: 5’-AAGCCTCCTCTTAGCCTCCA-3’ 172 60 NC_005109.4 
IL-17a Interleukine-17a FW: 5’-CATCCATGTGCCTGATGCTG-3’ RV: 5’-GCCTCCCAGATCACAGAAGG-3’ 265 59 NM_001106897.1 
IL-23 Interleukine-23 FW: 5’-ATGACCAGCTTCCTTCCACC-3’ RV: 5’-TCACCTCACCTCGTTGTTCC-3’ 198 60 NC_005106.4 
iNOS Inducible nitric oxide synthase 
FW: 5’-GAGACGCACAGGCAGAGG-3’ 
RV: 5’-CAGGCACACGCAATGATGG-3’ 121 60 NM_012611.3 
Mhc1 
Major 
histocompatibility 
complex-1 
FW: 5’-TGACCAACCTTTCCACAGCAT-3’ 
RV: 5’-CAAGACCAGAGCATCACACCA-3’ 198 60 NC_005112.4 
TNFα Tumor necrosis factor-α 
FW: 5’-CCCCTTTATCGTCTACTCCTCA-3’ 
RV: 5’-TTCAGCGTCTCGTGTGTTTC-3’ 134 58 NM_012675.3 
Table 2.2 - RT-PCR primers and conditions.  
Abbreviations are: FW = forward primer; RV = reverse primer. 
 
2.1.8.0 Statistical analysis 
Graphpad Prism v6.0 (USA) was used for statistical analysis and graph generation. All 
graphs represent mean ± S.E.M. (standard error of the mean). All statistical analyses 
were two-tailed and considered significant when p < 0.05. The non-parametric Mann 
Whitney U-test was used to compare the severity of neurological deficits between 
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groups of treatment. Parametric tests were used for histological and RT-PCR analysis 
as following. Independent t-test was used when only two groups were compared. One-
way ANOVA with multiple comparison tests was used to compare multiple groups when 
only one variable was present (e.g. group of treatment). Two-way ANOVA with multiple 
comparison tests was used when multiple groups were compared and more than one 
variable (e.g. group of treatment and stage of disease) were taken in consideration. 
Dunnett’s correction was used to compare groups of treatment with the control and 
Sidak’s correction was used to analyse differences between groups.  
 
2.2.0.0 Results 
2.2.1.0 1-hour of oxygen treatment promptly improves neurological 
function 
To evaluate the acute effect of oxygen on neurological deficits, rats with active EAE (n 
= 10) were treated with 1 hour of 95% oxygen-enriched air at different levels of disease 
severity (n = 3 with impairment of tail motility, n = 3 with tail paralysis and hind limb 
paresis, and n = 4 with tail and hind limb paralysis). For a more detailed analysis of the 
efficacy of oxygen we employed the enhanced 30-point neurological scale as described 
in the material and methods (paragraph 2.1.2.0). The oxygen treatment was preceded 
and followed by 1 hour of room air.  One rat experienced an exacerbation of the 
neurological deficits during the first hour in room air (Figure 2.1), but during the 
following hour in oxygen, 5 out of 10 rats (1 mild, 1 moderate, 3 severe) improved in 
tail, hind limb motility and/or nociceptive perception, suggesting that oxygen can 
promptly ameliorate the neurological function even in paralysed rats (Figure 2.1; p = 
0.02). However, the neurological deficits returned when the rats were restored to room 
air for the next hour (Figure 2.1), highlighting a specific but transient beneficial effect of 
1-hour oxygen exposure. The remaining rats showed no changes in oxygen (or room 
air).  It remains unclear why some animals responded to oxygen and others did not.  
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Figure 2.1 - 1 hour of oxygen treatment (95%) at the peak of disease decreases 
neurological deficits in rats with active EAE.  
Rats with active EAE were exposed to 1 hour of 95% oxygen treatment at the peak of disease. 
The treatment was preceded and followed by 1 hour of room air. Neurological function was 
assessed using a 30-point behavioural test after each hour, and expressed as a difference in the 
absolute score after 1 hour compared with the score before entering in treatment. Blue lines 
represent changes in neurological score for single animals. Zero represents no changes in 
neurological function, whereas positive and negative scores represent an exacerbation or an 
improvement of neurological deficits respectively. Oxygen treatment promptly decreased 
neurological deficits from 1 up to 5 points at the behavioural test in 50% of treated rats after 1 
hour of exposure (p = 0.02). The beneficial effect disappeared when rats were returned in room 
air for another hour. Mann-Whitney U-test; n = 10. 
 
2.2.2.0 Timing of oxygen treatment: 24 hours of oxygen exposure at 
different stages of disease 
To explore what would be the optimal time to start the treatment, two independent trials 
of active EAE (Trial1: n = 18; Trial 2: n = 54) were performed. Rats with active EAE 
were randomly sorted to receive 75% oxygen or room air for 24 hours, from either the 
first, second or third day of disease (Trial1: n = 3 per group; Trial2: n = 9 per group). 
Both trials showed similar effects of oxygen treatment on the disease progression and 
the data were grouped and considered together as discussed below (Figure 2.2; n = 72, 
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12 per group). Interestingly, oxygen ameliorated disease progression regardless of 
whether the treatment was started on the first, second or third day of disease, 
compared with cohort controls maintained in room air (Figure 2.2). Indeed, we observed 
that rats breathing room air were affected by a more severe disease course after 24 
hours than animals treated with oxygen (Figure 2.2a-d). Interestingly, a significant 
amelioration of the disease progression was achieved when rats were treated at the 
first day of deficits. The improvement consisted of a 30% decrease, in the behavioural 
test, in the severity of neurological deficits compared with controls (Figure 2.2a, d; p = 
0.034). In this group, all room air controls accumulated new disabilities after 24 hours, 
experiencing an increase in score of up to 8 points upon neurological testing (mean 
difference in score after 24 hours = +4.25 ± 0.71; Figure 2.2d). In contrast, 3 out of 12 
rats treated with oxygen on the first day of disease did not develop further deficits, and 
the other 9 animals experienced a milder exacerbation of the disease compared with 
controls, showing an increase of neurological deficits of maximum 4 points upon 
neurological testing (mean difference in score after 24 hours = +2.08 ± 0.54; Figure 
2.2a, d).  A pronounced, although non-significant amelioration of the neurological 
deficits (reduction of 19% upon neurological testing) was also observed in rats treated 
with oxygen from the second day of disease compared with time-matched controls 
(Figure 2.2b). At this stage, 4 animals in both room air and oxygen-treated groups did 
not develop new deficits; 8 room air controls worsened in their deficit after 24 hours, but 
only 5 rats treated with oxygen progressed in disease severity. None of the rats 
exposed to room air improved after 24 hours, but 3 animals treated with oxygen at the 
second day of disease improved, with a decrease in score of up to 2 points (mean 
difference in score after 24 hours: room air = +1.91 ± 0.51, oxygen = +0.50 ± 0.49; 
Figure 2.2b, d). When the treatment started at the third day of disease, a decrease in 
the mean neurological score was observed in both oxygen-treated rats and room air 
controls (mean difference in score after 24 hours: room air = -0.5 ± 0.47, oxygen = -
0.75 ± 0.41; Figure 2.2c, d), indicating an overall spontaneous remission of the disease. 
Oxygen administration at this stage of disease resulted in a mild, non-significant 
improvement (8% in the neurological deficit score) of the neurological function 
compared with room air controls. Thus, although amelioration in neurological deficit was 
observed after therapy independently from the time-point of treatment initiation, the 
greatest improvement was achieved when oxygen was applied at the first day of 
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deficits, suggesting that the treatment at the very onset of disease expression may 
produce the best therapeutic effect.  
To evaluate further the effects of oxygen on the pathology of the disease, the spinal 
cord of rats included in Trial1 and 2 were collected and analysed histologically for 
markers of demyelination, inflammation, hypoxia, and for vascular and metabolic 
changes.  
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Figure 2.2 - 24 hours of oxygen (75%) treatment ameliorates the expression of 
neurological deficits when administered at the first, second or third day of disease.  
a- c) Neurological deficit score of rats with active EAE exposed to oxygen or room air for 24 
hours on either the first, second or third day of disease. Oxygen alleviated the disease 
progression compared with time-matched room air controls, irrespective of the stage of disease 
it was administered. d) Change in neurological deficit score shows that oxygen-treated rats 
experienced a milder exacerbation of neurological dysfunction after 24 hours compared with 
room air controls, and significantly milder when treatment started on the first day of disease (p = 
0.034), compared with controls. Change in score was calculated as the difference between the 
absolute score before and after the treatment. Mann-Whitney U-test. N = 12 per group. 
  
2.2.2.1 Spinal cord demyelination after 24 hours of oxygen 
administration at different stages of disease 
We examined demyelination using the luxol fast blue (LFB) staining for myelin in spinal 
cord cross-sections of rats included in the study described above. LFB is a copper 
phthalocyanine dye which binds lipoprotein expressed in the myelin sheath. Low or 
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absent LFB staining indicates partial or complete demyelination respectively. LFB 
staining of the spinal cords showed that while IFA controls kept in room air or exposed 
to oxygen for 24 hours did not have any sign of demyelination, EAE rats were 
characterized by myelin loss in the white matter. Perivascular and sub-meningeal 
demyelination was observed in rats with active EAE as early as one and two days after 
the onset of neurological deficits (Figure 2.3a), although not all rats at these early 
stages showed demyelination (data not shown). At three days after onset, all rats 
showed demyelination and this appeared more obvious and affected a larger part of the 
spinal cord white matter (Figure 2.3a and b). Interestingly, at all three stages of disease 
examined, when present the demyelination most frequently occurred in the dorsal 
columns (Figure 2.3a) and at the anteromedian area of the spinal cord. Another group 
(Lin et al., 2007) has also observed demyelination frequently in these spinal cord 
regions of mice with active EAE, but the mechanisms underlying this peculiar 
localization of the lesions remain unclear.    
We then evaluated whether continuous administration of oxygen for 24 hours from the 
first, second or third day of disease can protect from spinal cord demyelination. LFB 
quantification did not show any differences in white matter demyelination between 
oxygen-treated groups and time-matched room air controls (Figure 2.3a and b). 
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Figure 2.3 - 24 hours of oxygen treatment from either the first, second or third day of 
disease, does not change white matter demyelination in the spinal cord of rats with 
active EAE straight after treatment cessation. 
a) Lumbar spinal cord dorsal columns of IFA controls and rats with active EAE were stained for 
LFB (blue). EAE rats received either oxygen (75%) or room air for 24 hours on either the first, 
second or third day of disease. Absence of blue staining indicates demyelination. IFA controls 
did not show demyelination. Rats with active EAE were characterized by sub-meningeal and 
perivascular demyelination in the spinal cord white matter (WM) one and two days after the 
onset of deficits, whereas demyelination was greater on the third day of disease. Scale bar = 
200μm. b) Quantification of LFB staining showed no changes after 24 hours of oxygen treatment 
administered on either the first, second or third day of disease compared with room air controls. 
Two-way ANOVA with Sidak’s correction (p > 0.05). IFA: n = 4 per group; EAE: n = 12 per 
group. 
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2.2.2.2 Microglial activation, macrophage infiltration and iNOS 
expression do not change after 24 hours in oxygen 
Reactive microglia and infiltrated macrophages are key players of tissue damage during 
MS and EAE. To determine whether oxygen treatment (24 hours from the first, second 
or third day of disease) affects the abundance of activated microglia and macrophages 
in the spinal cord of rats with active EAE, we immunohistochemically labelled these 
cells using anti- ED-1. ED-1 immunoreactivity was observed in the spinal cord of rats 
with active EAE in areas characterized by hypercellularity (assessed using 
haematoxylin) probably due to inflammatory infiltrates, and often in areas that were also 
demyelinated (loss of LFB staining) (Figure 2.4a). Non-inflamed, non-demyelinated IFA 
controls did not show ED-1 labelling (Figure 2.4a, b). In animals with active EAE, the 
number of ED-1 positive cells gradually increased with the progression of the disease 
(Figure 2.4b, c). One and two days after the onset of the disease, activated microglia 
and macrophages were mainly observed in the sub-meningeal and perivascular regions 
of the spinal cord. At the third day of neurological deficits (peak of disease), activated 
microglia and macrophages were diffused, occupying a larger part of the spinal cord 
parenchyma (Figure 2.4b, c). ED-1 quantification did not reveal changes in the number 
of activated microglia and macrophages in rats exposed to oxygen compared with room 
air controls, 24 hours after treatment initiation on either the first, second or third day of 
disease (Figure 2.4c; p > 0.05).  
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Figure 2.4 - 24 hours of oxygen treatment from either the first, second or third day of 
disease, does not change microglial activation and macrophage infiltration in the spinal 
cord of rats with active EAE. 
a) Representative images of spinal cord dorsal columns stained for myelin (LFB; light blue) and 
cell nuclei (haematoxylin, H; dark blue), and labeled for activated microglia and macrophages 
(ED-1; brown) on adjacent sections. EAE rats showed demyelination (absence of LFB) in areas 
with hypercellularity (H, probably due to inflammatory infiltrates) and ED-1 positive cells. IFA 
controls had no demyelination, inflammation and macrophage/microglial activation. Scale bar = 
200μm. b) Lumbar spinal cord cross-sections labeled for ED-1, of IFA controls and EAE rats 
exposed to room air or oxygen (75%) for 24 hours from the first, second or third day of disease. 
Scale bar = 1mm. c) Quantification of ED-1 labelling after treatment showed no changes 
between oxygen and time-matched room air controls. Two-way ANOVA with Sidak’s correction 
(p > 0.05). IFA: n = 4 per group; EAE: n = 12 per group. 
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Activated microglia, infiltrated macrophages and reactive astrocytes have been 
reported to be the main sources of NO within the inflamed CNS. In these cells, NO is 
produced via the appearance of the inducible form of NO-synthase, iNOS. Augmented 
expression of iNOS indicates increased synthesis of NO. NO is an important 
inflammatory mediator involved in both oligodendrocytic and neuronal damage in MS 
(Smith and Lassmann, 2002). We followed the expression of iNOS in the spinal cord of 
rats with active EAE during the first three days of neurological deficits. As expected, 
iNOS labelling was not detected in non-inflamed IFA controls (Figure 2.5a). 
Immunohistochemistry for iNOS in EAE rats showed a similar distribution to ED-1 
labelling (sub-meningeal and perivascular, Figure 2.5b) during the first two days of 
disease, confirming the inflammatory association of this enzyme (Figure 2.5a). 
Surprisingly, the expression of iNOS was higher at the first day of neurological deficits 
and decreased to control levels by the third day after onset (Figure 2.5a, b). However, 
while iNOS expression returned to control levels, the severity of neurological deficits 
increased and was greater three days after the onset of the disease (Figure 2.5 and 
Figure 2.2); suggesting that iNOS may only partially and transiently account for the 
neurological dysfunction occurring in active EAE. We then evaluated whether 24 hours 
of oxygen treatment on the first, second, or third day of disease can affect the spinal 
expression of iNOS in active EAE. Histological comparison of iNOS expression showed 
no differences between oxygen-treated rats and time-matched room air controls (Figure 
2.5a, b). 
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Figure 2.5 - iNOS expression is not affected by 24 hours of oxygen administration on 
either the first, second or third day of disease. 
a) Lumbar spinal cord sections labeled for iNOS from IFA controls and rats with active EAE 
exposed either to oxygen (75%) for 24 hours, or room air, on either the first, second or third day 
of disease. EAE rats had higher iNOS expression one day after disease onset, but iNOS 
labelling gradually decreased on day two and three after onset. Scale bar = 1mm. b) iNOS 
quantification showed that oxygen administration to rats with active EAE on either the first, 
second or third day of disease, did not change iNOS expression compared with room air 
controls. Two-way ANOVA with Sidak’s correction (p > 0.05). IFA: n = 4 per group; EAE: n = 12 
per group. 
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2.2.2.3 HIF1α expression in the spinal cord of rats with active EAE 
is decreased by 24 hours of oxygen treatment  
To evaluate whether 24 hours of oxygen treatment administered at different stages of 
disease (first, second or third day of deficits) can reverse tissue hypoxia, spinal cord 
cross sections of rats with active EAE and IFA controls were labeled for HIF1α. 
Although HIF1α can be increased by inflammation in addition to hypoxia, the 
expression of HIF1α is tightly correlated with the concentration of oxygen. Indeed, in 
normoxic conditions HIF1α is hydroxylated through an oxygen-dependent mechanism 
and it is promptly destroyed via proteasome degradation. In hypoxic conditions, HIF1α 
is not hydroxylated and therefore degraded; thus it binds the subunit HIF1β and 
translocates into the nucleus where activates the transcription of genes involved in the 
response to hypoxia (for more information see Introduction 1.10.1.0). 
Immunohistochemistry for HIF1α strongly labeled the spinal cord of rats with active 
EAE. In particular, HIF1α immunoreactivity increased with the progression of the 
disease and it was more intense three days after the onset (Figure 2.6a). In contrast, 
IFA controls had very low or absent HIF1α labelling (Figure 2.6a). Interestingly, in rats 
with active EAE the level of HIF1α was decreased after 24 hours of oxygen exposure 
from the first, second or third day of disease (Figure 2.6a), and significantly when 
oxygen was administered on the first (p = 0.015) and third (p = 0.003) day of disease 
(Figure 2.6b). 
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Figure 2.6 - Oxygen treatment for 24 hours from the first, second or third day of disease 
decreases tissue hypoxia in the spinal cord of rats with active EAE. 
a) Immunohistochemical labelling for HIF1α (marker of tissue hypoxia) of spinal cord sections of 
IFA controls and rats with active EAE exposed to room air or oxygen for 24 hours on either the 
first, second or third day of disease. Representative images show the ventral grey matter area 
of the spinal cord. Rats with active EAE were characterized by a greater labelling for HIF1α than 
IFA controls, with labelling of motor neurons particularly prominent. The level of HIF1α increased 
with the progression of the disease and it was higher in rats at the third day after the onset of 
deficits (peak of disease). Rats with active EAE treated with oxygen for 24 hours showed 
reduced levels of HIF1α compared with room air controls. Scale bar = 200μm. b) Quantification 
of HIF1α immunolabelling shows that oxygen treatment decreased HIF1α expression in rats with 
active EAE independently of whether the treatment started on the first, second or third day of 
disease.  HIF1α is significantly reduced in rats treated with oxygen on the first (p = 0.015) and 
third day of deficits (p = 0.003) compared with time-matched controls. Two-way ANOVA with 
Sidak’s correction. IFA: n = 4 per group; EAE: n = 12 per group. 
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2.2.2.4 Glycolysis in the spinal cord of rats with active EAE is not 
affected by oxygen administration 
There is evidence that markers of glycolysis are increased in the CNS of animals with 
active EAE (Sadeghian et al., 2016). Cells may activate glycolysis in an attempt to 
overcome an energy deficit due to insufficient oxygen to sustain mitochondrial 
respiration. However, each molecule of glucose leads to the production of 34 ATP 
molecules via oxidative phosphorylation through the electron transport chain, but only 2 
ATP molecules are made by glycolysis, suggesting that glycolysis may be not sufficient 
to compensate the energy deficit during active EAE. We hypothesized that by restoring 
tissue oxygenation via the administration of oxygen-enriched air, it may be possible to 
restore a more physiological cellular respiration able to overcome the activation of 
glycolysis. To investigate whether 24 hours of oxygen administration can reduce the 
cellular need for glycolysis, spinal cords of rats with active EAE were histologically 
labeled for an enzyme involved in glycolysis, namely PFK-2.  Consistent with previous 
observations (Sadeghian et al., 2016), we observed that while PFK-2 labelling was very 
low in healthy IFA controls, its expression was markedly higher in rats with active EAE 
(Figure 2.7a). Interestingly, PFK-2 signal was greater one and two days after disease 
onset, but it returned to control level by the third day of disease (Figure 2.7a, b). 
Analysis of the PFK-2 immunoreactivity in active EAE rats showed no differences after 
24 hours of oxygen administration, independently of whether oxygen was applied on 
the first, second or third day of disease compared with time-matched cohort of rats kept 
in room air (Figure 2.7a and b). 
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Figure 2.7 - 24 hours of oxygen administration does not change the expression of the 
glycolysis marker PFK-2 in the spinal cord of rats with active EAE. 
a) Lumbar spinal cord cross sections of room air and oxygen-treated IFA controls and rats with 
active EAE were labeled for PFK-2, a marker of glycolysis. Oxygen was administered for 24 
hours starting on either the first, second or third day of disease. Immunolabelling for PFK-2 was 
low in IFA rats. PFK-2 immunoreactivity was increased one and two days after EAE onset and 
returned to control levels by the third day after onset. Scale bar = 1mm. b) PFK-2 quantifications 
shows increased level of PFK-2 in rats with active EAE compared with healthy (IFA) controls. 
PFK-2 levels decreased during the progression of the disease and were not changed by oxygen 
administration. Two-way ANOVA with Sidak’s correction (p > 0.05). IFA: n = 4 per group; EAE: n 
= 12 per group. 
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2.2.2.5 Oxygen therapy: effects on size and density of spinal cord 
blood vessels  
Changes in blood oxygen concentration can lead to several adaptations aimed at 
restoring the optimal oxygen supply to the tissue requirements. One of the first organ 
responses to increased oxygen in the blood stream is the vasoconstriction of 
capillaries, which results in reduced blood flow to restore a normal oxygenation of the 
tissue. Therefore, it is reasonable to think that the administration of oxygen-enriched air 
may cause vasoconstriction that could impede the desired oxygen supply at the 
inflamed CNS. To evaluate whether oxygen therapy causes vasoconstriction in the 
CNS of rats with active EAE, the spinal cords were histologically labeled for Reca1, a 
marker of endothelial cells. Rats with active EAE treated with oxygen for 24 hours from 
the first, second or third day of disease were compared after treatment cessation with 
time-matched room air controls and IFA animals (exposed and non-exposed to oxygen 
for 24 hours). No changes in blood vessel size were observed in IFA controls exposed 
to oxygen compared with ones kept in room air (Figure 2.8a, b). Consistent with 
observation by Davies and colleagues (Davies et al., 2013), rats with active EAE were 
characterized by increased vessel size compared with healthy controls, and this 
difference was significantly greater two days after disease onset (p = 0.002; Figure 
2.8a, b). The enlargement of vessels may be a consequence of both inflammation and 
hypoxia occurring in active EAE. Interestingly, oxygen did not change the size of 
vessels compared with room air controls at any of the disease stages analysed (Figure 
2.8a, b). 
Then, we examined whether oxygen treatment affects the vascular network of the 
spinal cord by counting the number of Reca1 positive vessels. We did not detect any 
changes in IFA rats exposed to oxygen for 24 hours compared with IFA breathing room 
air (Figure 2.8a, c). A significant increase in Reca1 labeled vessels was instead 
measured in rats with active EAE at the second and third day of disease (p = 0.016 and 
p = 0.032 respectively) compared with healthy controls (Figure 2.8a, c). Oxygen-treated 
rats at the first, second or third day of disease for 24 hours did not show any difference 
compared with their respective controls maintained in room air (Figure 2.8a, c). 
Although more sophisticated and precise techniques exist for the evaluation of 
endothelial function, vasodilation, angiogenesis and tissue vascularisation (Flammer et 
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al., 2012; Simons et al., 2015), our histological data provide a preliminary indication that 
the administration of oxygen for 24 hours may not affect the size and number of spinal 
vessels during EAE.   
  
 
Figure 2.8 - Effects of 24 hours of oxygen administration on either the first, second or 
third day of disease on the spinal cord blood vessels in animals with active EAE. 
a) Representative images show spinal cord anteromedian areas of rats with active EAE and IFA 
controls labeled for Reca1, a marker of endothelial cells. Rats with active EAE were treated with 
oxygen (or maintained in room air) for 24 hours from either the first, second or third day of 
disease and analysed after treatment cessation. IFA controls kept in room air or exposed to 
oxygen for 24 hours were used for comparison. Scale bar = 100μm. b) The size of Reca1-
positive vessels appeared increased in rats with active EAE compared with IFA controls, and it 
was significantly increased in rats treated or untreated with oxygen at the second day of disease 
(p = 0.018 and p = 0.002 respectively) compared with their treatment-matched IFA controls. No 
changes were observed at each stage of disease between rats with active EAE treated with 
oxygen or kept in room air. c) The number of Reca1-positive particles was significantly 
increased in rats with active EAE at the second and third day of disease  (p = 0.016 and p = 
0.032 respectively) compared with IFA controls. No changes were observed between oxygen-
treated and room air controls at each stage of disease. Two-Way ANOVA with Dunnett’s 
correction. IFA: n = 4 per group; EAE: n = 12 per group. 
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2.2.3.0 Duration of oxygen treatment: 24, 48 and 72 hours of oxygen 
treatment from the onset of deficits 
In the previous paragraphs, evidence was provided that oxygen is able promptly to 
improve neurological function in rats with active EAE even when administered for only 1 
hour at the peak of disease, but the specific beneficial effect was transient. Next, we 
investigated the optimal timing to start the treatment by administering oxygen for longer 
(24 hours) on either the first, second or third day of disease. Interestingly, we 
discovered that oxygen treatment can ameliorate the disease progression 
independently of the stage of disease at which it is administered, although the greatest 
beneficial effect was observed when oxygen exposure started at the onset of 
neurological deficits. Thus, the administration of oxygen at the very early stage of 
disease appeared to be most effective in producing the largest improvement of the 
disease. Here we examine different durations (24, 48 and 72 hours) of oxygen 
exposure from the onset of neurological deficits. The aims are 1) to evaluate what is the 
optimal duration for oxygen therapy, 2) how long the beneficial effect persists after 
treatment cessation, and 3) whether prolonged exposure to oxygen can change the 
pathology of active EAE. 
2.2.3.1 Oxygen treatment from the onset of neurological deficits 
ameliorates disease progression  
Rats with active EAE (n = 28) were randomly allocated to receive oxygen (75%) for 24, 
48 or 72 hours from the onset of disease (respectively: n = 6, n = 8 and n = 7). Control 
rats were not exposed to oxygen but kept in room air for the entire duration of the trial 
(n = 8). After treatment with oxygen, the animals were returned in room air, and the 
magnitude of the neurological deficits was followed up to 9 days after the onset of 
neurological signs (second peak of disease). Interestingly, we observed that oxygen 
ameliorated the severity of the disease even when administered only for the first 24 
hours (Figure 2.9). During the first peak of disease (first three days after onset) more 
than 30% of the rats in all treated groups (33% in the 24 hours, 50% in the 48 hours 
and 43% in the 72 hours oxygen-treated groups) did not develop hind limb paralysis, 
whereas 75% of animals receiving room air lost voluntary motor control of their hind 
limbs (score > 8; Figure 2.9). Remarkably, the beneficial effect of oxygen persisted for 
several days after treatment cessation, and all oxygen-treated groups displayed an 
average score for neurological dysfunction always lower than the room air control 
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(Figure 2.9). Notably, rats treated with oxygen for 24, 48 or 72 hours experienced a 
better recovery of the neurological function after the first attack of disease (remitting 
phase) compared with controls, and particularly when treated for the first 72 hours 
(Figure 2.9). However, although oxygen administered at the onset of disease 
attenuated the overall severity of deficits providing a better and longer recovery during 
the remitting phase, it did not avoid the development of the second peak of neurological 
deficits (Figure 2.9). 
 
Figure 2.9 - Treatment with oxygen (75%) for 24, 48 or 72 hours from the onset of 
neurological deficits attenuates disease progression for several days after treatment 
cessation.  
Disease progression in rats with active EAE randomly allocated to receive either oxygen for 24, 
48 or 72 hours from the onset of neurological signs (day 0; vertical dashed line), or room air. 
After treatment, rats were returned to room air and the neurological deficits were monitored for 
up to 9 days after the onset of deficits (second peak of disease). All durations of oxygen 
exposure (24, 48 or 72 hours) ameliorated disease progression and the beneficial effect 
persisted for several days after treatment cessation. In contrast with the room air group, the 
mean average score of rats treated with oxygen always lay on or below score 8 (indicating hind 
limb paralysis; horizontal dashed line). Rats treated with oxygen experienced a more 
pronounced remission of the neurological deficits after the first peak of disease compared with 
room air controls, which was significant at day six in rats treated for 72 hours with oxygen (p = 
0.039). Mann Whitney U-test. Room air, n = 7; 24h 75% O2, n = 6; 48h 75% O2, n = 8; 72h 75% 
O2, n = 7. 
 
-1 0 1 2 3 4 5 6 7 8 9
0
1
2
3
4
5
6
7
8
9
10
Days after disease onset 
N
eu
ro
lo
gi
ca
l d
ef
ic
it 
sc
or
e Room air
24h 75% O2
48h 75% O2
72h 75% O2
Treatment
begins
*
75% O2
75% O2
75% O2
Room air
Room air
Room air
 87 
 
We then performed another independent active EAE trial (n = 36) in which rats were 
similarly treated with oxygen from the onset of disease for 24, 48 or 72 hours 
(respectively: n = 10, n = 9 and n = 9). Rats treated with oxygen for 24 and 48 hours 
were returned to room air after oxygen administration. Rats with active EAE that 
received only room air (n = 8) were used as controls. All animals were sacrificed at the 
third day of disease (peak of disease) for histological analysis. Consistent with the 
previous trial, we observed that oxygen ameliorated disease severity in all treated 
groups and the beneficial effect persisted even after rats were returned to room air 
(Figure 2.10a). At the peak of disease, rats treated with oxygen for 24, 48 or 72 hours 
showed on average a reduction in the severity of the disease respectively of 18%, 25% 
and 15% at the neurological examination compared with controls (Figure 2.10a and b). 
In particular, more than 50% of rats in all oxygen groups did not develop hind limb 
paralysis (score < 8; Figure 2.10b), whereas 7 out of 8 rats in the room air control group 
reached score 8 or 9 upon behavioural testing (Figure 2.10b). In particular, rats 
exposed to oxygen for 48 hours showed the greatest improvement in neurological score 
compared with controls (p = 0.038; Figure 2.10b). Furthermore, we weighed rats with 
active EAE on a daily base from the day of immunization, and the weight was 
considered as a parameter of general health. Indeed, healthy rats gradually increase 
their body weight over time, but they start progressively to lose weight when 
neurological deficits appear (Figure 2.10c). The magnitude of body weight loss is 
considered a bad prognosis for disease. Interestingly, we noticed that rats with active 
EAE treated with oxygen were characterized by reduced body weight loss compared 
with control rats breathing room air (Figure 2.10c). Notably, the percentage of body 
weight lost at the peak of disease was significantly decreased in rats treated with 
oxygen for 72 hours compared with controls (p = 0.030; Figure 2.10d). 
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Figure 2.10 - Oxygen treatment (75%) for 24, 48 and 72 hours from the onset of disease 
ameliorates the severity of neurological deficits at the first peak of disease. 
a) Progression of neurological deficits during the first peak of active EAE in rats treated with 
oxygen from the onset of disease (day 0; vertical dashed line) for 24, 48 or 72 hours or 
maintained in room air. Rats treated with oxygen for 24 and 48 hours were returned to room air 
up to the third day of disease. All oxygen-treated groups displayed less severe progression of 
the disease overall compared with room air controls. b) Neurological deficit score at the peak of 
disease (3 days after onset) shows that more than 50% of rats treated with oxygen did not 
develop hind limb paralysis (score < 8), whereas only one rat in the room air control group 
showed a score lower than 8. The severity of neurological dysfunction at the peak of disease 
was significantly reduced in rats treated with oxygen for 48 hours (p = 0.038) compared with 
room air controls. Mann-Whitney U-test. c) Rats with active EAE experienced a gradual 
decrease in body weight from the onset of neurological deficits (day 0; vertical dashed line) that 
was less severe in the ones treated with oxygen. d) Analysis of body weight loss at the peak of 
disease shows that rats treated with oxygen lost less weight than room air controls, and 
significantly less when treated for 72 hours (p = 0.030). One-way ANOVA with Dunnett’s 
correction. Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 75% O2, n = 9.  
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As mentioned before, the rats included in this trial were sacrificed at the peak of 
disease (3 days after onset) and the spinal cords collected for histological and analysis. 
IFA control rats (n = 8) were included and used for comparison. Demyelination, 
hypoxia, integrated stress response, inflammation and oxidative damage were 
evaluated as described in the following paragraphs.  
2.2.3.2 Oxygen protects from spinal cord demyelination  
Demyelination was evaluated by staining the spinal cord of rats included in the previous 
trial with LFB, or immunolabelling for MOG. Healthy rats (IFA) were also analysed and 
used as negative (non-demyelinated) controls. Rats with active EAE were treated with 
oxygen from the onset of neurological deficits for 24, 48 or 72 hours, whereas control 
rats were exposed to room air only. All animals were sacrificed and analysed at the 
third day of disease (peak of neurological deficits). Histology for LFB and MOG showed 
a similar pattern of demyelination in the white matter (Figure 2.11a). However, 
immunohistochemistry for MOG disclosed a sharper difference between demyelinated 
lesions and intact white matter compared with LFB staining (Figure 2.11a); thus MOG 
labelling was preferred to LFB for the quantification of the extension of demyelinated 
lesions. Interestingly, we observed that white matter demyelination was reduced in rats 
treated with oxygen in proportion to the duration of the treatment (Figure 2.11a, b). 
Indeed, rats treated for 72 hours were the most protected ones compared with room air 
controls (p = 0.002; Figure 2.11b). To investigate which areas of the spinal cord were 
more affected by demyelination, the sacral, lumbar and thoracic levels of the spinal 
cord were considered separately (Figure 2.11c). The sacral spinal cord sections were 
severely demyelinated and such demyelination affected a larger portion of the white 
matter surface compared with the lumbar and thoracic levels (Figure 2.11c). 
Interestingly, all oxygen-treated groups showed a general reduction of demyelination at 
all levels of the spinal cord compared with room air controls, although the protective 
effect was greater in the sacral segment, and particularly so in rats treated with oxygen 
for 48 (p = 0.002) and 72 (p < 0.0001) hours compared with room air controls (Figure 
2.11c). These data suggest that oxygen administered at the onset of deficits can reduce 
the overall spinal cord demyelination at the first peak of disease in a proportional 
manner to the duration of the treatment and significantly when applied for 72 hours. In 
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particular, the protective effect occurred only at the sacral level of the spinal cord and in 
rats treated with oxygen for 48 and 72 hours. 
 
Figure 2.11 - Oxygen administration (75%) for 24, 48 and 72 hours from the onset of 
neurological deficits protects from spinal cord demyelination at the peak of disease in 
proportion with the duration of the treatment.  
a) Representative images show adjacent lumbar spinal cord sections of IFA controls and EAE 
rats at the peak of disease stained for LFB (blue) or immunolabeled for MOG (brown). Rats with 
active EAE were exposed to room air or treated with oxygen from the onset of disease for 24, 48 
or 72 hours. Absence of LFB staining or MOG labelling highlights demyelinated areas. IFA 
controls were not demyelinated. LFB staining and MOG immunolabelling disclosed a similar 
pattern of white matter (WM) demyelination in rats with active EAE. Scale bar = 1mm. b) 
Quantification of MOG labelling in animals with active EAE showed reduced demyelination in the 
WM of rats treated with oxygen in proportion to the duration of the treatment. 72 hours treated 
rats were significantly less demyelinated than room air controls (p = 0.002). One-way ANOVA 
with Dunnett’s correction. c) Demyelination was more severe in the WM of the sacral level 
compared with the lumbar and thoracic levels of the spinal cord. Oxygen resulted in reduced 
demyelination at all levels of the spinal cord, and significantly in the sacral area in rats treated 
for 48 (p = 0.002) and 72 (p < 0.0001) hours compared with controls. Two-way ANOVA with 
Dunnett’s correction. IFA, n = 8; Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 
75% O2, n = 9.  
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2.2.3.3 HIF1α expression at the peak of disease after 24, 48 and 72 
hours of oxygen exposure  
We have previously demonstrated that oxygen can decrease the level of HIF1α (a 
marker of tissue hypoxia) in the spinal cord of rats with active EAE straight after 24 
hours of administration, and independently of the stage of disease at which the 
treatment was applied (paragraph 2.2.2.3). Here, we examine if oxygen therapy 
administered at the onset of deficits can reduce spinal cord hypoxia at the peak of 
disease (3 days after onset) even in rats which are returned in room air after oxygen 
exposure. Rats with active EAE were treated with oxygen from the first day of 
neurological signs for either 24, 48 or 72 hours. Rats exposed to oxygen for 24 and 48 
hours were then returned to room air for two or one extra days respectively. All rats 
were examined at the peak of disease (third day of disease) and compared with room 
air controls. HIF1α was labeled histologically to demarcate tissue hypoxia. While IFA 
controls showed very low HIF1α labelling in the spinal cord, HIF1α expression was 
higher in rats with active EAE at the peak of disease and diminished in animals treated 
with oxygen (Figure 2.12a). Indeed, quantification of HIF1α immunoreactivity showed a 
non-significant trend of reduced HIF1α expression in rats treated with oxygen for 24, 48 
or 72 hours from the onset of disease. Notably, this trend of reduced expression of 
HIF1α was proportional to the duration of the treatment (Figure 2.12b). 
Administration of oxygen-enriched air in rats with active EAE from the onset of disease 
for 24, 48 or 72 hours, did not significantly change the level of tissue hypoxia at the 
peak of neurological deficits, but it was observed a trend of decreased HIF1α 
expression compared with room air controls (Figure 2.12). The level of HIF1α was 
higher in rats that were treated for only 24 or 48 hours and then returned in room air 
compared with the ones that were exposed to oxygen up to the peak of disease (72 
hours; Figure 2.12b). This finding suggests that tissue hypoxia can reappear when rats 
are returned in room air after oxygen, but such hypoxia is attenuated at least up to two 
days after treatment cessation compared with room air controls (Figure 2.12b).   
 92 
 
 
Figure 2.12 - HIF1α expression at the peak of disease is reduced by oxygen 
administration from the onset of deficit for 24, 48 or 72 hours and proportionally to the 
duration of the treatment. 
a) Immunohistochemistry for HIF1α in spinal cord of rats with active EAE at the peak of disease 
and in IFA controls. Representative images show the grey matter (ventral horn) of the spinal 
cords. Rats with active EAE were exposed to room air or treated with oxygen for 24, 48 and 72 
hours from the onset of deficits. Increased HIF1α labelling was observed in rats with active EAE 
compared with IFA controls. The magnitude of HIF1α immunoreactivity inversely correlated with 
the duration of oxygen treatment. Scale bar = 200μm. b) Quantification of spinal cord cross-
sections labeled for HIF1α showed diminished HIF1α levels in rats with active EAE that were 
exposed to oxygen for 24, 48 or 72 hours from the onset of disease compared with room air 
controls. The reduction in HIF1α labelling was proportional to the duration of the treatment. One-
way ANOVA with Dunnett’s correction (p > 0.05). IFA, n = 8; Room air, n = 8; 24h 75% O2, n = 
10; 48h 75% O2, n = 9; 72h 75% O2, n = 9. 
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2.2.3.4 Oxygen decreases the integrated stress response and 
promotes oligodendrocyte survival 
A number of studies have reported the activation of stress related mechanisms, known 
as the integrated stress response, in different cells within the CNS during active EAE 
(Kumagami et al., 1999; Chakrabarty et al., 2004; Lin and Popko, 2009) as well as in 
MS (Allen et al., 2001; Kutzelnigg et al., 2005; Cunnea et al., 2011; McMahon et al., 
2012; Ní Fhlathartaigh et al., 2013).  Stress conditions, such as hypoxia, viral infection, 
glucose deprivation, ER stress and inflammation, have been reported to enhance the 
integrated stress response (Donnelly et al., 2013). The hallmark of the integrated stress 
response is the phosphorylation of eIF2α, a key factor involved in protein translation. 
Phosphorylation of eIF2α (p-eIF2α) leads to a general attenuation of protein synthesis 
and to downstream expression of cytoprotective genes (Donnelly et al., 2013). Hypoxia 
is believed to induce phosphorylation of eIF2α in the cellular attempt to save energy by 
decreasing the rate of protein synthesis (Koumenis et al., 2002). However in active 
EAE, the phosphorylation of eIF2α has been mainly attributed to inflammation and in 
particular to a mechanism mediated by IFNγ (Lin and Popko, 2009). Here, we 
compared cellular stress in rats with active EAE and healthy controls (IFA) by histology, 
using p-eIF2α as a marker. Furthermore, we evaluated whether the administration of 
oxygen in EAE rats affected the level of p-eIF2α expression in the inflamed CNS.  
P-eIF2α was first evaluated in neurons by labelling the neuronal cell bodies with NeuN 
(Figure 2.13). Both animals with active EAE and IFA controls were characterized by the 
presence of p-eIF2α positive foci in the neuronal cytoplasm (Figure 2.13). We did not 
observe any differences between IFA controls and rats with active EAE, suggesting that 
part of the eIF2α pool in neurons is normally phosphorylated in the healthy condition, 
and this does not increase at the first peak of active EAE (Figure 2.13).  
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Figure 2.13 - Immunofluorescence of neurons co-labeled for NeuN and p-eIF2α in a rat 
with active EAE and in an IFA control.  
Neurons were co-labeled in immunofluorescence using NeuN (red, a marker of neuronal cell 
bodies) and p-eIF2α (green, a marker of integrated stress response). DAPI was used to mark 
cell nuclei. P-eIF2α positive foci were observed in the cytoplasm of neurons of rats with active 
EAE as well as in IFA controls. Scale bar = 100μm.   
 
Next, we examined the expression of p-eIF2α in CC1 labeled mature oligodendrocytes 
at the peak of disease (Figure 2.14). Consistent with previous studies (Chakrabarty et 
al., 2004; Lin and Popko, 2009), while IFA controls did not show any CC1 positive 
oligodendrocytes co-labeled for p-eIF2α, CC1/p-eIF2α double positive cells were 
present in the spinal cord of rats with active EAE (Figure 2.14). P-eIF2α positive 
oligodendrocytes were detected in both oxygen-treated (for 24, 48 or 72 hours from the 
onset of deficit) and room air control-rats (Figure 2.14). 
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Figure 2.14 - Some oligodendrocytes show p-eIF2α labelling at the peak of active EAE. 
Immunofluorescence for CC1 (red, marker of mature oligodendrocytes) and p-eIF2α (green) in 
the spinal cord of IFA controls and rats with active EAE exposed to room air or oxygen for 24, 48 
or 72 hours from the onset of disease. DAPI was used to mark cell nuclei. IFA controls did not 
show CC1 positive oligodendrocytes co-labeled for p-eIF2α. In contrast, CC1/p-eIF2α double 
positive oligodendrocytes were observed in rats with active EAE at the peak of disease in all 
oxygen-treated, and in room air controls. Scale bar = 20μm.   
 
We then evaluated whether oxygen treatment administered at the onset of neurological 
deficits for 24, 48 or 72 hours, changed the number of p-eIF2α positive 
oligodendrocytes at the peak of disease. CC1/p-eIF2α double positive cells were 
counted within the dorsal column and the anteromedian area of the spinal cords, as 
these areas were the most commonly affected by inflammation and demyelination in 
room air control rats with active EAE. The number of CC1/p-eIF2α double positive cells 
was then expressed as a percentage of the total number of CC1 positive cells counted 
in the same areas (see Matherial and Methods 2.1.6.0). We did not find any CC1 
positive oligodendrocyte labeled for p-eIF2α in IFA controls (Figure 2.15), but a 
significantly increased number of p-eIF2α positive oligodendrocytes was detected in 
rats with active EAE breathing room air (p = 0.004; Figure 2.15b). Interestingly, the 
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amount of CC1/p-eIF2α double-positive cells was decreased in all oxygen-treated 
groups compared with room air controls, and significantly decreased in rats treated for 
72 hours (p = 0.011; Figure 2.15).  
 
Figure 2.15 - Oxygen treatment for 24, 48 or 72 hours from the onset of neurological 
deficits reduces the number of p-eIF2α positive oligodendrocytes at the peak of disease. 
a) Immunofluorescence for CC1 (red, oligodendrocytes), p-eIF2α (green) and DAPI (blue, cell 
nuclei) in the spinal cord of IFA controls and rats with active EAE at the peak of disease after 
exposure to room air or oxygen for 72 hours. White arrowheads indicate CC1/ p-eIF2α double 
positive cells. High magnification insets show: absence of p-eIF2α labelling in CC1 positive 
oligodendrocyte in IFA controls, but CC1/p-eIF2α double labelling in rats with active EAE. Scale 
bar = 20μm. b) Cell counting revealed a significant increase of oligodendrocytes immunoreactive 
for p-eIF2α in rats with active EAE (p = 0.004) compared with IFA controls. The number of 
CC1/p-eIF2α double positive oligodendrocytes was decreased after treatment with oxygen, and 
significantly decreased in animals exposed to oxygen for 72 hours (p = 0.011) compared with 
room air controls. Scale bar = 20μm. One-way ANOVA with Dunnett’s correction. IFA, n = 8; 
Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 75% O2, n = 9. 
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Although the integrated stress response is a protective mechanism that cells use to 
tolerate stress conditions, it can lead to apoptosis if the initial insult persists for too long 
and a physiological rate of protein synthesis is not restored (Tabas and Ron, 2011). 
Therefore, we investigated whether the reduced phosphorylation of eIF2α in oxygen-
treated rats with active EAE was affecting oligodendrocyte survival. We counted the 
number of CC1 positive oligodendrocytes in rats with active EAE treated and untreated 
with oxygen and in IFA controls (Figure 2.16). At the peak of disease, rats with active 
EAE receiving room air experienced a remarkable loss of oligodendrocytes, expressed 
by a significantly lower number of CC1 positive cells compared to IFA controls (p = 
0.008; Figure 2.16b). Interestingly, oxygen treatment resulted in an increased 
oligodendrocyte survival in proportion to the duration of the exposure (Figure 2.16b). 
Notably, rats treated with oxygen for 72 hours showed a significantly higher number of 
oligodendrocytes compared with room air controls (p = 0.005), and the average number 
of oligodendrocytes in this group was similar to IFA control (Figure 2.16b). 
The findings above suggest that hypoxia can contribute to cellular stress in 
oligodendrocytes during active EAE. Notably, oxygen administration from the onset of 
deficit can reduce eIF2α phosphorylation (a marker of cell stress) in these cells at the 
peak of disease, probably restoring a more physiological rate of protein synthesis. 
Interestingly, this phenotype was proportional to the duration of oxygen exposure. 
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Figure 2.16 - Oxygen treatment (75%) from the onset of neurological deficit for 24, 48 or 
72 hours protect from oligodendrocyte loss at the peak of disease. 
a) Representative images show immunofluorescence for CC1 (red, oligodendrocytes) in the 
spinal cord dorsal column of IFA controls and rats with active EAE at the peak of disease. Rats 
with active EAE were maintained in room air or exposed to oxygen from the onset of deficits for 
either 24, 48 or 72 hours. Scale bar = 100μm. b) CC1 positive cell counts at the peak of disease 
highlight a significantly decreased number of oligodendrocytes in rats with active EAE breathing 
room air (p = 0.008) compared with IFA controls. Oxygen protected from oligodendrocyte death 
in proportion to the duration of the treatment and significantly in rats exposed to oxygen for 72 
hours (p = 0.005) compared with room air controls. One-way ANOVA with Dunnett’s correction. 
IFA, n = 8; Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 75% O2, n = 9. 
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2.2.3.5 Oxygen does not affect T-cell infiltration in the spinal cord 
To investigate whether oxygen treatment affects the inflammatory response in rats with 
active EAE, we evaluated: 1) T-cell infiltration, 2) microglial activation, macrophage 
infiltration, and iNOS expression, and 3) gene expression of pro- and anti-inflammatory 
markers.  
Here we examined T-cell infiltration in the spinal cord of rats with active EAE 
maintained in room air or treated with oxygen (75%) from the onset of neurological 
signs for 24, 48 or 72 hours. All animals were histologically analysed three days after 
the onset of disease (peak of disease). T-cells were labeled using antibodies against 
CD3, and isolated T-cells or clusters of T-cells were considered separately (Figure 
2.17a). IFA controls did not show any T-cell infiltration into the spinal cord (Figure 
2.17a). The number of isolated CD3-positive cells dispersed within the spinal cord 
parenchyma of rats with active EAE did not change between oxygen-treated groups 
and rats in room air (Figure 2.17b). Similarly, oxygen treatment did not alter either the 
number or size of CD3-positive cell clusters compared with room air controls (Figure 
2.17c and d). 
These data suggest that oxygen treatment administered at the onset of deficits does 
not change the number of T-cells present in the CNS of rats with active EAE at the 
peak of disease.  
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Figure 2.17 - T-cell infiltration at the peak of disease does not change after 24, 48 or 72 
hours of oxygen treatment from the onset of deficits in active EAE. 
a) T-cells were labeled by immunofluorescence for CD3 (green). Images show isolated T-cells 
and clusters of T-cells into the spinal cord of rats with active EAE at the peak of disease after 
room air or oxygen exposure for 72 hours from the onset of deficits. No CD3-positive cells were 
detected in the spinal cord of IFA controls. Scale bar = 50μm. b) Quantification of the number of 
CD3-positive cells in the spinal cord of rats at the peak of disease did not show changes 
between room air and oxygen-treated groups. c-d) The number and size of CD3-positive 
clusters within the spinal cord of rats at the peak of disease did not change in animals treated 
with oxygen for 24, 48 and 72 hours from the onset of deficits, compared with room air controls. 
One-way ANOVA with Dunnett’s correction (p > 0.05). IFA, n = 8; Room air, n = 8; 24h 75% O2, 
n = 10; 48h 75% O2, n = 9; 72h 75% O2, n = 9. 
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2.2.3.6 Microglial activation and macrophage infiltration is reduced 
in rats treated with oxygen from the onset of disease 
Activated microglia and infiltrated macrophages in the spinal cord of rats with active 
EAE were immunohistochemically labeled for ED-1. ED-1 has been shown to be 
expressed by blood-derived monocytes/macrophages and activated microglia during 
active EAE and ischaemic stroke in rats (Bauer et al., 1994; Nicot et al., 2003; 
Jacobowitz et al., 2012). However, in the early phase of active EAE, as examined in 
this study, it has been suggested that only few ED-1+ cells are activated microglia while 
the majority of ED-1+ cells are infiltrated macrophages (Bauer et al., 1994). Consistent 
with this observation, in our model the sub-meningeal and perivascular labelling for ED-
1 suggests that, at least at the early stage of disease, the largest number of ED-1+ cells 
may be represented by infiltrated macrophages rather than activated microglia. 
Nonetheless, as both macrophages and activated microglia can express ED-1 during 
EAE (Bauer et al., 1994) and we did not separately examine these two cell populations, 
in the course of this thesis we will refer to ED-1+ cells as activated microglia and 
infiltrated macrophages. At the peak of neurological deficits, rats with active EAE 
showed a considerably increased labelling for ED-1 compared with healthy controls 
(Figure 2.18a). Interestingly, at this stage of disease, ED-1 immunoreactivity was 
decreased in rats treated with oxygen compared with rats breathing room air (Figure 
2.18a). Quantification of ED-1 at the sacral, lumbar and thoracic level of the spinal cord, 
underlined greater microglial/macrophage activation in the sacral compartment 
compared with the lumbar and thoracic levels (Figure 2.18b). Furthermore, at the sacral 
level, ED-1 labelling was significantly reduced in all oxygen-treated groups compared 
with room air control (p = 0.001, p = 0.043 and p = 0.005 respectively; Figure 2.18b). 
Average of ED-1 labelling within all segments of the spinal cords disclosed a general 
reduction of microglial activation and macrophage infiltration in rats exposed to oxygen 
from the onset of neurological signs, and significantly in animals treated for 72 hours (P 
= 0.036; Figure 2.18c).   
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Figure 2.18 - Reduced microglial activation and macrophage infiltration in the spinal cord 
of rats with active EAE at the peak of disease after 72 hours of oxygen treatment from 
the onset of deficits. 
a) Lumbar spinal cord cross-sections labeled for ED-1 (brown), a marker of macrophages and 
activated microglia. Rats with active EAE at the peak of disease showed a remarkably stronger 
labelling for ED-1 compared with IFA controls. ED-1 labelling was reduced in groups treated with 
oxygen for 24, 48 or 72 hours from the onset of disease compared with room air controls. Scale 
bar = 1mm. b) Histological quantification highlighted greater ED-1 immunoreactivity at the sacral 
part of the spinal cord compared with the lumbar and thoracic levels. A trend of reduced 
microglial/macrophage activation was observed in oxygen-treated groups at all levels of the 
spinal cords, and significantly at the sacral level in rats treated with oxygen for 24, 48 and 72 
hours (respectively: p = 0.001; p = 0.043 and p = 0.005) compared with room air controls. Two-
way ANOVA with Dunnett’s correction. c) Overall, ED-1 immunoreactivity was decreased in the 
spinal cords of rats treated with oxygen and significantly in the ones treated for 72 hours (p = 
0.036). One-way ANOVA wth Dunnett’s correction. IFA, n = 8; Room air, n = 8; 24h 75% O2, n = 
10; 48h 75% O2, n = 9; 72h 75% O2, n = 9. 
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Next, we evaluated the expression of iNOS, a pro-inflammatory mediator mainly up-
regulated in active microglia and macrophages, in the spinal cord of rats with active 
EAE at the peak of disease. At this stage of disease, immunohistochemical labelling 
showed a higher, although still small number of iNOS positive cells in the spinal cord of 
rats with active EAE compared with IFA controls (Figure 2.19a), which is consistent with 
what our data at the peak of neurological deficits and discussed previously in this thesis 
(paragraph 2.2.2.2). iNOS quantification at the peak of disease did not disclose any 
differences between rats treated with oxygen (for 24, 48 or 72 hours from the onset of 
deficits) and room air controls (Figure 2.19b). 
Briefly, oxygen treatment administered from the onset of neurological deficits for 24, 48 
or 72 hours decreased the number of ED-1-positive cells (activated microglia and 
macrophages) in the spinal cord of rats with active EAE at the peak of disease. The 
greatest reduction in ED-1-positive inflammatory cells was observed in rats treated with 
oxygen for 72 hours compared with room air controls. iNOS expression was not 
affected by oxygen administration. 
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Figure 2.19 - iNOS expression in the spinal cord of rats with active EAE is not changed 
by oxygen treatment for 24, 48 and 72 hours from the onset of deficits. 
a) Lumbar spinal cord cross-section labeled for iNOS in a healthy rat (IFA), and a rat with active 
EAE at the peak of disease. iNOS labelling is absent in the spinal cord of the IFA control. At the 
peak of EAE, iNOS is expressed within the white matter of the spinal cord. High magnification 
inset shows iNOS positive cells in the sub-meningeal area of the spinal cord of a rat with active 
EAE. Scale bar = 1mm. b) Quantification of iNOS labelling showed increased expression of 
iNOS in the spinal cord of rats with active EAE at the peak of disease compared with IFA 
controls, but such expression is not changed by oxygen treatment for 24, 48 or 72 hours from 
the onset of neurological deficits. One-way ANOVA with Dunnett’s correction (p > 0.05). IFA, n = 
8; Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 75% O2, n = 9.  
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2.2.3.7 Gene expression analysis of pro-inflammatory and anti-
inflammatory markers after oxygen exposure 
To investigate further whether oxygen treatment administered from the onset of deficits 
changes the inflammatory response in active EAE, the expression of pro- and anti- 
inflammatory markers was analysed. The RT-PCR analysis was carried out on mRNA 
extracted from spinal cord of rats included in an independent trial of active EAE (n = 
10). In common with the previous trials (paragraph 2.2.3.1), rats with active EAE were 
randomly sorted to receive room air or be treated with oxygen (for 72 hours) from the 
onset of deficits (n = 5 per group). The spinal cord were collected and processed for 
gene expression analysis at the peak of disease (3 days after onset). IFA controls (n = 
6) were included for comparison. In this experiment, it was examined only the 72 hours 
oxygen treatment because, as showed before, this duration of exposure produced the 
greatest beneficial effect and pathological changes in the spinal cord of rats with active 
EAE. Consistently with the other EAE trials discussed previously (paragraph 2.2.3.1) 
also here oxygen again ameliorated the severity of neurological deficits at the first peak 
of disease compared with room air controls (Figure 2.20).  
 
 
Figure 2.20 - Progression of neurological deficits at the first peak of disease in rats with 
active EAE exposed to room air or oxygen for 72 hours from the onset of dysfunctions. 
Rats with active EAE were treated with oxygen for 72 hours from the onset of deficits or 
maintained in room air. Oxygen treatment ameliorated disease progression compared with room 
air controls. Mann-Whitney U-test (p > 0.05). N = 5 per group.   
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RT-PCR analysis underlined an increased level of pro-inflammatory markers within the 
spinal cord of rats with active EAE compared with IFA controls. In particular, high levels 
of mRNA encoding for surface markers and pro-inflammatory cytokines produced by T-
cell effectors and/or activated macrophages and microglia, were detected at the peak of 
disease, including: Ccr5, IFNγ, IL2, IL17a, IL23a, MHC1 and TNFα (Figure 2.21). 
Interestingly, an over-expression of pro-inflammatory genes such as iNOS and IL12b, a 
cytokine produced by macrophages, was not observed in rats with active EAE 
compared with healthy controls (Figure 2.21). The level of mRNA encoding for iNOS at 
the peak of neurological deficits was similar to healthy controls and correlated with the 
reduced quantity of iNOS protein (to control level), observed histologically at the same 
stage of disease (paragraphs 2.2.2.2 and 2.2.3.6).  
Rats with active EAE were also characterized by a greater spinal cord expression of 
Foxp3 encoding mRNA (Figure 2.21). Foxp3 is the prototypical marker of T-regulatory 
lymphocytes (Treg), a population of T-cells involved in the control and suppression of 
inflammatory and autoimmune reactions; these data suggest the presence of anti-
inflammatory mechanisms in the spinal cord of rats with active EAE at the peak of 
disease. However, no changes in Arg1 expression, another anti-inflammatory marker 
(M2 type microglia/macrophages), were observed between rats with active EAE and 
IFA controls (Figure 2.21). 
Importantly, oxygen administration for 72 hours from the onset of neurological signs did 
not significantly change the expression of any of these markers compared with time-
matched animals breathing room air (Figure 2.21). This finding suggests that oxygen 
does not affect the overall pro- and anti-inflammatory response in the spinal cord of rats 
with active EAE. 
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Figure 2.21 - Gene expression analysis for pro- and anti- inflammatory markers in the 
spinal cord of rats with active EAE at the peak of disease after exposure to room air or 
oxygen (75%) for 72 hours. 
Rats with active EAE were maintained in room air or treated with oxygen for 72 hours from the 
onset of neurological deficits. At the peak of disease (3 days after onset), RT-PCR analysis 
showed no changes in the expression of pro- and anti- inflammatory markers between oxygen 
treated and room air control rats. a) ΔΔCt analysis over IFA controls shows the abundance of 
pro- and anti-inflammatory gene transcripts in the spinal cord of rats with EAE treated and 
untreated with oxygen. Independent t-test (p > 0.05). b) Fold change representation of the gene 
expression analysis relative to IFA controls. IFA, n = 6; EAE, n = 5 per group.   
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2.2.3.8 Oxygen treatment and oxidative damage 
A potential safety concern is that oxygen administration might increase superoxide 
production causing cell toxicity. The safety of normobaric oxygen therapy in MS is still 
largely unknown and the usage of oxygen in the clinic has to be considered with 
caution. In this study, we aimed also to investigate the safety of the treatment in active 
EAE with particular regard to oxidative stress. We have evaluated the presence of 8-
OHdG (a marker for oxidized DNA and RNA; Figure 2.22a) and E06 (marker of oxidized 
phospholipids; Figure 2.22b) at the peak of disease after 24, 48 or 72 hours of oxygen 
exposure and in room air and IFA controls. The spinal cord of rats with active EAE 
showed a significantly higher number of positive cells for 8-OHdG and E06 (p < 0.0001 
and p = 0.003 respectively) compared with IFA control animals (Figure 2.22c and d). 
Quantification of the labelling showed no increased 8-OHdG and E06 levels in any of 
the oxygen-treated groups (24, 48 or 72 hours of administration) compared with room 
air controls (Figure 2.22c and d).  
Surprisingly, the level of E06 was significantly decreased in the spinal cord of rats with 
active EAE treated with oxygen for 72 hours compared with rats breathing room air (p = 
0.014; Figure 2.22d).  
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Figure 2.22 - Oxygen administration (75%) from the onset of deficits for either 24, 48, or 
72 hours does not exacerbate the oxidative damage at the peak of disease. 
a-b) Representative images show spinal cord dorsal columns labeled for 8-OHdG (a marker of 
oxidized DNA and RNA) or E06 (a marker of oxidized phospholipids) in IFA controls and rats 
with active EAE exposed to room air or oxygen treatment for 72 hours from the first day of 
disease. Scale bar = 250μm. c) Quantification of 8-OHdG shows increased labelling in rats with 
active EAE (p < 0.0001) compared with healthy controls, but no changes between room air and 
oxygen-treated groups. d) E06 quantification displayed a higher number of E06 positive cells in 
the spinal cord of rats with active EAE (p = 0.003) compared with IFA controls. Phospholipid 
oxidation was not exacerbated at the peak of disease by oxygen treatment for 24, 48 or 72 
hours starting from the onset of deficits. E06 labelling was significantly decreased in rats treated 
with oxygen for 72 hours (p = 0.014) compared with room air controls. One-way ANOVA with 
Dunnett’s correction. IFA, n = 8; Room air, n = 8; 24h 75% O2, n = 10; 48h 75% O2, n = 9; 72h 
75% O2, n = 9.  
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 2.2.4.0 Prophylactic oxygen treatment 
Oligodendrocyte apoptosis, the expression of hypoxia-related antigens and cerebral 
hypoperfusion have been identified as early changes in newly forming demyelinating 
lesions in MS by a number of studies (Lassmann, 2003; Barnett and Prineas, 2004; 
Juurlink, 2013; D’haeseleer et al., 2015), raising the possibility that treatment with 
oxygen may be beneficial when applied even before the establishment of a new lesion. 
Here we examined whether oxygen can modify disease progression when administered 
prophylactically (before the onset of neurological deficits). 
Rats with active EAE (n = 16) were randomly allocated to receive either oxygen (75%, n 
= 8) from the day of immunisation for 23 days or room air (n = 8). Interestingly, in rats 
treated with oxygen neurological deficits appeared on average 1 day later (12 d.p.i.) 
compared with rats kept in room air (11 d.p.i.) (Figure 2.23a, Table 2.3). Furthermore, 
the prophylactic treatment with oxygen significantly ameliorated the disease 
progression, decreasing the severity of the neurological disabilities of approximately 
38% at the neurological test compared with controls (p = 0.04; Figure 2.23a). Notably, 
only 3 out of 8 rats exposed to oxygen developed a full spectrum of EAE neurological 
disabilities (tail and bilateral hind limb paralysis, score = 9), whereas the other 5 
animals showed only tail paralysis and hind limbs weakness, maintaining the ability to 
walk with an unsteady gait (score ≤ 6; Table 2.3). In contrast, 7 out of 8 rats breathing 
room air developed both tail and bilateral hind limb paralysis (score = 9; Table 2.3), 
losing the ability to walk using their hind limbs. Indeed, the average maximum 
neurological deficit score reached by rats treated with oxygen was significantly lower (p 
= 0.001) compared with room air controls (Figure 2.23b). Furthermore, the cumulative 
score 23 days after the immunization that represents another measure of the burden of 
the disease (Fleming et al., 2005), was significantly reduced in animals treated with 
oxygen compared with room air controls (p = 0.026; Figure 2.23c). 
Thus, oxygen administration in the pre-symptomatic phase of the disease, significantly 
ameliorates and even delays the onset of neurological deficits. However, the effects of 
prolonged exposure (longer than 72 hours) to high concentration of oxygen have to be 
better investigated with regard to organ toxicity (e.g. lung) and oxidative damage within 
the inflamed tissue (e.g. demyelinating lesions). 
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Figure 2.23 - Oxygen treatment (75%) administered from the day of immunization for 23 
days delays the onset of neurological deficits and ameliorates the severity of the 
disease. 
a) Oxygen treatment (75%) administered prophylactically from the day of immunization for 23 
days, delayed the onset of disease and significantly attenuated disease progression compared 
with room air controls (p = 0.044). In particular the mean score in the oxygen-treated group was 
always lower than the room air control, and below a score of 6, indicating that rats treated with 
oxygen preserved the ability to walk using their hind limbs. b) The average maximum score for 
neurological deficit reached by rats treated with oxygen prophylactically was significantly lower 
compared with room air controls (p = 0.001). c) Cumulative neurological deficit score at the end 
of treatment (23 days after immunization) was significantly reduced in rats treated with oxygen 
prophylactically compared with room air controls (p = 0.026). Mann-Whitney U-test. Room air. N 
= 8 in each group.  
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 Room air 75% O2 
Number of rats with active 
EAE 
8 8 
Treatment No treatment, room air controls 
75% oxygen enriched air 
applied from the day of 
immunisation up to 23 days 
Asymptomatic 0 0 
Day of onset 11 ± 0.68 12 ± 0.55 
Rats that developed 
bilateral hind limb paralysis 
(score = 9) 
 
7 (85.7%) 
 
 
3 (37.5%) 
 
Table 2.3 - Table outlining the protocol and outcomes of prophylactically treating rats 
with active EAE with oxygen. 
 
2.3.0.0 Discussion 
2.3.1.0 Demyelination, inflammation, hypoxia and metabolic changes in 
non-treated animals with active EAE. 
The pathology of active EAE is characterised by inflammation and demyelination of the 
spinal cord (Stromnes and Goverman, 2006a). In active EAE as well as in MS, the loss 
of neurological function has typically been attributed to demyelination, however studies 
in passive EAE (Linington et al., 1993) and MS (Moreau et al., 1996; Bitsch et al., 1999) 
suggest that neuroinflammation per se can also cause neurological deficits.  
2.3.1.1 Demyelination in active EAE 
Interestingly, in this thesis we have seen that demyelination only partially correlates 
with the severity of the neurological deficits in rats with active EAE. Indeed, at the very 
early phase of disease (first and second day after disease onset), although neurological 
deficits were evident, some animals did not show spinal cord demyelination upon 
histological examination (data not shown), suggesting that other pathological 
mechanisms contribute to the loss of neurological function. Demyelination was limited 
(sometimes absent) during the early, symptomatic phase of disease and it became 
more prominent at the peak of neurological deficits, but it did not increase proportionally 
with the worsening of neurological function. In particular, we observed that in active 
EAE, although the neurological deficits were often worse at the second day of deficits 
compared with the first day of disease, the demyelination at these two time-points 
appeared similar. Nonetheless, the magnitude of demyelination along the spinal cord 
spatially correlated with the caudal to rostral severity of the neurological dysfunction, 
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and indeed, it was more prominent in the sacral region compared with more rostral 
(lumbar and thoracic) levels of the spinal cord. 
2.3.1.2 Inflammation in active EAE: activated microglia and 
macrophages  
As mentioned before, evidence in passive EAE suggests that neuroinflammation alone 
is sufficient to cause neurological deficits in the absence of demyelination (Linington et 
al., 1993)( see also Chapter 3). Furthermore, more recent studies in this model 
revealed that the infiltration of T-cells into the CNS starts before the onset of the deficits 
(Flügel et al., 2001; Bartholomäus et al., 2009; Murphy et al., 2010) and it is 
accompanied by the activation of resident microglia (Murphy et al., 2010). Interestingly, 
in active EAE, it has been shown that the activation of the endogenous microglia 
correlates with the initiation of disease expression, and it is the subsequent recruitment 
of macrophages that drives the progression of the disease to severe paralysis (Ajami et 
al., 2011). Therefore, it is possible that the activation of microglia and the recruitment of 
macrophages into the spinal cord correlate better with the progression of the disease 
than does demyelination. Here, we followed microglial activation and macrophage 
infiltration in the spinal cord of rats with active EAE during the first peak of disease by 
histologically labelling these cells for ED-1. We noticed an increased number of ED-1 
positive cells in rats with active EAE already from the early phase of disease (already 
present one day after onset of deficits), and their number increased as the disease 
progressed over the following days. Consistent with this finding, previous studies 
revealed a higher number of ED-1 positive cells (Davies et al., 2013), and, by MRI, an 
increased infiltration of magnetic-labeled monocytes (Engberink et al., 2010), into the 
spinal cord of animals with active EAE at the peak of deficits compared with early stage 
of the disease. Interestingly, we observed that microglial activation and macrophage 
infiltration were already evident one day after onset, whereas, as mentioned before, at 
this stage of disease demyelination was limited, affecting only sub-meningeal and 
perivascular areas of the spinal cord white matter, and even absent in some sick 
animals. Beside the temporal correlation between the abundance of activated microglia 
and macrophages and the severity of deficits, this inflammatory component correlated 
also with the spatial distribution of neurological dysfunction, and it was greater at caudal 
levels compared with more rostral regions of the spinal cord. However, the mechanisms 
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through which activated microglia and macrophages can harm neurological function, in 
the absence of demyelination, remain largely enigmatic. One possible mechanism 
includes the release at the site of inflammation of inflammatory mediators such ROS, 
NO and RNS, which can damage mitochondria causing an energy deficit (Mahad et al., 
2008; Nikic et al., 2011; Guo et al., 2013; Witte et al., 2014). In particular, NO has been 
indicated as a potent mediator of mitochondrial impairment (Brown and Cooper, 1994; 
Cleeter et al., 1994; Bolaños et al., 1997; Clementi et al., 1998) and during 
inflammation, it is synthesized by active microglia and macrophages via the enzymatic 
reaction catalyzed by iNOS (Stadelmann et al., 2005; Marik et al., 2007) (see also 
Chapter 1; paragraph 1.3.3.1). Dysfunctional mitochondria and the consequent 
inadequate synthesis of ATP can severely affect the function of neurons, which have 
high-energy demand to sustain their synaptic activity (Bélanger et al., 2011). Studies 
revealed that in active EAE (Cross et al., 1996; Schuh et al., 2014) as well as in MS 
lesions (Stadelmann et al., 2005; Haider et al., 2011; Fischer et al., 2012) the 
expression of iNOS is prominent. Briefly, NO has a high affinity and competes with 
oxygen for binding to the oxygen binding-site of mitochondrial complex-IV (Brown and 
Cooper, 1994; Cleeter et al., 1994). The binding of NO to complex-IV blocks oxidative 
phosphorylation with consequent reduction of ATP synthesis (Brown and Cooper, 
1994). Furthermore, NO reacts avidly with superoxide to form the strong oxidizing agent 
peroxynitrite (a RNS), which can in turn irreversibly damage the structure, and thereby 
the activity, of mitochondrial complexes I and IV (Clementi et al., 1998; Smith and 
Lassmann, 2002; Zhang et al., 2005; Mahad et al., 2008). Interestingly, evidence 
reveals that NO can block conduction in both normal, and, especially demyelinated, 
axons (Redford et al., 1997). In this study, we followed histologically the expression of 
iNOS in the spinal cord of rats with active EAE to understand whether increased 
synthesis of NO could explain the loss of function. Interestingly, we observed that the 
spinal expression of iNOS in rats with active EAE was higher during the first days of 
disease, but returned to control levels by the third day after onset. This histological 
observation was also confirmed by a gene expression analysis, which highlighted at the 
third day of disease a similar level of mRNA encoding for iNOS with healthy controls. 
These results are consistent with previous observations in active EAE (Schuh et al., 
2014) and in contrast to what has been described in active MS lesions (Marik et al., 
2007; Fischer et al., 2012). The transient expression of iNOS suggests that NO may 
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contribute to the loss of neurological function at the beginning of disease, but not in 
more advanced stages. Indeed, while the expression of iNOS decreases, the 
neurological deficits continue to get worse, underlining the probability that other 
mechanisms contribute to the deficits. 
2.3.1.3 Hypoxia, metabolic changes and cell stress in active EAE 
Hypoxia is another possible pathological event that could explain, at least in part, the 
neurological deficits in active EAE. Interestingly, tissue hypoxia has been reported to 
correlate closely with the spatial and temporal progression of neurological deficits 
(Davies et al., 2013). Davies and colleagues (2013) have shown that spinal hypoxia is 
initially more intense in the sacral level of the spinal cord, and it reaches the lumbar and 
thoracic levels concomitantly with the extension of the neurological deficits to involve 
the hind limbs (Davies et al., 2013). Furthermore, the severity of hypoxia has been 
found to increase proportionally with the severity of the neurological signs (Davies et 
al., 2013). In this thesis, we confirmed that the spinal cord of rats with active EAE was 
characterized by tissue hypoxia as exemplified by the expression of HIF1α, and that 
such hypoxia temporally correlated with the progression of the disease. Indeed, HIF1α 
expression was already significantly increased at the first day of deficits compared with 
healthy controls, and its expression increased in the following days in proportion with 
the severity of the disease. Furthermore, HIF1α expression was augmented also in sick 
animals that were not characterized by histological signs of spinal demyelination. 
However, the reason(s) why the inflamed spinal cord becomes hypoxic are still 
unknown and will be part of the discussion in the next chapter of this thesis (Chapter 3; 
paragraph 3.3.1.0). 
These findings raise the possibility that tissue hypoxia could play a critical role in the 
onset and progression of neurological deficits due to neuroinflammation. Indeed, 
insufficient oxygen supply can severely affect CNS function (LaManna, 2007; le Feber 
et al., 2016) due to reduction in oxidative phosphorylation and the subsequent decrease 
in ATP synthesis (Solaini et al., 2010), and this detrimental effect could be exacerbated 
by the inflammatory-mediated damage to mitochondria (Mahad et al., 2008; Nikic et al., 
2011; Guo et al., 2013; Witte et al., 2014). In order to survive with an inadequate 
oxygen availability and in an attempt to restore an adequate oxygen supply, the CNS 
undertakes a number of adaptations to hypoxia (LaManna et al., 2004). One of the 
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mechanisms by which a cell can overcome an energy deficit caused by a shortage of 
oxygen and/or mitochondrial dysfunction is activation of the glycolytic pathway. 
Glycolysis may compensate for the loss of energy by producing ATP via the anaerobic 
catabolism of glucose, which may provide enough energy to sustain neuronal activity, 
or at least neuronal survival (Trapp and Stys, 2009). However, PFK-2 labelling indicates 
that the activation of glycolysis in rats with active EAE is transient, and gradually returns 
to control levels three days after the onset of disease. Activation of glycolysis followed a 
similar pattern to iNOS expression, suggesting that glycolysis may be related to the 
concentration of NO in the tissue. In support of this hypothesis, a connection between 
iNOS and glycolysis has previously been described in the brain (Keeney et al., 2013) 
and in the pancreas (Eckersten and Henningsson, 2012).  
Vasodilation of capillaries is another mechanism aimed to increase the blood supply 
and oxygenation of the tissue during hypoxia. Vasodilation occurs in active EAE from 
the very early phase of disease, as shown by previous studies (Boroujerdi et al., 2013; 
Davies et al., 2013), and in this thesis by the increased size of Reca1-positive vessels. 
Interestingly, Boroujerdi and colleagues (2013) reported a significant increase in vessel 
size during the pre-symptomatic phase of active EAE. This vasodilation can be caused 
by inflammation but it could also be indicative of hypoxia- and metabolic-related 
changes within the CNS of animals with active EAE, which can occur even before the 
onset of deficits.  
Surprisingly, we detected an apparently higher number of Reca1-positive vessels in the 
spinal cord of rats with active EAE, and the number appeared to increase gradually with 
the progression of disease. Increased vessel number may reflect angiogenesis in the 
inflamed spinal cord, but previous reports suggest that the formation of new vessels 
occurs at later stages of the disease compared to the ones investigated in this thesis 
(Seabrook et al., 2010; Davies et al., 2013). A possible explanation for the elevated 
number of vessels detected could be that the increased vessel size resulted in an 
apparent overexpression due to the fact that larger vessels will be more likely to appear 
in different sections. A stereological analysis of a larger volume of the spinal cord (e.g. 
by using the Neurolucida Stereoinvestigator, MBF Bioscience, USA) may help in 
clarifying this doubt.   
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Hypoxia as well as other conditions such as glucose deprivation, ER stress, viral 
infection and inflammation, can cause cell stress resulting in the activation of the 
integrated stress response (Donnelly et al., 2013). We found that the spinal cord of rats 
with active EAE was characterized by increased expression of p-eIF2α, a marker of the 
integrated stress response, in oligodendrocytes, consistent with previous observation 
by other groups (Chakrabarty et al., 2004; Lin and Popko, 2009). In active EAE, this 
response has been linked to inflammation and in particular to the IFNγ-driven activation 
of PERK (Lin and Popko, 2009; Lin et al., 2012). However, the fact that by 
administering oxygen to rats with active EAE we have been able to reduce such cellular 
stress in oligodendrocytes suggests that at least part of the integrated stress response 
in active EAE is caused by hypoxia (see also discussion in paragraph 2.3.2.0). The aim 
behind the integrated stress response mediated by hypoxia, lies in the fact that cells try 
to save energy by limiting their protein synthesis, while cytoprotective mechanisms try 
to repair the damage caused by hypoxia. Hypoxia can lead to a state of cellular stress 
and decreased protein synthesis via a number of different mechanisms (Koumenis et 
al., 2002; L. Liu et al., 2006; Liu et al., 2008; Wouters and Koritzinsky, 2008). One 
mechanism includes a condition known as ER stress, which comprises the activation of 
three ER stress sensors: PERK, inositol-requiring protein 1 (IRE1) and ATF6 (Wouters 
and Koritzinsky, 2008). These are transmembrane proteins of the ER that signal luminal 
stress to the cytosol and the nucleus, and are involved in the inhibition of the protein 
synthesis via the downstream phosphorylation of eIF2α (Wouters and Koritzinsky, 
2008). During hypoxia, two mechanisms can trigger the ER-stress response as 
described below.  
In the ER, many chaperones assist nascent proteins to reach their native fold by 
consuming ATP (Saibil, 2013). In hypoxic conditions, the rate of ATP synthesis 
decreases due to impaired mitochondrial respiration, therefore an accumulation of 
misfolded and/or unfolded proteins in the ER may occur due to an insufficient energy 
supply to the chaperones (L. Liu et al., 2006). Following the accumulation of 
misfolded/unfolded proteins in the ER a specific chaperone, the immunoglobulin-heavy-
chain-binding protein (BiP), which in physiological condition is bound to PERK, IRE1 
and ATF6, is taken away from these stress sensors and recruited by the misfolded 
proteins in the last attempt to drive correct folding (Wouters and Koritzinsky, 2008). In 
physiological conditions, the binding of BiP to PERK, IRE1 and ATF6 inhibits their 
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activation, whereas, when BiP is shunted away and recruited by misfolded/unfolded 
protein, PERK, IRE1 and ATF6 are activated and cause the downstream inhibition of 
protein synthesis via the phosphorylation of eIF2α and the transcription of several 
cytoprotective genes (Wouters and Koritzinsky, 2008). Activation of PERK and IRE1 
has been reported to occur within minutes when cells are exposed to hypoxia, and the 
magnitude of the downstream inhibition of protein synthesis has been found to correlate 
with the intensity and duration of such hypoxia (Wouters and Koritzinsky, 2008). 
Activation of the third ER stress sensor ATF6 by hypoxia has not been directly 
demonstrated but is probable, based on the observation that many of its transcriptional 
targets are induced under hypoxic conditions (Wouters and Koritzinsky, 2008). In 
addition, hypoxia can cause ER stress by increasing the cellular production of ROS (to 
see how hypoxia enhances the synthesis of ROS see paragraph 5.3.0.0). ROS can 
cause ER stress exacerbating the energy deficit by damaging mitochondria, but also, 
ROS can react directly with proteins changing their structure or interfering with their 
folding, finally causing an accumulation of misfolded proteins and the activation of the 
ER stress response as described above (Liu et al., 2008).  
Furthermore, hypoxia can lead to a severe decrease in protein synthesis via a 
mechanism that is independent of the ER stress response. This mechanism involves 
the inhibition of the mechanistic target of rapamycin (mTOR), a kinase implicated in a 
multitude of signaling pathways associated with the regulation of cell survival and 
growth via changes in mRNA translation, ribosomal biogenesis, autophagy and 
metabolism (Wouters and Koritzinsky, 2008). During hypoxia, the promyelocytic 
leukaemia tumour suppressor (PML) has been reported to bind mTOR and inactivate it 
through sequestration in nuclear bodies (Wouters and Koritzinsky, 2008). In the 
absence of mTOR, the protein kinase R (PKR), a cytosolic kinase, is not 
phosphorylated and it is active and free to inhibit protein synthesis via the 
phosphorylation of eIF2α (Wouters and Koritzinsky, 2008). Inhibition of mTOR arrests 
also the phosphorylation of ribosomal protein S6 kinase (p70S6K) inactivating this 
kinase. Inactive p70S6K is unable to phosphorylate and activate the ribosomal subunit-
6, a molecule needed for the protein synthesis (Wouters and Koritzinsky, 2008). In 
addition, when mTOR is inhibited, the eukaryotic initiation factor 4E binding protein 1 
(4E-BP1), a cap-mediated inhibitor of the eukaryotic elongation factor 4E (eIF4E), is not 
phosphorylated. Non-phosphorylated 4E-BP1 binds eIF4E masking its  binding-site to 
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the eukaryotic elongation factor 4G (eIF4G); thereby eIF4E cannot dimerize with eIF4G 
to form the functional complex needed for the protein synthesis (Wouters and 
Koritzinsky, 2008). Briefly, hypoxia can markedly decrease the rate of protein synthesis 
in cells via several mechanisms that include the activation of the ER-stress response 
and/or the inhibition of mTOR (Wouters and Koritzinsky, 2008). In hypoxic conditions, 
the downstream attenuation of protein synthesis can occur via both the phosphorylation 
of eIF2α and the inhibition of other factors involved in protein synthesis such as the 
ribosomal subunit-6 and eIF4E (Wouters and Koritzinsky, 2008). Although a number of 
studies reports the overexpression of p-eIF2α in the CNS of animals with active EAE 
(Chakrabarty et al., 2004; Lin and Popko, 2009) and in MS lesions (Allen et al., 2001; 
Kutzelnigg et al., 2005; Cunnea et al., 2011; McMahon et al., 2012; Ní Fhlathartaigh et 
al., 2013), the finding that the inflamed CNS can be hypoxic (Davies et al., 2013) raises 
the possibility that reduced protein synthesis can occur also via molecular pathways 
which are independent to the phosphorylation of eIF2α.  
In summary, we have seen that the spinal cord of rats with active EAE is characterized 
by remarkable pathological alterations including inflammation, demyelination and a 
series of metabolic changes suggestive of tissue hypoxia and an energy deficit (HIF1α 
expression, activation of glycolysis, vasodilation and cell stress). The poor correlation 
between demyelination and the severity of the neurological deficits suggests that 
demyelination may not be the only factor causing the functional impairment.  In 
addition, the transient expression of iNOS and PFK-2 is in contrast with the more 
persistent inflammation, HIF1α expression and neurological deficits, indicating that NO 
cannot be responsible for the neurological deficits at late stage of disease and 
glycolysis is not enough to counteract the ongoing energy failure and loss of function. 
Hypoxia and microglial/macrophage activation instead, appear to correlate better with 
the severity and distribution of neurological deficits. 
 
2.3.2.0 Oxygen treatment ameliorates neurological deficits in active EAE: 
insights on optimal timing and duration for an effective therapy 
Our findings and previous evidence in MS (Aboul-Enein et al., 2003; Aboul-Enein and 
Lassmann, 2005; Trapp and Stys, 2009; Steen et al., 2013) and in active EAE (Davies 
et al., 2013) show the presence of tissue hypoxia during neuroinflammation, raising the 
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possibility that oxygen therapy may represent a suitable treatment for the neurological 
deficits due to MS. Here, we have shown that oxygen treatment can effectively 
ameliorate neurological deficits in an animal model of MS, namely active EAE, and we 
provide insights on the optimal time and duration for oxygen administration.  
We have seen that oxygen is able to improve the neurological function promptly, after 
just 1 hour of administration, even in paralysed animals. However, the beneficial effect 
achieved after 1 hour of oxygen exposure was transient, and disappeared after another 
hour in room air. Furthermore, only 50% of the rats improved after 1 hour of treatment, 
and why the other animals did not benefit from the therapy is not known. One possible 
explanation may lie in the different level of spinal expression of iNOS among animals. It 
is possible that some rats were characterized by a higher expression of NO than 
others, and this may have counteracted the beneficial effect of oxygen in these rats. 
Indeed, as mentioned previously, NO can block oxidative phosphorylation via binding to 
mitochondrial complex-IV (Brown and Cooper, 1994). Therefore, in the presence of 
elevated concentration of NO, increased oxygen availability may be not sufficient to 
restore an adequate energy supply, at least for short-term exposure to oxygen such as 
only 1-hour, because the oxygen-binding site of complex-IV is “occupied” by NO.  
We then investigated what the best time point would be to administer oxygen by 
treating rats with active EAE for 24 hours from either the first, second or third day of 
disease. Interestingly, oxygen ameliorated disease severity after 24 hours of treatment 
compared with time-matched controls breathing room air, independently of whether the 
treatment started on the first, second or third day of deficit. The greatest beneficial 
effect was achieved when oxygen was applied from the onset of disease. Interestingly, 
as discussed in the previous paragraph, demyelination is rare during the first days of 
disease, and when present, it is limited in the spinal cord of rats with active EAE. It is 
possible that the hypoxia and energy deficit drive, at least in part, neurological deficits 
during the early stage of disease, and this would explain the greatest beneficial effect 
achieved with oxygen administration at the beginning of the disease. This hypothesis is 
in line with a recent study in-vivo that showed the presence of an energy deficit in mice 
during the symptomatic phase of active EAE before the onset of demyelination 
(Sadeghian et al., 2016), and consistent with findings in-vitro that revealed that even 
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short-term exposure to hypoxia can severely impair the synaptic activity of neurons, 
and the damage is reversible upon prompt re-oxygenation (le Feber et al., 2016).  
To determine the best duration for oxygen administration, we treated rats with active 
EAE from the onset of disease for 24, 48 or 72 hours. All treatment durations resulted in 
an attenuation of the disease, and interestingly the severity of neurological dysfunction 
remained milder compared with room air controls for several days after treatment 
cessation. Rats treated with oxygen for 72 hours from the first day of neurological signs, 
experienced a better recovery of the neurological function during the remitting phase of 
disease, compared with room air controls and oxygen-treated groups for 24 and 48 
hours. Furthermore, treatment for 72 hours provided significant protection from some of 
the main pathological features of active EAE when compared with room air controls, 
including: loss of body weight, demyelination and death of oligodendrocyte. In 
summary, oxygen therapy administered from the onset of disease and maintained for 
the entire duration of the first peak of neurological deficits (72 hours treatment), led to a 
more pronounced and long-lasting amelioration of the disease and a greater protection 
from spinal cord damage. The reason responsible for the more pronounced recovery of 
the neurological function achieved after oxygen treatment for 72 hours from the onset of 
disease, could be due to the reduced demyelination at the first peak of disease. 
However, in these rats, oxygen treatment did not protect from the development of the 
second peak of deficits, possibly because inflammation and hypoxia reappear later in 
the disease (Davies et al., 2013), suggesting that repeated administrations of oxygen, 
probably from the onset of the new relapse, may be needed in order to attenuate 
progression of disease in the long-term.     
To evaluate whether oxygen therapy can change the pathogenesis of active EAE, 
oxygen was administered prophylactically (before the onset of deficit) from the day of 
immunization for 23 days (second peak of disease). Interestingly, oxygen delayed the 
onset of disease and significantly ameliorated the severity of neurological deficits 
compared with rats breathing room air. Prophylactic oxygen treatment resulted in a 
remarkable protection from loss of neurological function. Indeed, the majority of rats 
treated with oxygen (almost 75%) did not develop hind limb paralysis, whereas almost 
all rats (86%) exposed to room air lost motor control of their hind limbs. The outstanding 
beneficial effect achieved with prophylactic oxygen administration, raises the possibility 
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that a sub-clinical energy failure may occur even before the onset of clear neurological 
deficits, possibly caused by the early infiltration of lymphocytes into the CNS (Flügel et 
al., 2001; Bartholomäus et al., 2009; Murphy et al., 2010). However, other mechanisms 
may be implicated including a modulation of the autoimmune response by oxygen. A 
recent study showed that hypoxia can affect the differentiation of naïve T-cells into T-
cell effectors (T helper-17, Th17) rather than anti-inflammatory regulatory T-cells (Treg), 
through a HIF1α-dependent pathway (Dang et al., 2011). Th17 alongside with Th1 cells 
are the principal lymphocytes involved in the pathogenesis of active EAE (Hemmer et 
al., 2015). Interestingly, Dang and colleagues (2011) showed that conditional HIF1α 
knockout mice in T-cells were significantly protected from active EAE induction (Dang 
et al., 2011). In this regard, it is possible that the prophylactic administration of oxygen 
has decreased HIF1α level in the body, including HIF1α expression within naïve T-
cells, reducing their differentiation in Th17. To address this possibility, we have 
administered prophylactic oxygen treatment in rats with passive EAE. Passive EAE is 
induced by the injection in recipient rats of encephalitogenic T-cells reactive against 
MOG. Differentiated encephalitogenic T-cells are isolated from rats sensitized to rMOG 
and reactivated in-vitro before the injection, thus an effect of oxygen on their 
differentiation/activation is unlikely. This experiment is part of the next chapter (Chapter 
3) and it will be discussed later in this thesis. 
However the beneficial effects of oxygen were only partial. Indeed, the disease was 
only attenuated and not all treated-animals responded to the therapy, implying that 
some pathological mechanisms were not affected by oxygen. EAE is an autoimmune-
mediated encephalopathy, in which an early event is neuroinflammation. Our findings 
provide the first indications that oxygen may not have a major effect on the 
inflammation. Thus, it is possible that while oxygen administration plays its beneficial 
effect by sustaining the energetic demand of neurons and glial cells (e.g. 
oligodendrocytes), the inflammatory components within the CNS have still exerted a 
number of detrimental roles. Indeed, the abundance of infiltrating T-cells and mediators 
(e.g. TNFα) within the CNS of rats with active EAE did not change after oxygen 
administration. Therefore, it is possible that the inflammation has continued to harm the 
tissue (e.g. causing necroptosis of oligodendrocytes and neurons), explaining why, 
though attenuated, the disease did not stop in rats treated with oxygen.  
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In that case, oxygen may be particularly effective if applied in combination with anti-
inflammatory/immunomodulatory treatments, possibly providing a beneficial effect in 
which the reduced inflammation (provided by the anti-inflammatory/immunomodulatory 
treatments) could be combined with an increased metabolic support to the CNS (given 
by oxygen). 
 
2.3.3.0 Effects of oxygen treatment on the pathology of active EAE 
2.3.3.1 Hypoxia and metabolic changes in rats with active EAE after 
exposure to oxygen treatment  
Histopathological analysis of spinal cord of rats with active EAE revealed that oxygen is 
able to reduce the level of HIF1α promptly after 24 hours of exposure compared with 
room air controls, and significantly when administered at the first or third day of 
disease. Interestingly, when applied from the onset of disease for 24, 48 or 72 hours, 
oxygen decreased the expression of HIF1α at the peak of disease in proportion to the 
duration of the treatment, indicating a reduction of tissue hypoxia. In addition to hypoxia 
also microglial and macrophage derived inflammatory mediators, in particular TNFα, 
have been implicated in the upregulation of cellular HIF1α expression (Frede et al., 
2007; Imtiyaz and Simon, 2010). Nevertheless, we did not observe changes in 
microglial activation and macrophage infiltration after 24 hours of oxygen treatment 
from the first, second or third day of disease, and also, we did not detect significant 
differences in the gene expression of TNFα and other inflammatory markers after 72 
hours of oxygen exposure from the onset of deficits. Furthermore, previous findings 
from our group have shown that oxygen administration decreases pimonidazole 
labelling (a direct marker of tissue hypoxia) and restores a physiological oxygen partial 
pressure in the spinal cord of rats with active EAE (Davies et al., 2013). Thereafter, 
despite elevated HIF1α expression may result from both hypoxia and inflammation, we 
believe that the decreased level of HIF1α achieved after oxygen treatment in rats with 
active EAE is a consequence of reduced tissue hypoxia rather than an effect on 
inflammation.  
Intriguingly, the level of HIF1α at the peak of disease was lower in oxygen-treated rats 
compared with room air controls even after cessation of oxygen administration. It is 
reasonable to suppose that the expression of HIF1α remains low as long as a proper 
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oxygenation of the tissue is provided or until the cause of hypoxia is not removed, 
raising the question of why the expression of HIF1α is decreased even when the rats 
are returned to room air. A possible explanation may lie in the fact that the reduced 
HIF1α signal correlated with reduced demyelination and macrophage/microglial 
activation. Indeed, both demyelinated axons and active microglia and macrophages can 
consume vast amount of oxygen to sustain their activities (as described following). 
Evidence demonstrated that demyelinated axons are intrinsically more excitable (Smith 
and McDonald, 1980; Felts et al., 1995; Hamada and Kole, 2015) and the conduction of 
the electric impulse in the absence of myelin is more energy consuming (Trapp and 
Stys, 2009). As axons rely mainly on mitochondrial respiration to sustain their energy 
demand (Bélanger et al., 2011), it is easy to image that, when demyelinated, they 
consume a higher amount of oxygen. In addition, the reduced phagocytic activation of 
microglia and macrophages, detected in oxygen-treated rats at the peak of disease 
using ED-1, implies a decreased consumption of oxygen via the oxidative burst 
(Bellavite, 1988; Banati et al., 1991; Dahlgren and Karlsson, 1999) (see also Chapter 3; 
paragraph 3.3.1.0).    
We hypothesized that by increasing tissue oxygenation it would be possible to 
overcome the activation of glycolysis in the inflamed spinal cord. As discussed 
previously, despite tissue hypoxia persisting for several days in rats with active EAE 
breathing room air, the activation of glycolysis (assessed following PFK-2 expression) 
was transient and returned to control level by the third day of deficits, showing a similar 
pattern to iNOS expression. In contrast with our hypothesis, oxygen treatment did not 
decrease the level of PFK-2 after 24 hours of exposure. One possible explanation is 
that elevated NO concentration aside from hypoxia, can cause activation of glycolysis. 
Indeed, evidence indicates that NO-mediated inhibition of mitochondrial respiration 
leads to the activation of glycolysis in astrocytes (Moncada and Bolanos, 2006). In our 
EAE rats, iNOS expression did not change after oxygen treatment implying a similar 
concentration of NO in the spinal cord of oxygen-treated and untreated animals. 
Interestingly, we have seen that iNOS and PFK-2 immunoreactivity on adjacent spinal 
cord cross-sections localized in the same areas (Figure 2.24) and PFK-2 labelling 
showed morphological similarities with reactive astrocytes arguing in favour that, at 
least part of the PFK-2 positive cells may have been astrocytes. Possibly, elevated NO 
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concentration within the tissue may have contributed to enhance the activation of the 
glycolytic pathway despite the re-oxygenation achieved after oxygen treatment. 
 
Figure 2.24 - PFK-2 and iNOS labelling of adjacent spinal cord cross sections from a rat 
with active EAE. 
PFK-2 labelling localizes inside, and surrounds foci of, positive iNOS labelling, suggesting that at 
least part of the activation of glycolysis is due to NO-mediated impairment of mitochondrial 
respiration. Scale bar = 50μm.  
 
Elevated oxygen supply can lead to the vasoconstriction of capillaries in an attempt to 
restore normal oxygenation of the tissue by decreasing blood flow. Constriction of blood 
vessels could therefore occur during administration of oxygen-enriched air and 
counteract the re-oxygenation of the inflamed spinal cord. However, we did not observe 
differences in blood vessel size (and number) in rats treated with oxygen for 24 hours at 
different stages of the disease, compared with time-matched controls. A possible 
explanation for this finding could be that a rise in oxygen concentration in the blood 
does not induce vasoconstriction in inflamed hypoxic tissue as instead described under 
physiological conditions.  
2.3.3.2 Demyelination and oligodendrocyte survival in rats with 
active EAE treated with oxygen 
The most prominent and surprising histological finding was that oxygen decreased 
white matter spinal cord demyelination at the peak of neurological deficits (three days 
after onset) when administered from the first day of disease for 24, 48 or 72 hours. 
Instead, when administered for only 24 hours at different stages of disease (from the 
first, second or third day of deficits) no changes in spinal cord demyelination were 
observed straight after oxygen treatment, compared with time-matched room air 
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controls. A possible explanation could be that in rats treated with oxygen for 24 hours 
on either the first or second day of disease, at this stage, the demyelination was too 
limited to detect differences compared with controls, whereas, later in the disease, 
demyelination was already prominent and probably the tissue was too compromised to 
benefit from late administration of oxygen. These findings suggest that oxygen 
treatment can protect from demyelination when administered from the very early stage 
of disease, but the protective effect is delayed and it can be detected in advanced 
stages of disease, when, in non-treated animals, the demyelination becomes 
prominent. 
Interestingly, as mentioned before, in rats exposed to oxygen from the onset of deficits 
for 24, 48 or 72 hours, at the peak of disease, the protection from demyelination was 
proportional to the duration of the treatment, with the 72 hours treated-group showing a 
significant reduction of demyelination compared with room air control. The reduced 
demyelination might have been achieved via either enhanced remyelination through the 
differentiation of oligodendrocyte progenitor cells (OPCs), or via the protection of pre-
existing mature oligodendrocytes. Studies investigated the time needed for 
remyelination to occur in lysolecithin- (Miron et al., 2013) and LPS- (Felts et al., 2005) 
induced demyelinating lesions. Miron and colleagues (2013) induced demyelination via 
the stereotaxic injection of lysolecithin in the corpus callosum of mice, and this injection 
resulted in an almost instant, localized demyelination of the nerve fibers. Interestingly, 
this study revealed that OPCs migrate and reach the lesion site at the earliest 3-4 days 
post-lesion, but OPC differentiation and remyelination start only 10-14 days after 
lysolecithin injection, and demyelination is complete within 21-24 days (Miron et al., 
2013). Felts and colleagues (2005) induced focal demyelination in the spinal cord of 
rats via the injection of LPS into the dorsal column. In this model, demyelination was 
evident 5-7 days after LPS injection, remyelination started approximately 14 days after 
LPS injection, and it was mostly complete by 28 days (Felts et al., 2005). Taken 
together, these findings suggest that remyelination requires several days to occur. 
Therefore, we believe that the acute reduction of demyelination observed at the peak of 
disease (only 3 days after onset) in rats treated with oxygen from the onset of deficits, 
is due to a protective effect on mature oligodendrocytes rather than enhanced 
remyelination induced by the therapy. In support to this hypothesis, we discovered that, 
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at the peak of disease, oxygen-treated rats were characterized by an increased survival 
of mature oligodendrocytes in proportion to the duration of the exposure (24, 48 or 72 
hours from onset of disease), which was significant in rats treated with oxygen for 72 
hours compared with room air controls. 
It has been shown that cell stress conditions can cause apoptosis of oligodendrocytes 
(Lin and Popko, 2009; Roussel et al., 2013). Interestingly, the decrease in both 
demyelination and oligodendrocyte loss achieved with oxygen treatment was 
associated with reduced integrated stress response in oligodendrocytes at the peak of 
disease, as shown by a lower number of oligodendrocytes positive for p-eIF2α. In 
particular, a significant reduction of p-eIF2α positive oligodendrocytes was found in rats 
treated with oxygen for 72 hours from the onset of deficits. Several in-vitro and in-vivo 
studies recognized the integrated stress response to be protective in the short-term, but 
detrimental in the long-term because it can trigger the activation of apoptotic pathways 
(reviewed in Tabas and Ron, 2011). In addition, in active EAE, the phosphorylation of 
eIF2α can be both protective and detrimental depending on the stage of disease at 
which it occurs and on how long eIF2α remains phosphorylated (Lin et al., 2006, Lin et 
al., 2007, Lin et al., 2013; Lin and Popko, 2009; Way et al., 2016). A recent study 
demonstrated that by enhancing eIF2α phosphorylation before the onset of active EAE, 
it is possible to protect animals from neurological deficits and demyelination (Lin et al., 
2007). This effect might be a result of a pre-conditioning the tissue to stress, which may 
have prepared the oligodendrocytes to survive the ensuing damage. By contrast, the 
same group of researchers (Lin et al., 2006) showed that an increased and persistent 
activation of the integrated stress response after the onset of dysfunction (symptomatic 
phase) causes increased oligodendrocyte apoptosis and demyelination, exacerbation of 
neurological deficits and delayed recovery during the remitting phase (Lin et al., 2006). 
Thus, it is possible that the reduced p-eIF2α achieved with oxygen therapy during the 
symptomatic phase of the disease, might have protected oligodendrocytes from 
apoptosis and demyelination, subsequently ameliorating the disease course in oxygen-
treated rats. As discussed previously in this thesis, although several conditions 
including hypoxia can enhance the integrated stress response (Donnelly et al., 2013), 
increased expression of p-eIF2α in active EAE has been attributed only to inflammation 
and in particular to increased levels of IFNγ (Lin and Popko, 2009). Our finding that p-
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eIF2α is decreased in oligodendrocytes after oxygen administration, raises the 
possibility that hypoxia can also contribute to cell stress during active EAE, and the fact 
that oxygen did not change the spinal levels of inflammatory cytokines (including IFNγ) 
compared with controls, argues in favour of this hypothesis. Furthermore, we have 
previously discussed (paragraph 2.3.1.0) that hypoxia can also cause a reduction of 
protein synthesis via pathways that do not involve p-eIF2α (Wouters and Koritzinsky, 
2008). Therefore, it is possible that the quantification of p-eIF2α has even provided an 
underestimation of the restored protein synthesis resulting from oxygen therapy. 
2.3.3.3 Inflammation in rats with active EAE treated with oxygen 
To determine whether oxygen exerts its beneficial effect via immunomodulatory 
mechanisms, we have examined the spinal cord of rats with active EAE for the 
abundance of T-cells, active microglia and macrophages, and expression of pro- and 
anti-inflammatory markers. Although we did not detect differences in the number of 
infiltrating T-cells, we found a decreased number of ED-1 positive microglia and 
macrophages at the peak of disease in the spinal cord of rats treated with oxygen from 
the onset of deficits for 24, 48 or 72 hours, and significantly in rats exposed to oxygen 
for 72 hours compared with controls, raising the possibility that oxygen can play an anti-
inflammatory effect. A possible immunomodulatory role of oxygen has been suggested 
in the 1970’s in a study investigating the role of HBOT in active EAE (Warren et al., 
1978), however no further evidence has been provided in support of this observation. 
Nonetheless, recent studies revealed that hypoxia, via changes in pathways regulated 
by hypoxia-related transcription factors (such as HIF1α and HIF2α) and along with 
other cytokine-mediated signaling, can modulate the activation of macrophages to a M1 
(pro-inflammatory) rather than a M2 (anti-inflammatory) phenotype (Riboldi et al., 2013; 
Wang et al., 2014; Orihuela et al., 2016). However, at the peak of disease, we did not 
detect differences in the spinal expression of pro- and anti-inflammatory genes, 
including markers of M1 (iNOS) and M2 (Arg1) activation, in rats treated with oxygen for 
72 hours from the onset of the disease compared with room air controls. This finding 
argues against an anti-inflammatory effect of oxygen. 
A possible explanation for the reduced number of activated microglia and macrophages 
observed at the peak of disease in oxygen-treated rats from the onset of deficits may 
be that such reduction was a consequence of the decreased demyelination. 
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Demyelination releases cell debris in the tissue that has subsequently to be removed by 
phagocytic cells (Fu et al., 2014). Therefore, a decrease in demyelination would require 
a reduced number of activated scavenger cells (microglia and macrophages), 
suggesting that the effect of oxygen on the abundance of phagocytic cells (as detected 
via ED-1 histological examination) was indirect, rather than direct. In this regard, it is 
interesting to note that the distribution and abundance of active microglia and 
macrophages often correlated with the presence and extent of demyelination. Indeed, 
demyelination and activated microglia and macrophages, often co-localized and were 
more diffuse at the sacral level of the spinal cord, which in addition, has been shown to 
be also the more hypoxic region of cord (Davies et al., 2013) and in this thesis, 
appeared to benefit the most from oxygen therapy.  
However, recent studies in cancer have demonstrated that gradients of tissue hypoxia 
can affect monocyte/macrophage extravasation and migration within organs (Murdoch 
and Lewis, 2005; Chanmee et al., 2014). Indeed, it has been shown that these cells 
tend to be attracted to, and to migrate into, hypoxic regions (Murdoch and Lewis, 2005; 
Chanmee et al., 2014). Therefore, it cannot be excluded that the decreased number of 
ED-1+ cells in the spinal cord of rats treated with oxygen may be also a consequence of 
reduced macrophage infiltration due to decreased tissue hypoxia. 
Evidence in MS (Pikor et al., 2012) as well as in EAE (Linington et al., 1993; Mann et 
al., 2012) supports an important role for B-cells in the pathogenesis of the disease via 
antibody-mediated mechanisms. In EAE, it has been shown that the mechanisms 
through which antibodies trigger demyelination include complement activation on the 
plasma membrane of oligodendrocytes and Fc receptor engagement (Mann et al., 
2012). Complement activation can lead to a greater recruitment of inflammatory cells in 
the site of inflammation and it can also directly cause oligodendrocyte damage via the 
formation of a trans-membrane channel, which can lead to osmotic lysis (Peña et al., 
2013). Furthermore, antibodies against oligodendrocyte antigens have been shown to 
stimulate nearby macrophages by interacting with their Fc receptors (Griot-Wenk et al., 
1991). In-vitro, this coincides with the damage of oligodendrocytes due to increased 
release of toxic compounds such as ROS and TNFα from the stimulated macrophages 
(Griot-Wenk et al., 1991). However, in this study we did not investigate whether oxygen 
affects the recruitment and activation of B-cells into the CNS, or the synthesis/secretion 
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of antibodies during EAE.  We believe that the protective effect of oxygen is mainly 
mediated by metabolic-related mechanisms, which have increased the resilience of 
CNS cells against the inflammatory attack, rather than a direct, anti-inflammatory role of 
the treatment. As discussed before, this hypothesis is partially supported by our 
findings that oxygen does not change the number of T-cells infiltrating the CNS, and the 
expression of pro- and anti-inflammatory markers. The reduced p-eIF2α expression in 
oligodendrocytes upon oxygen administration suggests the restoration of a more 
physiological rate of protein synthesis in these cells, arguing in favour of this hypothesis 
(see paragraph 2.2.3.4). Nonetheless, a role of oxygen on B-cell activation cannot be 
excluded; therefore future experiments should aim to investigate what the effects of 
oxygen are on the B-cell component during EAE.   
Our findings provide preliminary indications that the efficacy of the therapy in 
attenuating neurological deficits and demyelination may not be mediated by anti-
inflammatory mechanisms. Rather, the persistent behavioural effect may be due to 
resolute, metabolic changes that could make, inter alia, oligodendrocytes more 
resistant to the inflammatory insult. 
2.2.3.4 Effects of hypoxia on oligodendrocyte metabolism 
As discussed previously, administration of oxygen to rats with active EAE resulted in a 
prominent protection of oligodendrocytes, suggesting that oxygen may be beneficial by 
attenuating the energy deficit in these cells. However, although mitochondrial 
respiration plays an important role in immature oligodendrocytes providing energy for 
oligodendrocyte differentiation and myelination (Rinholm et al., 2011, 2016; Amaral et 
al., 2016), a recent study shows that the anaerobic glycolysis is the main source of 
energy in mature oligodendrocytes (Fünfschilling et al., 2012). In addition, it has been 
shown that mature oligodendrocytes have fewer mitochondria compared with other glial 
cells and neurons, and these mitochondria are characterized by fewer cristae in the 
inner membrane, suggesting a decreased ATP production via oxidative phosphorylation 
(Rinholm et al., 2016). These findings suggest that mature oligodendrocytes do not 
require much oxygen to fuel their energy supply. However, other observations may 
seem conflicting with this hypothesis (see following). An in-vitro study has shown that 
virtual hypoxia, induced by the inhibition of the mitochondrial complex-IV, causes injury 
and death of mature oligodendrocytes and impairs OPCs differentiation (Ziabreva et al., 
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2010). In addition, mature oligodendrocytes have been reported to be particularly 
susceptible to ischaemic stroke in-vivo (Petito et al., 1998; Dewar et al., 2003) and to 
be strongly labeled for markers of hypoxia during active EAE (Davies et al., 2013). A 
possible explanation for the high susceptibility of oligodendrocytes to (virtual and true) 
hypoxia might be that in these cells, mitochondria, although less in number and maybe 
less efficient compared with the mitochondria in other glial cells and neurons, could still 
account for a small but important portion of the energy supply needed by 
oligodendrocytes. In addition, this role may be even more relevant in pathological 
conditions (e.g. demyelination), where the mitochondrial activity could probably 
increase in order to provide enough energy to repair the damage.  
Another possibility is represented by the fact that oxygen is not only important for ATP 
synthesis but also for lipid homeostasis. Lipid, cholesterol and oxidative metabolism are 
particularly relevant to produce and support myelin membrane (Blissman et al., 1996). 
A number of enzymes (oxygenases), which use (heme and non-heme) iron and oxygen 
as co-factors, have been identified as involved in the homeostasis of myelin (Morell and 
Toews, 1984; Thompson, 1992; Alderson et al., 2006) (see also General Discussion; 
paragraph 5.3.0.0). Interestingly, a recent study identified the fatty acid 2-hydroxylase 
(FA2H), an iron-containing and oxygen-consuming monooxygenase, to be a key 
enzyme for the synthesis of 2-hydroxy ceramides (Alderson et al., 2006). 2-hydroxy 
ceramides are relatively minor species of membrane lipids but, in mammals, these 
lipids are uniquely abundant in myelin galactosylceramides and sulfatides (Alderson et 
al., 2006). Galactosilceramides and sulfatides (3-sulfate ester of galactoceramides) 
represent approximately one-third of all lipids in the myelin membrane (Alderson et al., 
2006), and they are synthetized by the ceramide galactosyltransferase (CGT) via the 
transfer of a galactosyl group to a 2-hydroxy ceramide (Alderson et al., 2006). 
Interestingly, CGT knock-out mice, which lack of galctosylceramides and sulfatides, are 
characterized by uncompacted myelin and progressive demyelination and hind limb 
paralysis (Bosio et al., 1996; Coetzee et al., 1996; Fewou et al., 2005). It is possible 
that also an impaired function of one or more of the upstream enzymes that lead to the 
final formation of galactosylceramides and sulfatides may have similar effects. For 
example, insufficient oxygen and/or iron availability could impair the activity of upstream 
hydroxylases (such as FA2H) reducing the formation of 2-hydroxyl ceramides (the 
substrate of CGT); and this, similarly to what is observed in CGT knock-out mice, may 
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alter the formation and homeostasis of myelin. In support of this hypothesis, it has been 
shown that iron deficiency (Todorich et al., 2009) and hypoxia (Bilali et al., 2008) are 
associated with hypomyelination of the developing brain during the post-natal life. 
Although it is easy to imagine that myelin synthesis is prominent during development 
(Baumann and Pham-Dinh, 2001), relatively little is known about myelin lipid turnover in 
the adult brain, although studies in mice indicate a necessity to renew myelin lipids in 
adulthood (Ando et al., 2003; Chrast et al., 2011). Presumably, the turnover of myelin 
lipids may be augmented during pathological conditions such as demyelination, and this 
could lead to higher demand for oxygen to sustain the enzymatic activities, raising the 
possibility that oxygen therapy in active EAE exerts its protective role on 
oligodendrocytes, at least in part supporting lipid homeostasis. However, it is still 
unknown what the impact of lipid biogenesis is on oligodendrocytic oxygen 
consumption, and how long and severe the exposure to hypoxia has to be in order to 
impair these mechanisms in the adult CNS.   
2.2.3.5 Oxygen therapy and oxidative damage in active EAE 
A big concern about the use of oxygen for the treatment of MS is that it can increase 
oxidative damage (Haider et al., 2011; Fischer et al., 2012). Interestingly, we have seen 
that increased concentration of oxygen not only did not increase the expression of 
markers of oxidative damage in the inflamed spinal cord, but resulted in a significant 
reduction of oxidized phospholipids (E06) in rats exposed to oxygen for 72 hours from 
the onset of deficits, compared with room air controls. The reduced phospholipid 
oxidation observed at the peak of disease after 72 hours of oxygen therapy could result 
from the decreased tissue hypoxia in these rats, given that hypoxia (as well as 
hyperoxia) can contribute to the production of reactive oxygen species (Xu et al., 2004; 
Strapazzon et al., 2016) (see also Chapter 5; paragraph 5.3.0.0). Interestingly, reduced 
phospholipid oxidation may have contributed to oligodendrocyte survival, as 
oligodendrocytes are especially sensitive to phospholipid oxidation due to the high 
content of polyunsaturated fatty acid in their myelin sheaths (Dewar et al., 2003). 
Oxidative damage has been reported to be one of the mechanism causing cell stress 
(including eIF2α phosphorylation) and apoptosis (Liu et al., 2008; Donnelly et al., 2013). 
However, E06 positive cells were mainly observed in the sub-meningeal areas whereas 
p-eIF2α positive oligodendrocytes were diffusely located throughout the entire white 
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matter, suggesting a poor correlation between these two markers. Nonetheless, it 
cannot be excluded that the decreased phospholipid oxidation achieved after oxygen 
treatment also occurred in oligodendrocytes, contributing to the reduced integrated 
stress response observed in these cells. Future experiments, including the co-labelling 
of oligodendrocytes with markers for phospholipid oxidation (E06) and p-eIF2α, will help 
to clarify this aspect. In addition, other markers have to be considered in order to 
establish the safety of oxygen therapy in neuroinflammatory diseases, including 
markers of nitrative damage such as nitrotyrosine. However, the transient expression of 
iNOS suggests that the nitrative damage caused by NO could be also transient, and 
limited to only the early stage of disease. Our preliminary results provide encouraging 
indications that oxygen therapy could be a safe treatment to avoid neurological deficits 
and demyelination due to neuroinflammation (see also Chapter 5; paragraphs 5.3.0.0 
and 5.4.0.0). 
  
2.3.4.0 Conclusion 
The data support the hypothesis that oxygen therapy can decrease the neurological 
deficit due to active EAE. Oxygen was able promptly to attenuate the severity of the 
deficits when administered for only 1 hour, and it produced a long-lasting amelioration 
of the disease when applied for longer (24, 48 or 72 hours) from the onset of the 
disease. Prolonged administration (from 24 up to 72 hours) of treatment, starting at the 
first day of deficits, ameliorated disease progression, and the beneficial effect persisted 
for several days after treatment cessation, indicating a disease-modifying role of 
oxygen. Oxygen treatment from the onset of disease resulted in reduced 
oligodendrocytes loss, demyelination, microglial activation and macrophage infiltration 
at the peak of disease, but it did not change T-cell infiltration and the level of pro- and 
anti- inflammatory markers in the inflamed spinal cord.  We have seen that oxygen 
treatment starting at the onset of disease decreased the integrated stress response in 
oligodendrocytes by preventing the inhibition of the protein synthesis machinery, 
possibly contributing to the greater oligodendrocytes survival achieved after oxygen 
exposure. However, it cannot be entirely excluded that the increased survival of 
oligodendrocytes achieved by oxygen administration may be due to an anti-
inflammatory effect of the treatment. Although we have seen that oxygen does not 
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change T-cell infiltration and the expression of some pro- and anti-inflammatory 
markers in the CNS, we did not examine the effects of oxygen on B-cells (Mann et al., 
2012), or whether the trafficking and migration of macrophages is decreased by the 
reduced tissue hypoxia in the spinal cord (Murdoch and Lewis, 2005; Chanmee et al., 
2014) (see also paragraph 2.3.3.3). While the role of oxygen on the B-cell driven 
damage to oligodendrocytes (such as antibody-mediated) (Griot-Wenk et al., 1991; 
Mann et al., 2012; Pikor et al., 2012) remains to be examined, the gene expression 
analysis provides preliminary indications that the macrophage-mediated death of 
oligodendrocytes may not be affected by oxygen. Recent studies have demonstrated 
that macrophages can cause cell death via the secretion of inflammatory mediators that 
can trigger apoptosis and necroptosis in oligodendrocytes and neurons during EAE 
(Jurewicz et al., 2005, 2006; Ofengeim et al., 2015). Here, we have shown that oxygen 
treatment increases oligodendrocyte survival but does not change the overall 
expression of two major cytokines involved in the inflammation-mediated cell death (via 
apoptosis and necroptosis), such as TNFα and IFNγ (Newton and Manning, 2016), 
raising the possibility that hypoxia may also contribute to the death of oligodendrocytes 
during active EAE. However, before excluding any direct effect of oxygen on the 
macrophage-mediated necroptosis of oligodendrocytes, further experiments are 
necessary in order to evaluate whether oxygen changes macrophage trafficking into the 
CNS and/or the expression of other macrophage-derived mediators of tissue damage 
(such as TRAILs). 
Importantly, oxygen applied at the onset of disease for up to 72 hours did not increase 
oxidative damage in the inflamed spinal cord, suggesting that oxygen (75%, 
normobaric) may be an effective treatment for neurological deficits with relative low side 
effects. 
Interestingly, we discovered that oxygen is particularly beneficial when administered 
prophylactically (before the onset of neurological signs). Prophylactic treatment with 
oxygen delayed the onset and attenuated the deficits, suggesting a potential role of 
oxygen in changing the pathogenesis of the disease. 
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CHAPTER 3 
3. HYPOXIA AND NEUROLOGICAL DEFICITS IN AN 
INFLAMMATORY NON-DEMYELINATING MODEL OF 
MULTIPLE SCLEROSIS 
 
3.0.0.0 Background 
Evidence has shown that inflammation in the CNS of patients with MS can induce 
neurological deficits even in absence of further demyelination (Moreau et al., 1996), 
leading to the paradigm that neuroinflammation alone can cause loss of neurological 
function (Bitsch et al., 1999, 2000). However, the mechanisms by which inflammation 
alters regular neuronal activity are not entirely clear. We hypothesized that hypoxia and 
the consequent energy deficit, possibly caused by inflammation, can contribute to the 
genesis of neurological dysfunction in absence of demyelination. To address this 
possibility we used an animal model of MS, namely passive EAE, in which neurological 
deficits occur in the absence of major structural damage in the CNS, including 
demyelination. Passive EAE is induced in rodents via the administration of exogenous 
encephalitogenic T-cells auto-reactive against MOG (Linington et al., 1993; Stromnes 
and Goverman, 2006b). In passive EAE, the absence of myelin degradation does not 
promote prominent macrophage recruitment and microglial activation in the CNS, 
resulting in a short-term inflammatory reaction (Linington et al., 1993). Indeed, in this 
model the duration of neurological deficits entirely depends on the persistency in the 
circulation of the injected encephalitogenic T-cells, and the disease spontaneously 
recovers when these T-cells die (Linington et al., 1993). In passive EAE, first we 
studied if the spinal cord of sick animals is hypoxic and then, if the hypoxia contributes 
to the neurological deficits in this model.  
Furthermore, we speculated that in passive EAE, oxygen treatment should not be able 
to induce an anti-inflammatory response because the disease is mainly driven by the 
exogenous T-cells, reactivated in-vitro, and therefore the encephalitogenic response is 
unlikely to be changed once these cells are injected in the recipient rat.  Thus, if 
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observed, a beneficial effect of oxygen therapy would argue in favour of a metabolic-
mediated mechanism rather than an anti-inflammatory role of oxygen, consolidating the 
hypothesis of a prominent role of hypoxia in contributing to the neurological dysfunction.  
 
3.0.1.0 Aims 
• To determine whether the inflamed spinal cord of rats with passive EAE is 
hypoxic.  
• To investigate the contribution of hypoxia to the neurological deficits in passive 
EAE and whether oxygen therapy can play a beneficial effect.  
• To examine the role of oxygen treatment on the pathogenesis of the disease. 
 
3.1.0.0 Material and methods 
3.1.1.0 Animal model: induction of passive EAE  
Female DA rats (n = 65; 8-9 weeks-old, ~150g, Harlan, UK) were kept in standard 
cages with food and water ad libitum on a twelve-hour light - dark cycle. One week, 
between the arrival of the rats and induction of passive EAE, was left to acclimatize the 
rats at the new environment. Passive EAE was induced by the injection of 
encephalitogenic T-cells reactive against MOG. Encephalitogenic T-cells were isolated 
from donor DA rats sensitized to rMOG (active EAE) obtained from Prof. Christopher 
Linington (University of Glasgow, UK). T-cells were then reactivated in-vitro as 
described below, before being injected in the recipient rats. First, T-cells were thawed 
and cultured for 1 day in T-cell grow factor medium (complete DMEM + 15% horse 
serum + 15% MLA supernatant). The next day, T-cells were centrifuged, washed with 
fresh DMEM without serum and co-cultured with irradiated (30 Gy) thymocytes (108 
thymocytes with 2-4 x 106 T-cells) for 3 days in T-cell restimulation medium (complete 
DMEM + 1% rat serum + 10μg/mL rMOG). After 3 days T-cells were forming clusters 
indicating proliferation and reactivation against the antigen (rMOG). At this stage, live T-
cells were counted using trypan blue (irradiate thymocytes were dead by the third day 
in culture), and suspended in RPMI medium in order to have 5 million T-cells per 
millilitre. 5 million reactive T-cells (in 1mL of RPMI medium) were injected 
intraperitoneally in recipient rats to induce passive EAE (n = 52). Control rats received 
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an injection of 1mL RPMI medium without cells (n = 13). All experiments were 
performed in accordance with the UK Animals (Scientific Procedures) Act of 1986, and 
the ARRIVE guidelines. 
 
3.1.2.0 Behavioural assessment of the neurological deficits 
All behaviour assessments and analysis were performed blinded. Disease progression 
was monitored on a daily basis, including assessment of general health (weight) and 
neurological function. Our standard 10-point scale neurological test was used as 
described previously in paragraph 2.1.2.0.  
 
3.1.3.0 Evaluation of spinal cord hypoxia 
The presence of hypoxia in the spinal cord of rats with passive EAE has been 
investigated both in-vivo and ex-vivo as following. 
3.1.3.1 In-vivo measurement of oxygen partial pressure  
Oxygen concentration in the spinal cord of rats with passive EAE (n = 8) and healthy 
controls (RPMI controls, n = 8) was measured in-vivo by inserting an oxygen-sensitive 
probe (50μm diameter) into the grey matter (as described in Davies et al., 2013). In 
brief, rats were deeply anesthetized with 5% isoflurane gaseous anesthesia. Next, 
general anesthesia was maintained with 2.5% isoflurane for the entire duration of the 
experiment. A laminectomy was performed to expose the spinal cord at the lumbar level 
(L3), and the oxygen probe was inserted in the posterior ventral horn of the grey matter. 
When the signal was steady, oxygen tension was recorded for at least 2 minutes before 
retracting the probe.    
3.1.3.2 Tissue probe: pimonidazole 
Tissue hypoxia was examined ex-vivo by histologically labeling spinal cord cross-
sections for pimonidazole adducts. Pimonidazole was injected intravenously in the 
femoral vein of rats with passive EAE (n = 9) and in RPMI controls (n = 5) under 
general anesthesia (2.5% isoflurane). Pimonidazole, injected intravenously, readily 
penetrates all tissues (including the CNS) and it is enzymatically reduced if the oxygen 
tension is low (approximately < 10mmHg), forming protein adducts that are detectable 
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immunohistochemically (see also paragraph 1.10.2.0). Rats were then intracardially 
perfused 4 hours after the injection. The spinal cords were collected and processed for 
histological analysis.  
 
3.1.4.0 Tissue processing and histology 
Rats, under general anaesthesia (2.5% isoflurane), were intracardially perfused with 
PBS containing heparin followed by 4% PFA in PB solution for tissue fixation. The 
spinal cords were further post-fixed overnight in 4% PFA in PB solution and then 
cryoprotected in 30% sucrose in PBS for at least 5 days. Next, the spinal cords were 
cut in 5 segments of 1 cm each, at the following levels: sacral, lower lumbar, upper 
lumbar, lower thoracic and upper thoracic, using the lumbar enlargement as reference. 
The tissue was then embedded in blocks with TissueTek O.C.T and frozen in 2-
methylbutan (Sigma) in liquid nitrogen at -150° C. Tissue blocks were stored at -80°C 
prior to cryosectioning (12 μm transverse sections) and immunohistochemical 
examination. 
3.1.4.1 Neuropathology and immunohistochemistry 
Neuropathological staining for myelin with LFB, and DAB immunolabelings of spinal 
cord cross-sections were performed as described before in paragraph 2.1.5.1. 
Immunohistochemistry with mouse anti-pimonidazole adducts (Pimo) and rabbit anti-
HIF1α were used to disclose tissue hypoxia. Labeling with mouse anti-ED1 was used to 
mark activated microglia and infiltrated macrophages (Table 3.1).   
3.1.4.2 Immunofluorescence 
Immunofluorescent labeling was performed as described previously in paragraph 
2.1.5.2. A combination of double labeling for Pimo and CNS cell lineage markers was 
used to examine which types of cell are hypoxic during passive EAE. In particular, 
primary antibody combinations included rabbit anti-Pimo with mouse anti-neuronal cell 
nuclei (NeuN, neurons), rabbit anti-Pimo with mouse anti- adenomatous poli coli protein 
(clone CC1, oligodendrocytes), mouse anti-Pimo with rabbit anti- ionised calcium 
binding adaptor molecule-1 (Iba1, microglia), and mouse anti-Pimo with rabbit anti- glial 
fibrillary acidic protein (GFAP, astrocytes) (Table 3.1). 
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Antibody Origin Target Marker Dilution Source 
CC1 Mouse (mAb) 
Adenomatous poli 
coli protein,clone 
CC1 
Oligodendrocyte 
cell body 
1/200 Abcam; 
ab16794 
ED-1 Mouse (mAb) Rat CD68 
Activated 
microglia and 
macrophages 
1/200 AbD Serotec; 
MCA341G 
GFAP Rabbit (pAb) 
Glial fibrillary acidic 
protein Astrocytes 
1/1000 Dako; Z0334 
HIF1α Rabbit (pAB) 
Hypoxia inducible 
factor-1α Tissue hypoxia 
1/200 Abcam; 
ab85886 
Hydroxyprobe-
1-anti-
pimonidazole 
Mouse 
(mAb) 
Rabbit 
(pAB) 
Pimonidazole 
adducts (Pimo) Hypoxia 
1/500 HPI Inc. 
Iba1 Rabbit (pAb) 
Ionised calcium 
binding adaptor-1 Microglia 
1/500 Wako;  
019-19741 
NeuN Mouse (mAb) Neuronal nuclei 
Neuronal cell 
body 
1/200 Millipore; 
MAB377 
Table 3.1 - Primary antibodies.  
Antibodies were used on rat tissue for immunohistochemistry and/or immunofluorescence as 
described in the material and methods. mAb = monoclonal antibody, pAb = polyclonal antibody. 
 
3.1.5.0 Microscopy and histological analysis 
Spinal cord sections stained with DAB and LFB were viewed using an Axiophot light 
microscope (Zeiss, Germany) and pictures taken with a Nikon D300 camera (Nikon, 
USA). Quantification was carried out on 10 spinal cord sections per rat at 5 different 
levels (sacral, lower lumbar, upper lumbar, lower thoracic and upper thoracic; 2 
sections per each level). Sections within the same level of the spinal cord were 120μm 
from each other, whereas 1 cm was the distance between sections in adjacent levels of 
the spinal cord. ImageJ software (NIH, USA) was used for image analysis. Analysis of 
DAB labeling for ED1 and Pimo was done by making the images binary, tracing the 
area around the whole spinal cord sections with the freehand selection tool, before the 
number of pixels above a set threshold were counted and expressed as the percentage 
coverage of the total cross-sectional spinal cord area. LFB analysis for demyelination 
was done by tracing the area around the white matter and measuring the surface 
covered by LFB above a set threshold. This area was then subtracted to the total area 
of the selection and expressed as the percentage of demyelination of the white matter. 
Where no demyelinated lesions were detected a value of zero was given. All the values 
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were then averaged within each rat and used for statistical analysis. All quantification 
was carried out in a blinded manner. 
Fluorescently labeled tissue was viewed and imaged acquired using an AxioImager-Z.2 
confocal microscope (Zeiss, Germany). 
 
3.1.6.0 Oxygen administration 
Rats were placed in a chamber (Biospherix, USA) where gaseous concentrations in the 
air can be selected at will. Oxygen-treated rats were exposed to 75% normobaric 
oxygen enriched-air, whereas control rats received room air (21% oxygen) as described 
below.  
3.1.6.1 Therapeutic and prophylactic treatment with oxygen  
Therapeutic treatment with oxygen was administered from the onset of the disease. In 
particular, rats with passive EAE (n = 18) were randomly sorted to receive oxygen 
(75%) for either 24 or 48 hours from the first day of neurological signs (n = 9 per group). 
Rats were then returned to room air and the neurological deficits assessed up to 4 days 
after the complete recovery of neurological function. 
Prophylactic oxygen treatment (75%, n = 8) was administered before the onset of 
neurological deficits, and in particular from the day of passive EAE induction, 
continuously up to 4 days after the complete remission of the disease. Control animals 
(n = 9) were maintained in room air. 
 
3.1.7.0 Statistical analysis 
Graphpad Prism v6.0 (USA) was used for statistical analysis and graph generation. All 
graphs represent mean ± S.E.M. All statistical analyses were two-tailed and considered 
significant when p < 0.05. Mann Whitney non-parametric U-test was used to compare 
the severity of neurological deficits between groups. Parametric Student’s t-test was 
used for histological comparisons.  
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3.2.0.0 Results 
3.2.1.0 Disease course of passive EAE 
Intraperitoneal injection of encephalitogenic T-cells reactive against MOG in DA rats, 
induced a neurological disease characterized by ascending motor paresis and paralysis 
(Figure 3.1). In contrast to rats with active EAE, where neurological deficits appeared 
around 11 days post-immunisation, passive EAE was characterized by an early 
development of neurological signs (4 ± 0.6 days post-immunisation), and the peak of 
disease was reached within 2 days after the onset (3 days in active EAE; Figure 3.1). 
However, the severity of the neurological deficits in rats with passive EAE was milder 
compared with rats actively immunized with rMOG (Figure 3.1). Indeed, while rats with 
active EAE developed both tail and bilateral hind limb paralysis, rats with passive EAE 
mostly only expressed tail paralysis and hind limb weakness, maintaining the ability to 
walk with an unsteady gait (score < 6; Figure 3.1). Furthermore, passive EAE caused a 
monophasic disease course characterized by a complete recovery of the neurological 
function within few days after the peak of deficits; in contrast active EAE resulted in a 
relapsing-remitting disease (Figure 3.1). 
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Figure 3.1 - Disease course in rats with passive and active EAE. 
Rats with passive EAE (black line) developed neurological deficits 4 (± 0.6) days after the 
injection of encephalitogenic T-cells.  Rats reached the peak of disease within 2 days after the 
onset, and neurological deficits included tail paralysis and hind limb weakness. The majority of 
rats with passive EAE maintained the ability to walk using their hind limbs (score < 6, horizontal 
dashed line). Passive EAE caused a monophasic disease, and normal neurological function was 
spontaneously and permanently restored within 11 days after the injection of the T-cells. By 
contrast, active EAE (grey line) caused a relapsing-remitting disease in which rats developed 
neurological signs 11 (± 2.05) days post-immunisation. In active EAE, neurological deficits 
included tail and bilateral hind limb paralysis and the peak of disease was reached by the third 
day after the onset of the first neurological sign. After the first attack of disease, neurological 
deficits were spontaneously, but partially recovered during the remitting phase. However, a full 
spectrum of neurological disabilities reappeared a few days after the remission (relapse). 
Passive EAE, n = 9; active EAE, n = 8. 
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3.2.2.0 Neuropathological characterization of rats with passive EAE 
Histological comparison of spinal cords of rats with active and passive EAE at the peak 
of neurological deficits, revealed several differences between these two models of MS. 
Indeed, LFB staining at the peak of disease disclosed a prominent myelin loss in the 
white matter of rats with active EAE, whereas rats with passive EAE did not show the 
clear presence of any demyelination (p = 0.003; Figure 3.2a, c); consistent with 
previous reports in active EAE (paragraph 2.2.2.1) and with reports by other groups in 
passive EAE (Linington et al., 1993). Furthermore at the peak of disease, the amount of 
activated microglia and recruited macrophages labeled for ED-1 was significantly lower 
in rats with passive EAE compared with active EAE animals (p = 0.0008; Figure 3.2b, 
d). In particular, ED-1 positive cells in passive EAE were detected mainly in the sub-
meningeal area and around a few blood vessels, and these cells were not spread in the 
CNS parenchyma as observed in active EAE (Figure 3.2b, d).  
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Figure 3.2 - Demyelination, microglial activation and macrophage infiltration in the spinal 
cord of rats with passive and active EAE. 
a, c) Representative images of lumbar spinal cord sections stained with LFB (blue, myelin) of 
rats with active or passive EAE. Active EAE rats showed demyelination (absence of LFB) in the 
white matter (WM) at the peak of disease, whereas no demyelination was observed at the peak 
of neurological deficits in rats with passive EAE. Scale bar = 1mm. Quantification of LFB staining 
displayed significant demyelination in rats with active EAE (p = 0.0003), but no demyelinated 
lesions in rats with passive EAE. b, d) Representative images of lumbar spinal cord sections 
labeled for ED-1 (brown, activated microglia/macrophages) in rats with active or passive EAE at 
the peak of neurological deficits. Scale bar = 1mm. Rats with active EAE showed significantly 
more abundant ED-1 labeling compared with passive EAE rats (p = 0.0008). Student’s t-test. 
Active EAE, n = 6; passive EAE, n = 9.   
 
3.2.3.0 Hypoxia in the spinal cord of rats with passive EAE 
To investigate whether passive EAE causes spinal cord hypoxia, we measured in-vivo 
the PaO2 in rats with passive EAE (n = 8) at the peak of disease, and in RPMI healthy 
controls (n = 8), by inserting an oxygen-sensitive probe in the ventral horn of the spinal 
cord grey matter. Interestingly, we observed that whereas in RPMI controls the PaO2 
was at a physiological level (30.26 ± 2.90 mmHg), in rats with passive EAE the PaO2 
was lower (25.03 ± 3.41 mmHg) and comparable with the PaO2 values observed by 
Davies et al. (2013) in rats with active EAE which were expressing the same (relatively 
mild) disease severity (score = 5) (Figure 3.3a, b). 
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Figure 3.3 - Spinal cord oxygen tension, measured in-vivo, is decreased in rats with 
passive EAE. 
a) Measurement in-vivo of the oxygen partial pressure (PaO2) in the spinal cord of two 
representative animals: one with passive EAE (black line) and one RPMI healthy control (grey 
line). The rapid drop in oxygen concentration shows when the probe has been inserted in the 
spinal cord. PaO2 was recorded for at least 2 minutes, and the values at the steady state were 
averaged within each rat, and used for comparisons. The increased PaO2 at the end of the 
measurement shows when the probe was retracted. The rat with passive EAE had reduced 
PaO2 compared with the healthy control. b) PaO2 quantification shows reduced oxygen 
concentration in the spinal cord of rats with passive EAE compared with RPMI controls. 
Student’s t-test; n = 8 per group. 
 
To confirm this observation and examine whether the decreased oxygen tension can 
cause tissue hypoxia, we performed an independent trial of passive EAE (n = 9) in 
which rats were sacrificed at the peak of neurological deficits and the spinal cords 
labeled for pimonidazole adducts (Pimo, a tissue probe for hypoxia) and HIF1α. RPMI 
controls (n = 5) were used for comparison. Reassuringly, the labeling for HIF1α, an 
endogenous, physiological marker of hypoxia, showed a similar pattern to Pimo (Figure 
3.4a). At low magnification, both labeling for Pimo and HIF1α were more intense in 
passive EAE rats than controls, and most obvious in the grey matter (Figure 3.4a).  
Inspection at higher magnification revealed strong, cell-specific labeling within the white 
matter, as also observed in immunofluorescence (Figure 3.6).  Histological analysis of 
Pimo revealed that, compared with controls, Pimo labeling was significantly greater in 
the spinal cord of sick animals compared with healthy (RPMI) controls (p = 0.0001; 
Figure 3.4b).   
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Figure 3.4 - Spinal cord of rats with passive EAE shows increased labeling for marker of 
tissue hypoxia. 
a) Lumbar spinal cord cross-sections labeled for Pimo and HIF1α (markers of tissue hypoxia) in 
rats with passive EAE and RPMI controls. Pimo and HIF1α labeling show a similar pattern and 
are more intense in the spinal cord of rats with passive EAE compared to RPMI controls. Scale 
bar = 1mm. b) Histological quantification of Pimo showed a significant increased labeling in rats 
with passive EAE compared with RPMI controls (p = 0.0001). Student’s t-test. RPMI control, n = 
5; passive EAE, n = 9.  
 
Moreover, Pimo labeling was significantly stronger in all analysed spinal cord levels 
(sacral, lumbar and thoracic; Figure 3.5a, b), with the most intense labeling in the 
lumbar region (Figure 3.5a, b). 
 147 
 
 
Figure 3.5 - Pimo labeling is increased at the sacral, lumbar and thoracic level of the 
spinal cord of rats with passive EAE. 
a) Representative images of spinal cord sections at the sacral, lumbar and thoracic level labeled 
for Pimo. Rats with passive EAE showed increased Pimo labeling at all levels of the spinal cord 
compared with RPMI controls. Scale bar = 1mm. b) Histological quantification of Pimo showed a 
significantly more intense labeling at all levels of the spinal cords (sacral, p = 0.011; lumbar, p = 
0.0007; thoracic, p = 0.008) compared with RPMI rats. Student’s t-test. RPMI control, n = 5; 
passive EAE, n = 9.   
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Double immunofluorescent labeling for Pimo and cell-specific markers revealed 
co-localization, and therefore low cellular oxygen concentration, in the majority 
of NeuN positive neuronal cell bodies, CC1 positive oligodendrocytes and GFAP 
positive astrocytes, whereas in only few Iba1 positive microglia (Figure 3.6). 
 
Figure 3.6 - Labeling for Pimo and markers of cell type. 
Immunofluorescence for Pimo (green) and markers of CNS cell types (red). Pimo labeled the 
majority of neurons (NeuN), oligodendrocytes (CC1) and astrocytes (GFAP) although it was 
detected least commonly in microglia (Iba1). Scale bar = 100μm. 
 
3.2.4.0 Oxygen therapy in passive EAE 
To assess whether oxygen can play a beneficial effect on the neurological deficits due 
to passive EAE, DA rats (n = 35) were injected with encephalitogenic T cells and 
randomly sorted to receive either oxygen (75%) or room air (n = 9). Oxygen 
administration was applied either therapeutically for 24 or 48 hours starting at the onset 
of neurological deficits (n = 9 in each group), or prophylactically (n = 8) starting on the 
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day of T-cell injection, and administered continuously up to the fourth day after the 
complete recovery of the neurological function. After the therapeutic treatment with 
oxygen (24 and 48 hours), rats were returned to room air and the neurological deficits 
were also monitored up to the fourth day after the complete recovery of the disease.  
All animals developed neurological disabilities within 3-4 days from immunization. In 
contrast with active EAE, oxygen administration at the onset of deficits (therapeutic 
treatment) for 24 and 48 hours did not ameliorate neurological dysfunction compared 
with room air controls, and the disease course was similar between treated and 
untreated rats (Figure 3.7). 
 
Figure 3.7 - Oxygen (75%) administered therapeutically does not change the disease 
course in rats with passive EAE. 
Rats with passive EAE were randomly sorted to receive oxygen (75%) treatment for 24 or 48 
hours from the onset of neurological deficits (day 0, horizontal dashed line). Controls were kept 
in room air. Oxygen did not change the severity of the neurological deficits and the treated 
groups (24 and 48 hours) showed a similar disease progression to room air control. Mann-
Whitney U-test (p > 0.05). Room air, n = 9; 24h 75% O2, n = 9; 48h 75% O2, n = 9. 
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Interestingly, when applied prophylactically, oxygen significantly improved neurological 
function compared with room air controls (Figure 3.8a), resulting in 58% decrease in the 
severity of the disease, and a significant reduction of both maximum neurological deficit 
score (p = 0.004) and cumulative score (p = 0.002) compared with room air controls 
(Figure 3.8b, c). Notably, 7 out of 9 rats kept in room air developed tail paralysis and 
hind limbs weakness (5 ≤ score ≤ 7), whereas rats treated prophylactically with oxygen 
displayed tail paresis/paralysis but preserved normal motor function in both their hind 
limbs (score < 5; Table 3.2). However, differently from what was observed in active 
EAE, the treatment did not delay the onset of the disease (Figure 3.8 and Table 3.2).  
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Figure 3.8 - Prophylactic oxygen (75%) treatment ameliorates severity of neurological 
deficits in rats with passive EAE. 
a) Rats with passive EAE were kept in room air or treated with oxygen (75%) from the day of 
disease induction up to 4 days after the complete remission of the disease. Prophylactic oxygen 
treatment significantly ameliorated the severity of neurological deficits compared with room air 
controls. Mann-Whitney U-test (★ = p < 0.05; ★★ = p < 0.01). b) The average maximum score 
at the neurological test reached by rats treated with oxygen prophylactically was significantly 
lower compared with room air controls (p = 0.004). c) Cumulative neurological deficit score at 
the end of treatment was significantly reduced in rats treated with oxygen prophylactically 
compared with room air controls (p = 0.002). Mann-Whitney U-test. Room air, n = 9; 75% O2, n = 
8.  
  
 152 
 
 Room air 75% O2 
Number of rats with EAE 9 8 
Treatment No treatment, room air controls 
75% oxygen enriched-air 
applied from the day of  
T-cells injection up to 12 days 
Asymptomatic 0 0 
Day of onset 4 ± 0.6 4 ± 0.5 
Rats that developed 
bilateral hind limb 
weakness (score = 5) 
 
7 (77.7%) 
 
 
0 (0%) 
 
Table 3.2 - Passive EAE in rats treated with oxygen prophylactically vs. room air controls. 
 
3.3.0.0 Discussion 
3.3.1.0 Hypoxia: a feature of the inflamed spinal cord 
Neurological deficits in MS and EAE have been mainly attributed to impaired axonal 
conduction due to extensive inflammation and demyelination. In this regard, the cause 
of the neurological deficits in passive EAE has previously been puzzling, given that 
there is no major structural damage and only limited microglial and macrophage 
activation, but we have found here that the explanation is that the deficit is probably due 
to spinal hypoxia. 
It was previously described that inflammation can cause a number of metabolic 
changes in the tissue, including nutrient depletion, increased oxygen consumption and 
ROS/RNS production that can finally result in tissue hypoxia and energy deficit 
(Kominsky et al., 2010; Colgan et al., 2016). However, the cause of tissue hypoxia in 
the CNS of patients with MS has been mainly suggested to arise from demyelination 
and mitochondrial impairment (Trapp and Stys, 2009). In particular, the propagation of 
the electric impulse through a demyelinated axon, therefore in absence of the normal 
saltatory conduction allowed by the myelin sheaths, requires more energy in a contest 
where many axonal mitochondria are not fully functional because they are damaged by 
the inflammation (Nikic et al., 2011; Sadeghian et al., 2016). Indeed, it has been shown 
that demyelinated axons have a higher firing rate due to increased spontaneous 
depolarization of the axolemma (Smith and McDonald, 1980; Felts et al., 1995; 
Hamada and Kole, 2015), implying augmented energy demand to sustain the increased 
excitability. At the same time inflammatory mediators such as RNS and ROS can cause 
mitochondrial damage by a number of mechanisms, making them dysfunctional (Mahad 
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et al., 2008; Nikic et al., 2011; Witte et al., 2014) (see also Chapter 1; 1.3.2.0). Thus, in 
demyelinated axons the increased energy demand combined with the inability of 
mitochondria to sustain it, results in increased mitochondrial stress and ROS/RNS 
production that leads to an exacerbation of the energy deficit in a vicious cycle that 
feeds on itself. Trapp et al. (2009) suggested that in demyelinating MS lesions, 
dysfunctional axonal mitochondria, even in the presence of oxygen, are not able to 
sustain the cellular energy demand (virtual hypoxia), similarly to what happens in a 
condition with inadequate oxygen supply (true hypoxia). Nevertheless, Davies et al. 
(2013) have demonstrated that in the spinal cord of rats with active EAE there is not a 
virtual hypoxia but an actual shortage of oxygen supply.  
Examination of rats with passive EAE revealed that also the inflamed- but non- 
demyelinated spinal cord of these rats can be hypoxic during the symptomatic phase of 
the disease. Hypoxia was evaluated using two independent immunohistochemical 
methods, namely pimonidazole and HIF1α, and optically using an oxygen-sensitive 
probe to measure the PaO2. While the measurement of the PaO2 in-vivo suggested a 
non-significant reduction of the oxygen tension, immunohistochemistry for pimonidazole 
adducts (Pimo) and HIF1α disclosed a striking labeling for tissue hypoxia in the spinal 
cord of sick animals compared with healthy controls, underlining a poor correlation 
between the spinal cord oxygen tension and the labeling for tissue hypoxia. This 
discrepancy could be explained by the fact that while the oxygen-sensitive probe 
measures the absolute concentration of oxygen, immunohistochemical detection of 
tissue hypoxia using pimonidazole does not give an exact indication about the amount 
of oxygen in the tissue. Indeed, DAB labelling does not follow Beer-Lambert’s law, 
therefore the intensity of the labelling does not linearly correlate with the amount of 
Pimo in the tissue. Thus, the immunohistochemical valuation of tissue hypoxia provides 
a merely arbitrary value if considered by itself, but it represents an important indications 
when different conditions are compared.  
Although the measurement of PaO2 disclosed only a modest reduction of the spinal 
oxygen concentration, this result was in line with increased Pimo and HIF1α labelling in 
the spinal cord of sick animals, supporting the conclusion that rats with passive EAE 
suffer spinal hypoxia. It is reasonable to think that even a mild reduction in the spinal 
oxygen concentration can affect the overall functionality of a highly energy consuming 
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organ such as the CNS (LaManna, 2007), leading to the overexpression of hypoxia-
related antigens like HIF1α.  
Although increased labeling for Pimo and HIF1α have been observed across the entire 
spinal cord cross-section of rats with passive EAE, the intensity of the signal was higher 
in the grey matter, and particularly intense in motor neurons. This pattern may be due 
to the fact that both HIF1α and pimonidazole label mainly the cell bodies, but not axons 
and myelin of which the white matter is enriched, raising the possibility that the elevated 
signal in the grey matter may be due to the higher density of cell bodies in this region. 
Nevertheless, inspection for Pimo at higher magnification, in DAB and 
immunofluorescence, revealed an increased number of pimo-labeled cells also in the 
white matter, and in particular in the cell body of oligodendrocytes and astrocytes, while 
microglial cells were mainly negative. As mentioned before, Pimo and HIF1α labeling 
were very intense and present in the vast majority of motor neurons. Neurons mainly 
rely on oxidative phosphorylation to sustain their energy demand (Bélanger et al., 
2011), consuming a large amount of oxygen. Therefore, it is possible that even a small 
decrease in the availability of oxygen in the tissue, as detected using the oxygen-
sensitive probe, can result in a marked reduction of cellular oxygen concentration inside 
neurons, and this could explain the pronounced pimo-labeling in these cells.  
Interestingly, a recent study has demonstrated that hypoxia is sufficient to reduce 
neuronal activity (le Feber et al., 2016). Le Feber and colleagues (2016) used an in-
vitro model system of the ischaemic penumbra, consisting of networks of cultured 
cortical neurons. In this model, neurons exposed to different levels of hypoxia for a 
short period (6 hours), showed a significant reduction in axonal activity at 
electrophysiological examination, and the dysfunction was completely reversed if a 
normal oxygen supply was restored within the first 12 hours after exposure to hypoxia 
(le Feber et al., 2016). However, when the neurons were exposed to hypoxia for longer 
(30 hours), they found not only a reduction in the axonal firing rate and capacity, but the 
majority of the functional connections between neurons were disrupted and the damage 
was largely irreversible upon re-oxygenation (le Feber et al., 2016). Importantly, Le 
Feber and colleagues (2016) discovered that the severity of the neuronal impairment 
correlated with the duration of the exposure rather than the depth of hypoxia. 
Accordingly, it is reasonable to think that even a relatively small, but prolonged 
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reduction in the spinal oxygenation could reduce the neuronal activity, explaining, at 
least in part, the neurological deficits occurring in passive EAE. Furthermore, the fact 
that the hypoxia-mediated impairment of the neuronal activity is more efficiently 
restored when oxygen is given as early as possible, support our observation that 
oxygen therapy in both active and passive EAE is more effective when administered at 
the very early phase of the disease. Also indicates from a therapeutic point of view that 
intermittent oxygenation should be good – it does not have to be continuous. 
The initial cause of tissue hypoxia and metabolic dysfunction in MS as well as in EAE 
remains unknown. The impairment of mitochondrial respiration caused by 
microglial/macrophage-derived inflammatory mediators, such as ROS and RNS (Mahad 
et al., 2008; Nikic et al., 2011; Fischer et al., 2012; Witte et al., 2014) cannot explain the 
actual reduction in the spinal oxygen concentration. Indeed, the inability of mitochondria 
to consume oxygen efficiently during the oxidative phosphorylation would imply an 
increase rather than a reduction of the oxygen available in the tissue.  
Two possible explanations are that inflammation per se can increase the oxygen 
consumption and/or impair the oxygen supply to the tissue. Increased oxygen 
consumption may result from the infiltration of metabolically active inflammatory cells in 
the CNS, while impairment in the oxygen supply may occur due to alterations in the 
vasculature, such as: arterial constriction, thrombosis (Koudriavtseva, 2014), adhesion 
of lymphocytes to the vessels, perivascular cuffs and endothelial damage (Davalos et 
al., 2012).   
Different inflammatory cell lineages have very different oxygen and metabolic demand. 
Indeed, while myeloid cells (e.g. macrophages) almost entirely rely on glycolysis for 
their energy (Borregaard and Herlin, 1982; Cramer et al., 2003; Kelly and O’Neill, 
2015), lymphocytes predominantly use oxidative respiration (Fox et al., 2005). 
However, activated inflammatory cells of the myeloid lineage, including microglia and 
macrophages, can utilize a vast amount of oxygen via the respiratory (or oxidative) 
burst during phagocytosis (Dahlgren and Karlsson, 1999). The respiratory burst is the 
process by which neutrophils, macrophages and microglia use oxygen to produce ROS, 
which then are used to degrade internalized particles during phagocytosis. The 
respiratory burst can lead up to a 50-fold increase of the oxygen intake in activated 
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leukocytes (Babior, 1984; Dahlgren and Karlsson, 1999), thereby reducing the amount 
of oxygen available in the tissue. The respiratory burst is mediated by the oxygen-
dependent enzyme NADPH oxidase. This enzyme is comprised of five phagocytic 
oxidase (phox) subunits: p40phox, p47phox, p67phox, p22phox and p91phox. In 
resting leukocytes, the enzyme is maintained inactive via the differential distribution of 
these subunits within the cell. Indeed, p40phox, p47phox and p67phox form a cytosolic 
complex, whereas p22phox and p91phox are localized in the plasma membrane. 
During phagocytosis, p47phox is hyperphosphorylated, and this post-translational 
modification induces the translocation of the cytosolic complex to the plasma 
membrane, where it binds the other two subunits to form the active oxidase (Babior, 
1999). Interestingly the expression of the active form of the NADPH oxidases has been 
recently demonstrated in active MS lesions (Fischer et al., 2012) and in a number of 
EAE models (Schuh et al., 2014). However, Schuh and colleagues (2014) revealed a 
milder expression of the active NADPH oxidase and low levels of markers for oxidative 
damage such as oxidized DNA and phospholipids in the spinal cord of rats with passive 
EAE compared with actively immunized animals and active MS lesions (Schuh et al., 
2014). In line with this finding, we revealed that the spinal cord of rats with passive EAE 
is characterized by a narrow expression of the microglial and macrophage phagocytosis 
marker ED-1. Therefore, the limited phagocytic activity of microglia and macrophages in 
passive EAE maybe account only for a small part of the reduced spinal oxygen 
concentration in this model.  
By contrast, T-cells intensively use glucose, amino acids and lipids as energy sources 
(Fox et al., 2005; Kominsky et al., 2010) to fuel oxidative phosphorylation. Indeed, 
glucose, fatty acids and amino acids are degraded into intermediates such as acetyl 
coenzyme A, which are then catabolized in the Krebs cycle to form NADH and FADH2, 
used to generate more ATP via oxidative phosphorylation (Fox et al., 2005). In resting 
T-cells, oxidative phosphorylation represents the main energetic pathway for the 
generation of ATP (Fox et al., 2005). As would be expected, activated T-cells increase 
their energy consumption in order to allow proliferation, migration inside the tissue 
(cytoskeleton remodeling) and sustain the elevated synthesis and secretion of proteins 
(e.g. cytokines, chemokines and adhesion molecules) (Fox et al., 2005). One early 
feature of T-cell activation includes an ATP-dependent alteration of the localization of 
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cations such as Ca2+ from intracellular stores (Fox et al., 2005). Ca2+ is released from 
the ER to the cytosol and it is actively transported into the mitochondria, where it 
stimulates the general rate of oxidative phosphorylation, in part by allosterically 
activating several key enzymes such as pyruvate dehydrogenase and ATP synthase 
(Fox et al., 2005). However, such increase in mitochondrial respiration has been shown 
to be moderate if compared with the remarkable increase of glycolysis that the T-cells 
undergo when activated (Fox et al., 2005). Indeed, a great part of the pyruvate 
produced during glycolysis is converted in lactate rather than entering the Krebs cycle 
and produce more energy via the oxidative phosphorylation (Fox et al., 2005). It seems 
paradoxical that an activated T-cell that is facing a number of energy-demanding 
processes prefers the relatively inefficient glycolysis instead of generating 10-times 
more ATP via mitochondrial respiration. One explanation is that in activated T-cells, 
some of the glucose metabolites resulting from glycolysis are used to fuel nucleotide 
biosynthesis and glutathione production (Fox et al., 2005). Nonetheless, the 
hyperinduction of glycolysis in activated T-cells correlates with a moderate, although 
not negligible, increase in mitochondrial respiration and oxygen consumption (Fox et 
al., 2005). Therefore, if we consider that T-cells consume a lot of oxygen when resting, 
and their net oxygen consumption further increases when activated (Fox et al., 2005; 
Kominsky et al., 2010), it is not difficult to image that a massive infiltration of these cells 
in the CNS, as observed in passive EAE (Schuh et al., 2014), may deprive this organ of 
an adequate oxygen supply. 
In addition, in EAE the adhesion of inflammatory cells at the luminal surface of venules 
could, at least temporarily, impede the blood flow and oxygenation of the perivenular 
tissue. Furthermore, the formation of perivascular cuffs could alter the normal diffusion 
of nutrients and oxygen from the blood stream into the tissue by increasing the distance 
between the parenchymal cells and the blood vessels. A number of studies showed that 
the supply of nutrients and oxygen to cells decreases with increasing distance to the 
blood vessel (Krogh, 1919; Groebe and Vaupel, 1988; Olive et al., 1992; Carmeliet and 
Jain, 2000). In particular, cells must be within 100-200μm (oxygen diffusion limit) from a 
vessel to prevent detrimental effects (Carmeliet and Jain, 2000). Moreover, because 
the distance between the parenchymal cells and the blood vessel is augmented by the 
interposition of a high number of oxygen-consuming cells (lymphocytes), the amount of 
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oxygen that from the blood stream diffuses and reaches cells distal from the blood 
vessel may be even less. Any of these events may contribute to CNS hypoxia, given 
the high-energy consumption that the CNS has in order to sustain its function.   
Interestingly, examination of the spinal oxygen tension in rats with passive EAE at the 
peak of disease revealed a similar PaO2 (~25mmHg) to rats with active EAE and the 
same, relatively mild severity of the neurological deficits (score 5) (Davies et al., 2013). 
Davies and colleagues (2013) discovered that the reduced oxygen concentration in the 
spinal cord of rats with active EAE correlates with the severity of the disease. Notably, 
the oxygen tension was non-significantly reduced in rats with a disease severity of 3-5 
points at the neurological score, but it was remarkably decreased in paralyzed rats at 
the peak of deficits (score 9) (Davies et al., 2013). A number of factors can explain why 
rats with passive and active EAE, and mild severity of the neurological signs (score 5), 
have a milder reduction of the spinal oxygen tension compared with rats with active 
EAE and more severe deficits (score 9). In chapter 2 of this thesis, we have shown that 
in active EAE, active phagocytic (ED-1 positive) microglia and macrophages appear in 
the spinal cord and their number increases with the progression of the disease 
(paragraph 2.2.2.2). This number is lower in rats with milder deficits (score 5) compared 
with severe ones (score 9; data not shown). Similarly, rats with passive EAE at the 
peak of disease (score 5) are characterized by a significantly lower number of ED-1 
positive cells compared with active EAE rats at the peak of deficits (score 9). It is 
possible that the higher number of phagocytic cells in rats with more severe deficits 
(score 9), contributes to a greater extent to the reduction of tissue oxygen via the 
respiratory burst, explaining the lower PaO2 measured in these animals (Davies et al., 
2013) compared with rats with passive or active EAE, but milder deficits (score 5).   
Furthermore, we have previously mentioned that demyelination per se may lead to 
higher energy (and oxygen) consumption due to the increased excitability of 
demyelinated axons (Smith and McDonald, 1980; Felts et al., 1995; Hamada and Kole, 
2015). In addition, demyelination can enhance the recruitment of phagocytic (oxygen-
consuming) cells in order to clear the tissue from myelin debris. At the peak of active 
EAE (score 9) demyelination was prominent and affecting a larger part of the spinal 
cord parenchyma (see Chapter 2; paragraph 2.2.2.1), whereas it was absent in rats 
with passive EAE, or rare and confined to few perivenular and sub-meningeal areas in 
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animals with active EAE and milder deficits (score 3-5; paragraph 2.2.2.1). Therefore, 
absent (or limited) demyelination in rats with passive EAE (or active EAE and milder 
deficits) may explain why these animals have a smaller reduction of the spinal oxygen 
tension compared with actively immunized rats at the peak of disease (Davies et al., 
2013). Interestingly, rats with active EAE and treated with oxygen for 24, 48 and 72 
hours from the onset of deficits, were protected from demyelination at the peak of 
disease (third day after onset), and such protection correlated with reduced 
microglial/macrophage activation and expression of the hypoxic marker HIF1α, even in 
rats that were returned to room air for 1 or 2 extra days after 48 or 24 hours of oxygen 
exposure respectively (see Chapter 2; paragraphs 2.2.3.2, 2.2.3.3 and 2.2.3.6). This 
finding supports the hypothesis that hypoxia may contribute to demyelination and vice 
versa. Indeed, oxygen treatment in rats with active EAE protects from spinal cord 
demyelination and it is possible that in turn, reduced demyelination contributes to keep 
lower the oxygen consumption and spinal hypoxia, even when oxygen administration is 
terminated. 
Intriguingly, histological labeling for tissue hypoxia in rats with passive EAE has similar 
intensity throughout the sacral, lumbar and thoracic levels of the spinal cord. By 
contrast in active EAE, Davies and colleagues (2013) reported a significantly greater 
labeling for Pimo in the sacral region compared with the lumbar and thoracic levels of 
the spinal cord. The reason(s) underlying this different distribution of tissue hypoxia 
between rats with passive and active EAE are not clear. A possible explanation may lie 
in a potentially different distribution of the inflammatory cells in the CNS due to the 
different routes of immunization. In active EAE, rMOG is inoculated subcutaneously at 
the very base of the tail, followed by the presentation of the antigen in the proximal 
secondary lymphoid organs (inguinal and abdominal lymph nodes). From these lymph 
nodes, primed T-cells reactive against MOG migrate in the blood stream and they may 
possibly first reach the closest CNS regions, namely the sacral and lumbar level of the 
spinal cord, causing hypoxia. In passive EAE instead, the intraperitoneal injection of 
already primed T-cells can directly lead to a wide systemic diffusion of these cells in the 
body that can readily enter and attack different regions of the spinal cord. Nonetheless, 
in passive EAE, it is still not clear why the inflammation is localized predominantly in the 
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spinal cord and the presence of encephalitogenic T-cells in the brain is rare (Stromnes 
and Goverman, 2006b). 
 
3.3.2.0 Contribution of hypoxia to the neurological deficits due to 
neuroinflammation  
To investigate whether hypoxia contributes to the neurological deficits in passive EAE, 
we administered oxygen-enriched (75%) air either therapeutically for 24 or 48 hours 
from the onset of neurological deficits; or prophylactically (before the onset of deficits) 
from the injection of the encephalitogenic T-cells, up to four days after complete 
remission of the disease.  
In contrast to active EAE, in passive EAE oxygen treatment did not reduce neurological 
deficits when administered therapeutically. However, oxygen significantly decreased 
the disease severity when applied prophylactically, confirming that an important 
component in the efficacy of the treatment is the stage when oxygen is administered. 
The faster development of neurological dysfunction in passive EAE compared with 
active EAE, may have contributed in reducing the therapeutic window during which the 
treatment is beneficial. Recently, a study demonstrated that in passive EAE, 
encephalitogenic T-cells reactive against MBP readily enter the CNS, even before the 
onset of clinical neurological deficits (Bartholomäus et al., 2009). In this study, 
encephalitogenic T-cells were retrovirally transduced to express GFP to track their 
distribution in the body after being injected in the recipient mouse (Bartholomäus et al., 
2009). Interestingly, Bartholomaus and colleagues (2009) found that approximately 
20% of the injected GFP-positive T-cells migrated in the spinal cord and localized in 
perivascular areas even 1.5 days after the transfer. It is easily imagined that this pool of 
infiltrated lymphocytes can initiate subclinical alterations of the CNS including hypoxia 
and energy dysfunction, and possibly reduce the efficacy of a later therapeutic 
administration of oxygen. In support to this hypothesis, as mentioned before, le Feber 
and colleagues (2016) reported that hypoxia impairs the synaptic activity of neurons in 
proportion to the duration of the exposure, and the ability to reverse the dysfunction by 
simply restoring a normal oxygenation, decreases as late as oxygen is administered. 
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In EAE, it is possible that oxygen treatment exerts its beneficial effect first on neurons 
given that these cells have high metabolic (and oxygen) consumption, and therefore 
they may be primarily affected by hypoxia; and secondly on other CNS cell types such 
as oligodendrocytes that, unless damaged, might rely less on oxygen for their energy 
supply and function (Fünfschilling et al., 2012). However, during demyelination, 
presumably oligodendrocytes increase their metabolic activity to counteract such 
damage, possibly consuming oxygen via increased mitochondrial respiration and 
biosynthesis of membrane lipids (see also paragraphs 2.3.2.0 and 5.3.0.0). Therefore, 
it is easy to imagine that during demyelination, the detrimental effect of hypoxia may be 
extended also to oligodendrocytes. This could explain why oxygen treatment, 
administered therapeutically, is effective in active EAE but not in passive EAE. In 
passive EAE demyelination does not occur, whereas in rats with active EAE 
demyelination, oligodendrocyte stress and death are prominent and appear after the 
onset of neurological deficits (Lin and Popko, 2009) (see chapter 2; paragraph 2.2.3.2 
and 2.2.3.5). In addition, therapeutic oxygen in active EAE has been observed to 
protect oligodendrocytes selectively, promoting their survival and reducing 
demyelination. In passive EAE instead, such a beneficial effect could not be so 
pronounced, given that demyelination does not occur. Presumably oligodendrocytes do 
not need to increase their metabolic activity and oxygen consumption, for example to 
repair myelin, thereby narrowing the beneficial role of therapeutic oxygen administration 
in this model.  
Alternatively, rats with passive EAE exposed to therapeutic oxygen may have benefited 
from the treatment but the beneficial effects could not have been detected through our 
standard 10-point scale neurological test. The 10-point neurological test employed in 
this study merely assesses changes in the voluntary motor control and muscle tone 
(paresis/paralysis), whereas several other neurological deficits such as loss of 
nociception, fatigue and impairment of bladder control can also occur in EAE. Many 
patients that received HBO in a clinical trial (Fischer et al., 1983) found the treatment 
particularly helpful in ameliorating fatigue. It is reasonable that an improvement of the 
CNS metabolism achieved via oxygen administration can result in less fatigue. 
Although it is relatively easy to assess the intensity of fatigue in patients with MS by 
subjecting them to physical exercises and/or simply talking with them to find out if they 
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feel fatigued, the fatigue assessment in animal models is rather difficult to evaluate. 
Indeed, despite the part that some EAE animals preserve the voluntary motor control of 
their limbs, maintaining the ability to walk, when sick they generally tend to limit their 
movements to the minimum necessary and it is difficult to understand if this is due to 
fatigue, a lack of motivation, or weakness. We believe that new methods capable to 
assess fatigue in EAE studies are of pivotal importance for a better understanding of 
the beneficial effects of therapies. Notably, therapies able to ameliorate fatigue can be 
extremely important in MS, as fatigue severely affects the daily life of patients. Oxygen 
therapy, by its own nature could be beneficial for the treatment of fatigue due to 
neuroinflammation and energy deficiency, although in this study, we missed the 
opportunity to evaluate this aspect. 
Furthermore, the fact that passive EAE causes less neurological dysfunctions 
compared with active EAE, reduces the spectrum and magnitude of disabilities that 
these rats can improve after treatment. For example, one marked beneficial effect 
achieved by therapeutic oxygen administration in active EAE was the reduced 
incidence of hind limb paralysis (paragraph 2.2.3.1), whereas the majority of the 
oxygen-treated rats still developed hind limb paresis. In passive EAE instead, hind limb 
paresis represent the most severe neurological dysfunction achieved, therefore the 
beneficial effect of oxygen in protecting from the development of paralysis cannot be 
appreciated in this model, underlining the narrower window of neurological deficit that 
rats with passive EAE can improve after treatment. 
The significant benefit achieved with prophylactic administration of oxygen suggests 
that pathological mechanisms such as hypoxia, energy deficiency and mitochondrial 
dysfunction may occur even before the onset of neurological deficits and they could 
represent an interesting therapeutic target to treat or even delay the beginning of new 
relapses. Furthermore, the efficacy of prophylactic oxygen treatment observed in 
passive EAE, in which the role of endogenous inflammation is limited and auto-reactive 
exogenous T-cells are primed in-vitro before being injected in the recipient rats, 
suggests that oxygen may play its beneficial role through a metabolic-related 
mechanism rather than an anti-inflammatory effect. However, another mechanism 
through which prophylactic treatment with oxygen has decreased the severity of 
neurological deficits may 
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encephalitogenic T-cells into the CNS, possibly due to a reduction in blood flow caused 
by the vasoconstriction effect of hyperoxia (Watson et al., 2000; Floyd et al., 2003). 
 
3.3.3.0 Conclusion 
We provide evidence that neuroinflammation per se, even in absence of demyelination, 
can cause tissue hypoxia in the spinal cord of rats with passive EAE, and such hypoxia 
can, at least in part, account for at least some of the neurological deficits in this model. 
We confirmed that an important factor for the efficacy of oxygen therapy is the stage of 
disease at which the treatment is administered. The fact that in both passive EAE and 
active EAE the therapy is particularly effective when applied during the asymptomatic 
phase consolidates the possibility that metabolic dysfunctions can occur even before 
the onset of neurological signs. 
Our findings in passive EAE suggest that the beneficial effect of oxygen therapy is due 
to a metabolic action on the hypoxia and energy deficit, rather than an anti-
inflammatory role. 
We conclude that hypoxia is an important but currently overlooked component in the 
development of neurological dysfunction due to neuroinflammation, and that oxygen 
can at least in part protect from the loss of neurological function. 
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CHAPTER 4 
4. ADMINISTRATION OF AN OXYGEN-CARRYING BLOOD 
SUBSTITUTE FOR THE TREATMENT OF NEUROLOGICAL 
DEFICITS IN A MODEL OF MULTIPLE SCLEROSIS 
 
4.0.0.0. Background 
In accord with the therapeutic effects of oxygen enriched-air discussed previously in 
this thesis; we have tested an alternative treatment aimed to increase tissue 
oxygenation in an inflammatory-demyelinating model of MS, active EAE. In particular, 
we investigated the effects on neurological deficits of treatment with polynitroxylated 
pegylated hemoglobin (PNPH). PNPH is a novel hemoglobin-based oxygen carrier 
produced by SynZyme Technology (USA), which consists of bovine hemoglobin coated 
with nitroxide (NO) and polyethylene glycol (PEG) (Hsia and Ma, 2012; Lewis and 
Ross, 2014). In addition to the oxygen-carrier function, PNPH has a superoxide 
dismutase (SOD)-mimetic activity that ameliorates oxidative stress, while the NO 
moieties enhance vasodilation. Furthermore, both SOD-activity and pegylation, which 
mask the hemoglobin reducing its interaction with the vascular surface, decrease the 
free radical cytotoxic effect that cell-free hemoglobin can exert on endothelial cells 
(Lewis and Ross, 2014). PNPH has also been reported to have a relatively long half-life 
(20 hours), similar or longer than other hemoglobin-based oxygen carriers (e.g. OxyVita 
(USA) and MP4 (USA), 6 and 20 hours respectively), giving the possibility of reducing 
the spare number of injections (Lewis and Ross, 2014). 
PNPH is proposed to increase tissue oxygenation via both enriching the oxygen content 
of the plasma, and NO-mediated vasodilation. Furthermore, the nanoscopic size of 
PNPH facilitates its delivery in constricted/collapsed capillaries, reaching poorly 
oxygenated areas of the tissue; and the colloid property of PEG has been reported to 
increase the intra-vasculature oncotic pressure with significant effects in reducing 
oedema (Brockman et al., 2013; Lewis and Ross, 2014). Interestingly, recent studies 
have shown that PNPH is beneficial for the treatment of stroke (Lewis and Ross, 2014), 
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traumatic brain injury and hemorrhagic hypotension in mice (Shellington et al., 2011; 
Brockman et al., 2013).  
 
4.0.1.0 Aim 
• To investigate whether PNPH administration ameliorates the neurological 
deficits in rats with active EAE. 
 
4.1.0.0 Material and methods 
4.1.1.0 Animal model: active EAE and PNPH administration 
Female DA rats (n = 16; 8-9 weeks-old, ~150g, Harlan, UK) were kept in standard 
cages with food and water ad libitum on a twelve-hour light - dark cycle. Active EAE 
was induced one week after the arrival of the rats to allow acclimatization to the new 
environment. Active EAE was induced by a subcutaneous injection at the base of the 
tail of rMOG (100μg) in incomplete Freund‘s adjuvant (IFA) (Davies et al., 2013). All 
experiments were performed in accordance with the UK Animals (Scientific Procedures) 
Act of 1986, and the ARRIVE guidelines. 
 
4.1.2.0 PNPH administration 
Rats with active EAE were randomly assigned to receive a daily injection of either 
PNPH or sterile saline solution (0.9% NaCl; sham controls) on the first three days of 
neurological deficits (first peak of disease; n = 8 per group). PNPH or saline was 
injected intravenously in the tail vein (5 mL/Kg). Neurological deficits were monitored up 
to 7 days after the onset of the disease.  
 
4.1.3.0 Behavioural assessment  
All behaviour assessments and analysis were performed blindly. Disease progression 
was monitored on a daily basis, including assessment of general health (weight) and 
neurological function. Progression of the neurological deficits was examined using a 10-
point behavioural test as described in paragraph 2.1.2.0. To evaluate the acute effect of 
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the treatment, our detailed 30-point behavioural test (see paragraph 2.1.2.0) was used 
before and after 1 hour from the injection of PNPH (or saline).   
 
4.1.4.0 Statistical analysis 
Graphpad Prism v6.0 (USA) was used for statistical analysis and graph generation. All 
graphs represent mean ± S.E.M. (standard error of the mean). All statistical analyses 
were two-tailed and considered significant when p < 0.05. Non-parametric Mann-
Whitney U-test was used to compare differences in the neurological deficit score 
between treated and untreated group. 
 
4.2.0.0 Results 
4.2.1.0 PNPH treatment for neurological dysfunction in rats with active 
EAE 
To investigate whether PNPH administration can be beneficial for the treatment of 
neurological deficits due to neuroinflammation, rats with active EAE (n = 16) were 
randomly sorted to receive intravenous injections (5 mL/Kg/day) of PNPH or saline 
(sham controls) at the first, second and third day of disease (n = 8 per group). We finely 
evaluated the acute effect of the treatment by assessing the neurological deficits 1 hour 
after the administration using our detailed 30-point neurological test. Furthermore, we 
assessed the effects of the treatment on the progression of the disease by monitoring 
the severity of neurological deficits up to 7 days after the onset. 
PNPH treatment did not significantly change the severity of neurological deficits 1 hour 
after administration on the first and third day of disease compared with sham controls 
(Figure 4.1a, c); but it significantly ameliorated the neurological function 1 hour after the 
administration on the second day of deficits (Figure 4.1b). 
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Figure 4.1 - Change in neurological deficit score 1 hour after PNPH administration. 
a-c) PNPH was administered intravenously on the first, second and third day of disease. A 30-
point behavioural test was used to assess the severity of neurological deficits after 1 hour from 
the injection, and it was expressed as a difference in the absolute score compared with the 
score before treatment administration. Zero represents no changes in neurological deficits after 
1 hour from the administration, whereas positive and negative scores represent an exacerbation 
or amelioration of the neurological function respectively. PNPH-treated group did not show acute 
changes in neurological function for administrations on the first and third day of disease (a, c), 
whereas PNPH significantly improved the neurological function when administered at the 
second day of disease compared with sham controls (b; p = 0.032). Mann-Whitney U-test. N = 8 
per group.  
 
PNPH treatment injected daily on the first three days of disease (first peak of disease) 
did not ameliorate the progression of the neurological deficits compared with sham 
controls (Figure 4.2), in contrast with our observation with oxygen treatment (Chapter 2; 
paragraph 2.2.3.1). Indeed, EAE rats treated with PNPH showed only a mild, non-
significant  reduction of neurological deficits compared with sham controls (Figure 4.2).  
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Figure 4.2 - PNPH treatment does not ameliorate the progression of the neurological 
deficits in rats with active EAE. 
Rats with active EAE received an intravenous injection of PNPH or saline (Sham controls) on 
the first, second and third day of disease. Severity of neurological deficits was assessed for 7 
days after the onset of the disease. PNPH treatment did not change the severity of neurological 
deficits compared with sham controls. Mann-Whitney U-test (p > 0.05). N = 8 per group 
 
4.3.0.0 Discussion 
4.3.1.0 Use of PNPH to improve tissue oxygenation and overcome the 
neurological deficits in a model of MS 
PNPH is a complex compound that at the hemoglobin-based oxygen-carrying role 
combines both NO-mediated vasodilation and an antioxidant mechanism played by a 
SOD-mimetic activity. We speculated that the administration of PNPH would have been 
beneficial for the treatment of the neurological deficits in active EAE based on previous 
observations that the inflamed spinal cord is hypoxic (Davies et al., 2013) and that re-
oxygenation of the tissue via inspired oxygen-enriched air could ameliorate the 
neurological dysfunctions. Therefore, we thought that PNPH administration, similarly to 
what we observed with oxygen treatment, could improve the neurological deficits due to 
active EAE by reversing hypoxia and in addition reduce the oxidative stress via its 
SOD-mimetic activity. Although PNPH treatment promptly improved the neurological 
function in rats with active EAE 1 hour after the injection on the second day of deficits, it 
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did not significantly ameliorate the overall progression of the disease, in contrast to rats 
treated with oxygen. The reasons explaining the different efficacy of oxygen and PNPH 
treatment could include the following.  
One mechanism that could limit the therapeutic outcome of PNPH in active EAE may 
be represented by the NO-mediated effect of the drug in vasodilation. Although 
increased volume of blood flow due to vasodilation can enhance the amount of oxygen 
transferred to the tissue, vasodilation may be detrimental during the acute phase of 
active EAE given the inflammatory/autoimmune nature of this model. Indeed, 
vasodilation causes a reduction in the velocity of the blood flow, thereby aiding the 
binding of leukocytes to the endothelial surface and their migration into the tissue 
(Smith and Lassmann, 2002). Furthermore, it has been described that NO can alter 
BBB permeability (Mayhan, 2000) and this effect may be further accentuated in animals 
with active EAE due to the compromised integrity of their BBB (Bennett et al., 2010). 
Accordingly, it is possible that the NO moieties of PNPH have increased the amount of 
inflammatory cells and mediators entering into the CNS of rats with active EAE, 
counteracting the eventual beneficial effect resulting from the increased oxygenation of 
the tissue. 
Another possible explanation for the limited therapeutic effect of PNPH administration in 
rats with active EAE, could be that the volume injected in our study (5 mL/Kg/day) was 
below the therapeutic dose. Although our dosage (5 mL/Kg) represents the maximum 
amount of liquid that we can inject intravenously in rodents according to the Home 
Office guidelines, other studies have reported beneficial effect on traumatic brain injury 
and hemorrhagic hypotension in mice by injecting higher volumes of PNPH (8 to 20 
mL/kg) (Brockman et al., 2013). Administration of PNPH below the therapeutic dose 
could explain the rapid improvement of neurological deficits 1 hour after the injection 
(on the second day of disease) and the absence of a long-lasting amelioration of the 
disease. 
We calculated that a single bolus of 5 mL/Kg of PNPH increases the amount of oxy-
hemoglobin in the blood by only 1%. In contrast, we observed that the administration in 
rats of inspired normobaric oxygen-enriched air (75%) results in an increment of arterial 
oxy-hemoglobin of approximately 3% (from ~97% to ~100%; data not shown). 
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Furthermore, it has been demonstrated that the administration of oxygen-enriched air 
(100%) at normobaric pressure, can increase by about 10%, the amount of 
hemoglobin-free oxygen dissolved in the arterial plasma (Nemoto and Betterman, 
2007). These findings suggest that the administration of oxygen-enriched air can lead 
to a greater oxygenation of the tissues compared with PNPH, at least for a dose of 
PNPH of only 5 mL/Kg, thereby explaining the different therapeutic efficacy of these two 
treatments in active EAE. 
 
4.3.2.0 Conclusion 
Despite PNPH treatment during the first three days of deficits (first peak of disease) did 
not significantly attenuate the disease course compared with sham controls. Both the 
acute improvement of the neurological function after 1 hour from administration (on the 
second day of deficits), and the mild (non-significant) amelioration of the disease 
progression observed in PNPH-treated rats compared with controls, are suggestive of a 
potential beneficial this drug for the treatment of neurological deficits due to 
neuroinflammation. However, the treatment with PNPH, at least at a dose of 5 
mL/Kg/day, was less effective than oxygen therapy. We think that the low efficacy of 
PNPH treatment may be due to 1) a modest increment of oxygen concentration in the 
blood, and/or 2) enhanced inflammatory infiltration in the spinal cord caused by NO-
mediated BBB damage. We believe that systemic injection of a higher dose of PNPH 
can lead to a greater oxygenation of the tissue thereby producing a greater 
improvement of the disease. In addition, administration of PNPH prophylactically can 
also be taken in consideration as it could have a more pronounced beneficial outcome 
on the progression of the disease (as observed for oxygen therapy) and possibly, 
overcome the NO-mediated detrimental effect on the BBB, given that the BBB is still 
intact during the asymptomatic phase of the disease. We also note that administration 
of PNPH may be more acceptable to some patients than regular intake of oxygen, 
especially if the half-life of PNPH is prolonged. PNPH may also be safer as a 
“smoother” increase in oxygen over time, rather than regular inspiratory “shots”. 
Therefore, further studies are needed to assess the optimal therapeutic dose, timing 
and duration of the treatment, along with the characterization of the pathological effects 
of PNPH on inflammation, oxidative stress and BBB permeability during active EAE, 
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before considering or excluding the application of this compound for the treatment of 
patients with MS.      
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CHAPTER 5 
5. GENERAL DISCUSSION 
 
5.1.0.0 Hypoxia and neuroinflammation 
This thesis provides evidence that tissue hypoxia is an important feature of the inflamed 
CNS in models of MS. Despite increasing evidence reporting the presence of a 
hypoxia-related energy deficiency in active MS lesions (Aboul-Enein et al., 2003; 
Graumann et al., 2003; Aboul-Enein and Lassmann, 2005; Paling et al., 2011; Steen et 
al., 2013; Yang et al., 2015), a role for tissue hypoxia in the pathology of this disease 
has been largely overlooked.  
In normal conditions, hypoxia has to be very severe before it impairs mitochondrial 
respiration and cause an energy crisis. This is due to the ability of the mitochondrial 
complex-IV to work at very low oxygen concentration thanks to its high enzymatic 
affinity (Km) for oxygen (<1μM) (Cooper et al., 2003). However, this advantage seems 
to be lost in inflammatory condition. A role for NO has been proposed based on the 
observation that NO has a higher affinity than oxygen for binding to complex-IV. Indeed, 
even at very low concentration, NO efficiently binds the oxygen-binding site of complex-
IV, raising the oxygen Km of this cytochrome (Cleeter et al., 1994; Cooper et al., 2003). 
Elevated Km means that the enzyme is less prone to bind the substrate and it is not 
normally saturated when the substrate is present at physiological concentration; so the 
rate of product formation will depend on the availability of the substrate in the cell. 
Thus, increased Km of complex-IV means that this complex needs higher concentration 
of oxygen in the tissue in order to maintain normal the rate of ATP synthesis. 
In some MS lesions, NO is largely produced by infiltrated macrophages and reactive 
microglia (Marik et al., 2007), and the NO-mediated mitochondrial impairment has been 
suggested to be one of the key mechanisms of axonal damage in MS  (Smith and 
Lassmann, 2002; Kapoor et al., 2003; Trapp and Stys, 2009). Indeed, a study has 
demonstrated that elevated NO concentration can block axonal conduction of both 
normal, and especially demyelinated axons (Redford et al., 1997). In addition, in 
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conditions involving increased release of NO, even a small reduction in oxygen supply 
to the tissue may have a large effect on the ATP production and the survival of the 
cells. We believe that NO is involved in the pathology of MS, and its detrimental effect 
on the mitochondrial respiration can be both a source of tissue hypoxia, as well as 
further accentuated by decreased oxygen level due to other mechanisms.  
Recent evidence showed that inflammation causes a series of metabolic changes 
within the tissue (Kominsky et al., 2010), which can result in tissue hypoxia. 
Lymphocytes greedily use glucose, amino acids and lipids as energy sources for 
oxidative phosphorylation (Kominsky et al., 2010). When reactive, lymphocytes are 
even more dependent on glucose and oxygen consumption to sustain their proliferation 
and migration through the tissue, and to support synthesis and secretion of 
inflammatory mediators (Kominsky et al., 2010). By contrast, inflammatory cells of 
myeloid lineage (polymorph nuclear leukocytes (PMN), microglia, monocytes and 
macrophages) are thought to rely predominantly on anaerobic metabolism, and to have 
a relatively small number of mitochondria. Nevertheless, during phagocytosis PMN and 
macrophages increase their oxygen consumption through a mechanism known as the 
respiratory (or oxidative) burst. The respiratory burst is mediated by the enzyme 
NADPH oxidase, which uses oxygen to generate superoxide anion (O2-) (Dahlgren and 
Karlsson, 1999). This oxygen metabolites gives rise to other ROS that act as pro-
inflammatory/ anti-microbial mediators (Dahlgren and Karlsson, 1999). ROS can also 
damage the surrounding tissue and further disrupt mitochondria, causing mitochondrial 
DNA mutation and impairment of the respiratory chain (Mahad et al., 2008; Nikic et al., 
2011; Guo et al., 2013; Witte et al., 2014), thereby exacerbating the energy deficit. As a 
result, sites of ongoing inflammatory activity including lymphocytes and/or oxidative-
active myeloid leukocytes can become rapidly depleted of both nutrients and oxygen 
(Kominsky et al., 2010).  
Infiltration into the CNS of a large number of energy-consuming lymphocytes (T-cells, 
B-cells and cytotoxic lymphocytes) and reactive leukocytes of the myeloid lineage 
(mainly macrophages) has been described in patients with MS (Hemmer et al., 2015). 
Furthermore, increased levels of the active form of NADPH oxidase have been found 
within MS active lesions (Fischer et al., 2012) in combination with markers of oxidative 
damage (oxidized DNA and phospholipids) (Haider et al., 2011; Fischer et al., 2012), 
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implying that, in MS, cells of the innate immune system are consuming oxygen via the 
oxidative burst. Studies in rodents demonstrated that a profound, innate immune 
response in the CNS can be sufficient in causing demyelination. In particular, the 
infiltration of innate immune cells in the spinal cord triggered by the injection of LPS in 
the dorsal column, can result in the formation of a demyelinating lesion in rats (Felts et 
al., 2005). A recent study from our lab has shown that this lesion has hypoxia-related 
properties including positivity for hypoxic markers such as pimonidazole and HIF1α 
(Desai et al., 2016). In these rats, the demyelinating lesion is not centered on the site of 
LPS injection, but occurs slightly distant and in particular at the white-grey matter edge 
in an area with a relatively lower density of blood vessels (Desai et al., 2016). 
Interestingly, in this model, oxygen treatment can protect from LPS-mediated 
demyelination (Desai et al., 2016).   
Intriguingly, among the inflammatory-mediated mechanism of tissue hypoxia, the brain 
of patients with MS can also suffer of reduced blood perfusion (D’haeseleer et al., 
2015). It is easy to image that a diminished blood supply to the CNS may cause 
hypoxia, however the mechanisms underlying this reduction are still unclear. Initially, it 
was suggested that the decreased cerebral blood flow (CBF) in patients with MS was a 
consequence of the decreased metabolic demand due to axonal degeneration and CNS 
atrophy. However, recent evidences have shown that also the NAWM of patients with 
MS may suffer of decreased blood supply (Paling et al., 2014). Thus, the widespread 
reduced perfusion of the CNS of patients with MS seems not to be secondary to axonal 
degeneration and CNS atrophy. A defect in cerebral venous drainage, which could 
affect the regular perfusion of the brain, has been proposed to correlate with the 
incidence and severity of MS. Zamboni and colleagues described an association 
between MS and a condition known as chronic cerebrospinal venous insufficiency 
(CCSVI) (Zamboni et al., 2009). CCSVI is characterized by high incidence of multiple 
stenoses in the internal jugular vein and azygos vein, which can impair the cerebral 
venous outflow of the blood. However, several independent studies failed to confirm 
any correlation between CCSVI and MS (reviewed in D’haeseleer et al., 2015).  
It cannot be excluded that the reduced perfusion in the NAWM of patients with MS 
could be secondary to a reduced axonal activity and/or astrocyte dysfunction. In normal 
conditions, the conduction of the electric impulse along the axons releases potassium 
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ions (K+) in the extracellular space. K+ is readily taken by astrocytes through K+ 
channels (Kir) and released into the perivascular space in a process that leads to 
arteriolar vasodilation (Knot and Nelson, 1998; Butt and Kalsi, 2006). Decreased 
neuronal activity might reduce K+ axonal release and its subsequent release by 
astrocytes in the perivascular space, possibly leading to a state of hypo-perfusion 
(D’haeseleer et al., 2011). Furthermore, this process of K+ uptake and release is highly 
energy consuming for the astrocytes due to the activity of the Na+/K+ ATPase. Na+/K+ 
ATPase is fundamental in maintaining the negative membrane potential of the 
astrocytes, necessary for the optimal intracellular K+ distribution and Kir functioning 
(Bolton et al., 2006).  
In addition, the energy metabolism of astrocytes has been described to be 
dysfunctional in MS. Indeed, astrocytes in patients with MS have been shown to be 
deficient in β2-adrenergic receptors (De Keyser et al., 1999), which regulate 
glycogenolysis, and have reduced phosphocreatine metabolism caused by decreased 
cytosolic creatine kinase B (Steen et al., 2010). Deficiency in astrocytic ATP synthesis 
could affect the normal function of the Na+/K+ ATPase, resulting in a dysfunctional 
regulation of vessel tone and decreased blood perfusion.     
Davies and colleagues revealed that also the spinal cord of rats with active EAE can be 
hypoxic, and such hypoxia consists of an actual reduction of the spinal cord oxygen 
concentration (Davies et al., 2013). Interestingly, they have seen that by giving rats 
normobaric oxygen-enriched air to breathe, it is possible to reverse the hypoxia and 
ameliorate the neurological deficits (Davies et al., 2013).  
In this thesis, we discovered that neuroinflammation per se can cause hypoxia in the 
spinal cord of rats with passive EAE. In contrast with active EAE, in passive EAE 
hypoxia occurs in the absence of major structural damage such as demyelination, in the 
presence of relatively mild microglial activation and macrophage recruitment, and low 
levels of oxidative stress (Schuh et al., 2014). The mechanisms underlying tissue 
hypoxia in rats with passive EAE are still unclear. While a role for the oxidative burst 
and NO-mediated mitochondrial dysfunction may be marginal in causing tissue hypoxia 
in this model (Schuh et al., 2014), a key part might be played by the infiltration of a 
large number of oxygen-consuming T-cells (Kominsky et al., 2010) in the spinal cord of 
these rats (Linington et al., 1993).  
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Importantly, the absence of demyelination in rats with passive EAE has led to the belief 
that the neurological deficits are due to inflammation, but via incompletely understood 
mechanisms. Here, we discovered that tissue hypoxia can help to explain the loss of 
neurological function in this model. 
 
5.2.0.0 Hypoxia and loss of neurological function: a role for oxygen 
therapy? 
Our findings provide evidence that hypoxia contributes to the neurological deficits due 
to neuroinflammation, and that by increasing tissue oxygenation it is possible to 
ameliorate the severity of the disease. 
In rats with active EAE, we confirmed that oxygen therapy can reverse tissue hypoxia, 
and we provide information on the optimal time and duration of the treatment.  
We have seen that oxygen therapy can result in a specific, transient improvement of 
neurological deficits when administered for only 1 hour, whereas it can ameliorate the 
disease progression when applied for longer.  
Although oxygen treatment (for 24 hours) ameliorated the neurological dysfunctions 
independently from the day of disease at which it was administered, the treatment was 
more effective when applied from the onset of deficits. Interestingly, when applied from 
the onset of the disease for 24, 48 or 72 hours, rats displayed a milder progression of 
the neurological deficits even after treatment cessation compared with room air 
controls, suggestive of a disease modifying effect of oxygen. In particular, oxygen 
treatment from the onset of disease resulted in a more pronounced amelioration of the 
deficits during the remitting phase, especially when applied for 72 hours. In addition, the 
treatment protected from demyelination at the peak of disease, in proportion to the 
duration of the exposure, suggesting that the efficacy of oxygen treatment increases not 
only dependently on the stage of disease at which it is administered (the earlier the 
better), but also with longer exposure. 
Intriguingly, oxygen treatment was remarkably effective when administered 
prophylactically. The fact that both in active and passive EAE, oxygen treatment 
significantly ameliorated the disease progression when administered during the 
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asymptomatic phase, raises the possibility that a metabolic dysfunction may occur even 
before the onset of neurological signs, and oxygen can change the pathogenesis of the 
disease. Furthermore, the efficacy of prophylactic oxygen in passive EAE supports our 
hypothesis that the beneficial effect of oxygen is due to a metabolic-related mechanism 
rather than an anti-inflammatory role.  
However, it remains unclear why therapeutic oxygen treatment in passive EAE, in 
contrast with active EAE, did not ameliorate the severity of the disease when 
administered at the onset of the neurological deficits.  
In this thesis, we also evaluated the role of a hemoglobin-based oxygen carrier (PNPH) 
in active EAE, as an alternative approach to deliver oxygen in the inflamed, hypoxic 
CNS. Although PNPH treatment significantly ameliorated the severity of deficits after 1 
hour from the injection on the second day of disease and resulted in a mild attenuation 
of disease progression compared with controls, its efficacy was lower relative to the 
treatment with oxygen-enriched air. Therefore, further investigations are needed to 
ascertain the advantages of administering PNPH as an alternative oxygen-based 
approach for the treatment of deficits in MS.     
 
5.3.0.0 Oxygen therapy and pathological implications  
The most important pathological finding was that oxygen treatment administered in rats 
with active EAE from the onset of deficits for 24, 48 or 72 hours, reduced 
oligodendrocyte loss and demyelination at the peak of disease. Furthermore, we have 
seen that oxygen decreased cellular stress in oligodendrocytes, highlighted by a 
reduction in eIF2α phosphorylation, which has possibly restored a normal rate of 
protein synthesis contributing to the greater oligodendrocytes survival achieved after 
the treatment. Notably, these protective effects of oxygen were proportional to the 
duration of the treatment and greater in rats treated for 72 hours. When applied from 
the onset of deficits for 72 hours, oxygen also reduced microglial activation and 
macrophage recruitment at the peak of disease, but did not change the amount of 
infiltrated T-cells and pro- and anti- inflammatory markers in the spinal cord. The 
reduced microglial and macrophage activation, in the absence of other evidence of 
reduced inflammation, may be a consequence of the reduced demyelination after 
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oxygen exposure, which may have led to a decreased demand of phagocytic cells for 
the clearance of myelin debris in the tissue. An alternative explanation for the reduced 
number of ED-1+ cells (macrophages and activated microglia) observed in the spinal 
cord of rats treated with oxygen, may include a reduced migration of macrophages into 
the CNS. This could have been caused by the reduced tissue hypoxia achieved with 
oxygen administration, given that hypoxia can act as a chemo-attractant for the 
recruitment of these cells within tissues (Murdoch and Lewis, 2005; Chanmee et al., 
2014). Furthermore, another important component in the pathogenesis of EAE and MS 
is represented by B-cells and the consequent antibody-mediated tissue damage (Griot-
Wenk et al., 1991; Mann et al., 2012; Pikor et al., 2012) (see also paragraph 2.3.3.3). 
However in this study we did not evaluate whether the oxygen treatment changes the 
trafficking and activation of B-cells during active EAE. 
Interestingly, the reduced level of eIF2α phosphorylation observed in oligodendrocytes 
after oxygen treatment, raises the possibility that hypoxia can affect the functionality of 
these cells. Until now, eIF2α phosphorylation in oligodendrocytes during active EAE 
has been attributed exclusively to an inflammatory-mediated activation of PERK led by 
increased levels of IFNγ (Lin and Popko, 2009; Stone and Lin, 2015). Our findings 
demonstrate that oxygen is able to decrease eIF2α phosphorylation without changing 
the level of IFNγ or other inflammatory markers, suggesting that in active EAE also the 
hypoxia can be a source of cellular stress in oligodendrocytes. Nevertheless, it remains 
unclear how a shortage of oxygen can cause stress in oligodendrocytes, given that 
these cells have been recently described to rely mainly on the anaerobic glycolysis for 
their energy need (Fünfschilling et al., 2012).  
Although glycolysis may represent the main energy source for oligodendrocytes, some 
studies reported an important, preserved activity of the mitochondrial respiration in 
these cells in-vitro (Ziabreva et al., 2010), and high susceptibility of oligodendrocytes to 
ischemic injury in-vivo (Dewar et al., 2003).  
Furthermore, it is possible that a significant amount of oxygen is used by 
oligodendrocytes to maintain lipid homeostasis. Indeed, a large amount of α-hydroxy 
fatty acids such as cerebronic acids are found in the mammalian brain as components 
of cerebrosides and sulfatides that are cell-membrane lipids of which oligodendrocytes 
are particularly enriched (Thompson, 1992). These lipids are formed from straight chain 
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fatty acids via the action of multifunctional oxygenases that require oxygen and NADPH 
(Thompson, 1992). In addition, lipid peroxidation, which is a mechanism of lipid 
degradation, can also account for part of the oxygen consumption. Lipid peroxidation 
can occur either non-enzymatically (via the action of free radicals) or through the action 
of specific enzymes such as cyclooxygenase and lipoxygenase (Thompson, 1992). As 
the names suggest, cyclooxygenase and lipoxygenase are enzymes that require 
oxygen as substrate to catalyze the reactions (Thompson, 1992; Filimonov and 
Vrzheshch, 2007). It has been estimated that, while under normal conditions lipid 
peroxidation accounts only for a small portion of lipid degradation, its level can increase 
5-fold during severe stress such as malignant growth, deficiency of vitamin E, and X-ray 
irradiation (Thompson, 1992). In addition, hypoxia has been demonstrated to increase 
cytosolic phospholipase A2 activity, liberating more unsaturated fatty acids from lipid 
membranes to act as substrates for cyclooxygenase and lipoxygenases (Barnett et al., 
2010).  
Oligodendrocytes are characterized by an extensive cell-membrane surface; therefore 
they may require a consistent amount of oxygen to sustain lipid homeostasis, making 
them particularly susceptible to hypoxia. In active EAE, myelin disruption could increase 
the amount of membrane lipids liberated in oligodendrocytes, boosting the 
cyclooxygenase- and lipoxygenases- mediated degradation. Furthermore, 
oligodendrocytes may try to repair the membrane damage by increasing the formation 
of polyunsaturated fatty acids. Therefore, these cellular mechanisms may be enhanced 
during inflammatory demyelination, augmenting the oxygen demand of 
oligodendrocytes. 
Interestingly, the majority of the cellular lipids are processed in the ER, while other 
specific fatty acids are metabolized in the mitochondria. In oligodendrocytes, during 
EAE, the increased lipid homeostasis in addition to the elevated protein synthesis 
caused by inflammation (Lin and Popko, 2009), may overload the ER working capacity 
causing ER stress and the consequent phosphorylation of eIF2α. 
A safety concern for the use of oxygen in MS is the fact that increased oxygenation can 
enhance oxidative stress. In active EAE, while nitrative stress may be marginal as 
indicated by the transient expression of iNOS and mild nitrative damage (e.g. 
nitrotyrosination of proteins) at the peak of disease (Schuh et al., 2014), oxidative 
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stress represents an important source of tissue damage. Interestingly, we observed that 
oxygen exposure up to 72 hours from the onset of the disease does not exacerbate 
oxidative stress at the peak of deficits, as indicated by markers of oxidative damage like 
oxidized DNA/RNA and phospholipids. Surprisingly, administration of oxygen for 72 
hours from the onset of deficits resulted in a significantly decreased level of oxidized 
phospholipids.  
It is possible that the lower phospholipid oxidation after oxygen exposure may be due to 
decreased oxidative stress resulting from the reduced hypoxia (Xu et al., 2004; 
Strapazzon et al., 2016), although the mechanisms through which hypoxia enhances 
oxidative stress are not entirely understood (see below).  
A mechanism involving “reductive stress” has been suggested. Reductive stress is a 
condition in which cells are in a more reductive state due to increased levels of 
reducing equivalents such as NADH and FADH2 (Clanton, 2007). These molecules can 
accumulate in hypoxic condition due to the decreased efficiency of mitochondrial 
oxidative phosphorylation. In oxidative phosphorylation, oxygen acts as the final 
electron acceptor, and in low cellular oxygen concentrations the lack of oxygen can 
slow mitochondrial respiration leading to an accumulation of NADH and FADH2 which 
are not oxidized upstream in the electron transport chain. NADH and FADH2 contain a 
pair of electrons with high transfer potential. At elevated concentrations, some NADH 
and FADH2 molecules can escape the respiratory chain, and directly transfer the 
electron to oxygen forming superoxide anions (O2-, a free radical) (Clanton, 2007).  
Reductive stress can be even more severe in the condition of virtual (or chemical) 
hypoxia. Virtual hypoxia is caused by an intrinsic impairment of mitochondrial 
respiration rather than from an actual shortage of oxygen supply. Antagonists of 
mitochondrial complexes such as NO (which inhibits complex-IV) can cause chemical 
hypoxia by either slowing down or blocking the electron transport chain. In this 
condition, the oxidative stress resulting from elevated levels of NADH and FADH2 can 
be even more severe. Indeed, during chemical hypoxia NADH and FADH2 accumulate 
in an environment rich in oxygen, so there is more oxygen available to which electrons 
can be transfered, causing a greater production of ROS (Clanton, 2007). 
All together, these findings provide evidence that oxygen therapy applied in a 
demyelinating model of MS (active EAE) can ameliorate the neurological deficits and 
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protect from demyelination without exacerbating the oxidative stress, indicating a 
beneficial role of oxygen with relatively low side effects.  
 
5.4.0.0 Limitations of methods 
In this study we examined whether oxygen therapy may be a suitable treatment for 
neurological dysfunction in MS using two models of MS in rat, namely passive and 
active EAE. These models are commonly used in pre-clinical research to study the 
mechanisms involved in the pathology of MS and to test the efficacy and safety of new 
therapeutic approaches before their application in patients (Stromnes and Goverman, 
2006a, 2006b). However, active and passive EAE mimic only a few features of MS and 
they do not reproduce the entire spectrum of disabilities and pathological mechanisms 
observed in the human disease (see also Introduction 1.2.0.0). In this regard, the 
differences between MS and EAE must be taken into consideration before applying to 
MS patients treatments that have been tested only in EAE. First, EAE is a purely 
autoimmune-mediated disease, whereas the mechanisms contributing to the pathology 
of MS are more complex and they remain largely unknown (Noseworthy et al., 2000; 
Stromnes and Goverman, 2006a), implying that some aspects of MS may not be 
represented in EAE studies. For example, while an important role for inflammation and 
autoimmunity has been recognized during the relapsing-remitting phase of MS, other 
mechanisms such as nitrative and oxidative damage, mitochondrial dysfunction, and 
energy crisis have been shown to be predominant during the progressive phase of MS 
(Lassmann et al., 2012; Witte et al., 2014), and these mechanisms are only partially 
reproduced in EAE. DA rats (Storch et al., 1998) and Biozzi AB/H mice (Baker et al., 
1990; Al-Izki et al., 2012), especially during advanced stages of active EAE, mimic 
some characteristics of progressive MS, but currently no animal models exist that 
reproduce the entire pathological spectrum of progressive MS (see also Introduction 
1.2.0.0). Thus, many treatments that have been proven to be effective in EAE, fail to 
reproduce a similar beneficial effect in progressive MS. 
Furthermore, the rodents used in this study were genetically identical and they were 
maintained in finely controlled environmental conditions in order to reduce both genetic 
and environmental variability among animals. This contributes to a decrease in the 
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number of possible confounding factors that could affect the outcome of the 
experiments. By contrast, in MS, the high environmental and genetic variability between 
patients can strongly impact the outcome of a clinical trial. This variability is one of the 
reasons why many treatments that have proven to be effective in EAE, sometimes do 
not reproduce the same outcome in MS and they need to be tested in a large number of 
patients in order to assess accurately whether they are beneficial or not in humans.  
As mentioned before in the course of this thesis, another important limitation of EAE 
models is that the oxidative and nitrative damage in the inflamed CNS is transient and 
less severe compared with the one occurring in active MS lesions (Schuh et al., 2014). 
This aspect is of fundamental interest in the characterization of oxygen as a potential 
treatment for MS, as hyperoxia may contribute to the oxidative damage due to 
neuroinflammation.  
In this study, RT-PCR analysis was performed on lumbar spinal cord cross-sections of 
rats with active EAE at the first peak of disease in order to evaluate whether treatment 
with oxygen affects the expression of pro- and anti-inflammatory markers. At the first 
peak of disease, inflammation is mainly localized in the sub-meningeal area of the 
spinal cord. Therefore, it is possible that via a gene expression analysis in a whole 
cross-section we may have diluted small, but possibly significant differences between 
groups. In this regard, a gene expression analysis on only the inflamed lumbar spinal 
cord dorsal column could be more precise and possibly highlight even small differences 
between groups.  
 
5.5.0.0 Oxygen therapy: clinical implications in MS 
The use of oxygen therapy in patients with MS has been evaluated in several clinical 
trials during the 1980s (Fischer et al., 1983; Massey et al., 1985; Murthy et al., 1985; 
Neiman et al., 1985; Wood et al., 1985; Confavreux et al., 1986; Harpur et al., 1986; 
Wiles et al., 1986; Barnes et al., 1987; Oriani et al., 1990). In these trials, oxygen was 
administered at hyperbaric pressure (hyperbaric oxygen treatment, HBOT) in patients 
with stable, chronic MS. Although many MS patients reported a transient improvement 
of neurological function after HBOT (Fischer et al., 1983; Murthy et al., 1985; Barnes et 
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al., 1987; Oriani et al., 1990), with some indicating a long-lasting attenuation of the 
disease severity up to 6 months after treatment cessation (Fischer et al., 1983); several 
other clinical trials did not detect any beneficial outcome from the use of HBOT in MS 
(Confavreux et al., 1986; Harpur et al., 1986; Massey et al., 1985; Neiman et al., 1985; 
Wood et al., 1985). Recently, a meta-analysis of HBOT trials in MS concluded that 
there is not enough evidence of clinical benefits to support the use of HBOT for the 
treatment of MS (Bennett and Heard, 2010). 
Increasing knowledge about the pathology of MS and use oxygen therapy in animal 
models is providing a number of observations that could explain the discordant 
therapeutic effects of HBOT in MS, along with important indications that can lead to a 
reconsideration of oxygen as a valuable treatment for this disease.  
First, the use of HBOT in MS was based on the belief that oxygen could play an anti-
inflammatory role (Warren et al., 1978). Instead, our findings in EAE suggest that 
oxygen treatment does not directly affect inflammation. In particular, we discovered that 
the beneficial effect of oxygen is mainly due to a metabolic- hypoxic-related 
mechanism. In this regard, studies revealed that only a subgroup of patients with MS 
have hypoxia-like lesions and suffer of a CNS energy deficit (Lucchinetti et al., 2000; 
Steen et al., 2013; Yang et al., 2015); therefore, it is possible that not all patients with 
MS can benefit from oxygen administration.  
The facts that only a subgroup of patients with MS could eventually benefit from oxygen 
treatment, and that the majority of HBOT clinical trials were performed on relatively 
small cohorts of cases, sometimes less than 30 patients were examined (Massey et al., 
1985; Neiman et al., 1985), it is possible that beneficial effects have been overlooked.  
Larger numbers of MS patients, in conjunction with the preventive use of MRI (Paling et 
al., 2011) or near-infrared spectroscopy (Yang et al., 2015) methods may help in 
identifying those MS patients that suffer from hypoxia and an energy deficit in the CNS, 
and that can possibly benefit the most from oxygen administration.  
Two other important factors that may also have reduced the efficacy of HBOT in MS 
could be 1) the stage of disease at which the treatment was applied, and 2) the duration 
of the exposure. We have seen that oxygen therapy in rats with EAE is more effective 
when administered at the early phase of disease. However, patients were treated with 
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HBOT during the chronic stage of MS. This might have reduced the efficacy of the 
treatment due to the advanced, severe status of the disease, which leaves little 
opportunity for any improvements following the therapy. Furthermore, our preclinical 
studies revealed that prolonged exposures to oxygen (≥ 24 hours) are more likely to 
result in a prominent long-term attenuation of the disease, whereas a short-term 
administration (1-hour) of oxygen results in a transient amelioration of the neurological 
function, and the beneficial effects disappear when animals are returned to room air. 
Interestingly, the great majority of HBOT trials investigated a course of 20 exposures 
with HBOT administered daily for only 90 minutes over 4 weeks (reviewed in Bennett 
and Heard, 2010). Similarly to what we observed in 1-hour oxygen-treated rats with 
active EAE, HBOT for 90 minutes (Fischer et al., 1983; Murthy et al., 1985; Barnes et 
al., 1987; Oriani et al., 1990) resulted in a mild, transient amelioration of neurological 
dysfunction in patients with MS; indicating that such short-term administration of 
oxygen, even if repeated daily, is not enough to establish a long-lasting attenuation of 
the disease. 
In addition, HBOT has been proposed to induce higher superoxide production than 
oxygen at normobaric pressure, increasing cell toxicity (Nemoto and Betterman, 2007; 
Singhal, 2007). Instead, normobaric oxygen therapy has been described to be safer 
and more effective than HBOT in animal models of ischaemic stroke (Singhal, 2007; 
Weaver and Liu, 2015), resulting in decreased infarct volume without exacerbating the 
oxidative stress (Singhal, 2007; Weaver and Liu, 2015). Indeed, a number of studies 
reported reduced levels of oxidative stress in mice with ischaemic stroke after 
normobaric oxygen treatment compared with untreated controls (reviewed in Weaver 
and Liu, 2015); whereas HBOT of ischaemic injury was associated with increased 
oxidative stress, mainly linked to the higher concentration of oxygen dissolved in the 
plasma (Nemoto and Betterman, 2007; Ding et al., 2014). It is possible that the 
increased oxidative stress following HBOT administration in patients with MS have 
counteracted the beneficial effect resulting from the increased oxygenation of the CNS. 
Nevertheless, MS patients exposed to HBOT did not report deleterious side effects 
after treatment (Bennett and Heard, 2010). 
Therefore, we believe that the failure of HBOT in MS clinical trials can be attributable to: 
1) advanced disease stage for therapy administration, 2) short-term exposure to 
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oxygen, 3) inadequate number of patients included in the trials, and 4) possible 
exacerbation of the oxidative damage due to pressurized inspired oxygen-enriched air.   
In the light of our preclinical studies, we suggest that oxygen therapy at normobaric 
pressure has a renewed relevance for the treatment of MS. Indeed, we discovered that 
prolonged exposures (≥ 24 hours) to normobaric oxygen therapy result in a long-lasting 
amelioration of the neurological deficits when applied from the early stages of the 
disease, seemingly without side effects. Indeed, consistent with studies in models of 
ischaemic stroke (Weaver and Liu, 2015), we have seen that, in active EAE, 
administration of normobaric oxygen does not exacerbate oxidative stress. However, 
Schuh and colleagues (2014) have demonstrated that animal models of MS, including 
active and passive EAE, fail in reproducing the same severity of the oxidative and 
nitrative stress observed in active MS lesions, revealing that EAE is an inadequate 
model to study the oxidative/nitrative damage occurring in MS. Nevertheless, the 
presence of only few side effects on both CNS and peripheral organs following 
normobaric oxygen therapy in patients with ischaemic stroke (Singhal et al., 2005; 
Singhal, 2007) suggests that oxygen treatment could be similarly safe also in MS. 
However, we advise caution in the use of oxygen in MS until the safety of oxygen 
therapy in this disease is fully established.  
An interesting opportunity to investigate the efficacy of normobaric oxygen therapy for 
the treatment of neuroinflammatory diseases in clinic is represented by patients with 
acute optic neuritis. Optic neuritis shares some pathological similarities with MS and 
represents a unique scenario for testing oxygen in a relatively simple 
inflammatory/demyelinating context. Indeed, optic neuritis is characterized by defined 
inflammatory demyelinating lesions of the optic nerve that cause loss of vision (partial 
or complete), whereas, in MS, focal lesions can arise everywhere in the CNS leading to 
a variety of signs and symptoms. Interestingly, recent observations from our lab have 
shown that sensitization with rMOG of Brown Norway rats often results in the 
inflammation of the optic nerve and importantly, the inflamed optic nerve is hypoxic 
(unpublished data). Accordingly, it is possible that patients with optic neuritis suffer 
tissue hypoxia at the level of the optic nerve, so they may benefit from oxygen 
administration. We suggest that patients with optic neuritis are treated with oxygen (60-
80% for 1 hour) as early as possible, as the earliest treatment is the most likely to 
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produce the greatest beneficial effect. Based on our preclinical studies, we believe that 
1 hour of oxygen exposure may already be sufficient to produce a specific, although 
probably transient beneficial effect. Furthermore, short-term administrations of oxygen 
minimize patient’s discomfort and are unlikely to induce side effects. Finally, the clinical 
outcome of the therapy can be simply assessed by measuring the visual evoked 
potential before and after oxygen administration. This trial may provide preliminary 
evidence of whether oxygen treatment is beneficial for inflammatory demyelinating 
diseases in humans, raising the opportunity to target other neuroinflammatory 
pathologies such as MS. 
 
5.6.0.0 Future perspectives  
In this thesis we used prolonged administration of inspired oxygen at high 
concentrations (≥75% for up to 72 hours) to maximize the effects on disease 
pathogenesis. Although, it is reasonable to believe that beneficial effects can be 
achieved even with lower concentrations and/or shorter exposure to the treatment. 
Indeed, we have seen that 1 hour of oxygen (100%) is already sufficient to promptly 
ameliorate the deficits, although the beneficial effects were transient. Future research 
may focus on investigating different doses and durations of oxygen treatment. Longer, 
daily administration of oxygen (e.g. 4 hours) applied from the early phase of the 
disease, may be effective in ameliorating neurological function, and protect from a 
worsening of the deficits. This would help in identifying a good compromise between 
long-term amelioration of the disease and a reasonable administration of the therapy 
which could be easily applied in patients’ homes, minimizing patient distress and 
possible side effects. 
Furthermore, we showed that oxygen plays a beneficial effect by mainly acting on 
tissue hypoxia and energy deficit in EAE, with seemingly few effects on the 
autoimmune response. Future research may focus on the role of oxygen when 
administered in addition to other therapeutic approaches for MS. Notably, oxygen could 
be administered in combination with neuroprotective drugs as phenytoin (sodium 
channel blocker) (Raftopoulos et al., 2016) or immunomodulatory treatments as 
Fingolimod or BG12. The different mechanisms of action between oxygen and these 
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drugs could lead to an additive or even synergetic beneficial effect when administered 
together. 
Here we have investigated the role of oxygen in ameliorating disease progression when 
administered at early stages of EAE (first peak of disease). However, it is possible that 
oxygen treatment may be effective also at more advanced stages, even though the 
greatest beneficial effect was achieved when oxygen was administered at the onset of 
neurological deficits. In advanced stages of MS, neurological deficits are mainly 
triggered by neuronal degeneration caused by metabolic-related cytodegeneration 
(Trapp and Stys, 2009; Lassmann, 2013) and inflammation caused by immune cells 
“trapped” within the CNS rather than new inflammatory cells entering from the blood 
stream (Lassmann, 2013). Similarly, in rats with active EAE neurodegeneration occurs 
at later stages of disease (including the second peak). At advanced stages of disease, 
a more prominent role for mitochondrial dysfunction and tissue hypoxia in 
neurodegeneration has been suggested in both MS and EAE (Trapp and Stys, 2009; 
Nikic et al., 2011; Witte et al., 2014). Therefore, it is possible that oxygen therapy, 
especially if started from the beginning of the neurological deficits, but also when 
applied during the progressive stage, may result in a long-term amelioration of the 
disease protecting from neurodegeneration.  
In this thesis, we also investigated the use of a hemoglobin-based oxygen carrier 
(PNPH, SynZyme, USA) as an alternative method to increase oxygen delivery in the 
inflamed, hypoxic spinal cord of rats with active EAE. Despite our preliminary results 
suggest that PNPH is less effective than normobaric oxygen-enriched air in 
ameliorating the severity of the disease, further investigation may help in understand 
whether an optimization of the time and dosage of the therapy can increase its efficacy. 
Importantly, while gaseous oxygen therapy is an off-patent treatment (Stoller, 2015) 
thereby it is not economically attractive for the investment of large amount of money in 
long and expensive clinical trials; hemoglobin-based oxygen carriers are patentable 
compounds and they may catalyze the scientific and economic interests of 
pharmaceutical companies and research agencies in investigating whether oxygen-
based therapies are effective for the treatment of patients with MS. 
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5.7.0.0 Concluding remarks 
This thesis provides further evidence that hypoxia may be an important factor in the 
pathology of neuroinflammatory disease. We discovered that neuroinflammation per se 
is sufficient in causing CNS hypoxia. Interestingly, this hypoxia can contribute to some 
of the key pathological features of MS including neurological deficits, demyelination and 
oligodendrocytes loss. Importantly, we discovered that oxygen therapy can protect from 
demyelination and oligodendrocyte death, and ameliorate the severity of the disease. 
However, the protective effect of oxygen in EAE was partial and some animals did not 
benefit from the therapy. These results suggest that hypoxia is only one of the 
mechanisms contributing to the pathogenesis and progression of the disease.  
We provide insights about the optimal time and duration of the treatment, revealing that 
oxygen therapy is more effective when administered at the very beginning of 
neurological signs and that the duration of the exposure, at least up to 72 hours, 
proportionally correlates with the spinal cord protection and long-term attenuation of the 
disease. Interestingly, oxygen therapy can also delay the onset of deficits if 
administered prophylactically, suggesting that an energy deficit may occur during the 
asymptomatic phase of the disease. These findings confirm our hypothesis that hypoxia 
may be an important player in neuroinflammatory diseases and oxygen therapy can 
protect from neurological deficits and CNS damage, representing a potential treatment 
for patients with MS.  
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Figure 5.1 – Schematic representation of the likely effects of oxygen treatment in active 
EAE. 
The graph above summarizes the main effects of oxygen therapy (75% for 72 hours from the 
onset of neurological deficits) in rats with active EAE, and it proposes a possible mechanism of 
action of the treatment. a) Immunisation of DA rats with rMOG (active EAE) leads to an 
autoimmune/inflammatory response consisting of an infiltration of T-cells, B-cells, and 
monocytes/macrophages into the CNS, and the activation of resident microglia. b) The 
inflammatory response in the CNS parenchyma is characterized by the release of inflammatory 
mediators, activation of cytotoxic pathways, tissue hypoxia, production of ROS/RNS, 
mitochondrial dysfunction and an energy deficit. c) The inflammatory insult can cause CNS 
damage (including demyelination, oxidative damage, phagocytosis, oligodendrocyte stress and 
death) and neurological deficits. d) Administration of oxygen in rats with active EAE ameliorates 
the severity of the neurological deficits and leads to the reduction of the following pathological 
features (solid red arrows): tissue hypoxia, demyelination, oxidative damage, oligodendrocyte 
cell stress and apoptosis, and phagocytic activation of microglia/macrophages. Dashed red 
arrows highlight a proposed mechanism through which oxygen may have attenuated disease 
severity. It is possible that by decreasing tissue hypoxia, oxygen leads to a reduced infiltration of 
macrophages, ROS/RNS production, mitochondrial damage and energy deficit, increasing the 
endurance of CNS cells at the inflammatory attack. 
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